#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Differential Responses to Infant Faces in Relation to Maternal Substance Use: An Exploratory Study
#Text=Background.
1-1	0-12	Differential	_	
1-2	13-22	Responses	_	
1-3	23-25	to	_	
1-4	26-32	Infant	_	
1-5	33-38	Faces	_	
1-6	39-41	in	_	
1-7	42-50	Relation	_	
1-8	51-53	to	_	
1-9	54-62	Maternal	_	
1-10	63-72	Substance	_	
1-11	73-76	Use	_	
1-12	76-77	:	_	
1-13	78-80	An	_	
1-14	81-92	Exploratory	_	
1-15	93-98	Study	_	
1-16	99-109	Background	_	
1-17	109-110	.	_	

#Text=Maternal substance use and addiction has been associated with negative consequences for parenting and may increase addiction vulnerability in the developing child.
2-1	111-119	Maternal	_	
2-2	120-129	substance	_	
2-3	130-133	use	_	
2-4	134-137	and	_	
2-5	138-147	addiction	_	
2-6	148-151	has	_	
2-7	152-156	been	_	
2-8	157-167	associated	_	
2-9	168-172	with	_	
2-10	173-181	negative	_	
2-11	182-194	consequences	_	
2-12	195-198	for	_	
2-13	199-208	parenting	_	
2-14	209-212	and	_	
2-15	213-216	may	_	
2-16	217-225	increase	_	
2-17	226-235	addiction	_	
2-18	236-249	vulnerability	_	
2-19	250-252	in	_	
2-20	253-256	the	_	
2-21	257-267	developing	_	
2-22	268-273	child	_	
2-23	273-274	.	_	

#Text=Neuroimaging research suggests that substance use may decrease the reward of caring for infants and heighten stress reactivity to affective infant cues.
3-1	275-287	Neuroimaging	_	
3-2	288-296	research	_	
3-3	297-305	suggests	_	
3-4	306-310	that	_	
3-5	311-320	substance	_	
3-6	321-324	use	_	
3-7	325-328	may	_	
3-8	329-337	decrease	_	
3-9	338-341	the	_	
3-10	342-348	reward	_	
3-11	349-351	of	_	
3-12	352-358	caring	_	
3-13	359-362	for	_	
3-14	363-370	infants	_	
3-15	371-374	and	_	
3-16	375-383	heighten	_	
3-17	384-390	stress	_	
3-18	391-401	reactivity	_	
3-19	402-404	to	_	
3-20	405-414	affective	_	
3-21	415-421	infant	_	
3-22	422-426	cues	_	
3-23	426-427	.	_	

#Text=Methods.
4-1	428-435	Methods	_	
4-2	435-436	.	_	

#Text=Thirty-two substance-using mothers and twenty-two non-substance-using mothers were presented with emotional face and cry stimuli generated from their own and a demographically matched unknown infant during fMRI scanning.
5-1	437-447	Thirty-two	_	
5-2	448-463	substance-using	_	
5-3	464-471	mothers	_	
5-4	472-475	and	_	
5-5	476-486	twenty-two	_	
5-6	487-506	non-substance-using	_	
5-7	507-514	mothers	_	
5-8	515-519	were	_	
5-9	520-529	presented	_	
5-10	530-534	with	_	
5-11	535-544	emotional	_	
5-12	545-549	face	_	
5-13	550-553	and	_	
5-14	554-557	cry	_	
5-15	558-565	stimuli	_	
5-16	566-575	generated	_	
5-17	576-580	from	_	
5-18	581-586	their	_	
5-19	587-590	own	_	
5-20	591-594	and	_	
5-21	595-596	a	_	
5-22	597-612	demographically	_	
5-23	613-620	matched	_	
5-24	621-628	unknown	_	
5-25	629-635	infant	_	
5-26	636-642	during	_	
5-27	643-647	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
5-28	648-656	scanning	_	
5-29	656-657	.	_	

#Text=Between-group differences in neural activity during task performance were assessed using whole-brain, mixed-effects models corrected for multiple comparisons (voxel-level p<0.001, pFWE<0.05).
6-1	658-671	Between-group	_	
6-2	672-683	differences	_	
6-3	684-686	in	_	
6-4	687-693	neural	_	
6-5	694-702	activity	_	
6-6	703-709	during	_	
6-7	710-714	task	_	
6-8	715-726	performance	_	
6-9	727-731	were	_	
6-10	732-740	assessed	_	
6-11	741-746	using	_	
6-12	747-758	whole-brain	_	
6-13	758-759	,	_	
6-14	760-773	mixed-effects	_	
6-15	774-780	models	_	
6-16	781-790	corrected	_	
6-17	791-794	for	_	
6-18	795-803	multiple	_	
6-19	804-815	comparisons	_	
6-20	816-817	(	_	
6-21	817-828	voxel-level	_	
6-22	829-830	p	_	
6-23	830-831	<	_	
6-24	831-836	0.001	_	
6-25	836-837	,	_	
6-26	838-842	pFWE	_	
6-27	842-843	<	_	
6-28	843-847	0.05	_	
6-29	847-848	)	_	
6-30	848-849	.	_	

#Text=Results.
7-1	850-857	Results	_	
7-2	857-858	.	_	

#Text=Relative to non-substance-using mothers, substance-using mothers exhibited greater activation when viewing their own infant’s face as compared to an unknown infant’s face across multiple brain regions, including superior medial frontal, inferior parietal, and middle temporal regions.
8-1	859-867	Relative	_	
8-2	868-870	to	_	
8-3	871-890	non-substance-using	_	
8-4	891-898	mothers	_	
8-5	898-899	,	_	
8-6	900-915	substance-using	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	
8-7	916-923	mothers	_	
8-8	924-933	exhibited	_	
8-9	934-941	greater	_	
8-10	942-952	activation	_	
8-11	953-957	when	_	
8-12	958-965	viewing	_	
8-13	966-971	their	_	
8-14	972-975	own	_	
8-15	976-982	infant	_	
8-16	982-983	’	_	
8-17	983-984	s	_	
8-18	985-989	face	_	
8-19	990-992	as	_	
8-20	993-1001	compared	_	
8-21	1002-1004	to	_	
8-22	1005-1007	an	_	
8-23	1008-1015	unknown	_	
8-24	1016-1022	infant	_	
8-25	1022-1023	’	_	
8-26	1023-1024	s	_	
8-27	1025-1029	face	_	
8-28	1030-1036	across	_	
8-29	1037-1045	multiple	_	
8-30	1046-1051	brain	_	
8-31	1052-1059	regions	_	
8-32	1059-1060	,	_	
8-33	1061-1070	including	_	
8-34	1071-1079	superior	_	
8-35	1080-1086	medial	_	
8-36	1087-1094	frontal	_	
8-37	1094-1095	,	_	
8-38	1096-1104	inferior	_	
8-39	1105-1113	parietal	_	
8-40	1113-1114	,	_	
8-41	1115-1118	and	_	
8-42	1119-1125	middle	_	
8-43	1126-1134	temporal	_	
8-44	1135-1142	regions	_	
8-45	1142-1143	.	_	

#Text=Substance-using mothers also had a decreased response to sad infant faces in the ventral striatum relative to the non-substance-using mothers.
9-1	1144-1159	Substance-using	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	
9-2	1160-1167	mothers	_	
9-3	1168-1172	also	_	
9-4	1173-1176	had	_	
9-5	1177-1178	a	_	
9-6	1179-1188	decreased	_	
9-7	1189-1197	response	_	
9-8	1198-1200	to	_	
9-9	1201-1204	sad	_	
9-10	1205-1211	infant	_	
9-11	1212-1217	faces	_	
9-12	1218-1220	in	_	
9-13	1221-1224	the	_	
9-14	1225-1232	ventral	_	
9-15	1233-1241	striatum	_	
9-16	1242-1250	relative	_	
9-17	1251-1253	to	_	
9-18	1254-1257	the	_	
9-19	1258-1277	non-substance-using	_	
9-20	1278-1285	mothers	_	
9-21	1285-1286	.	_	

#Text=Neural responses to own vs. unknown infant cries did not significantly differ between substance-using and non-substance-using mothers.
10-1	1287-1293	Neural	_	
10-2	1294-1303	responses	_	
10-3	1304-1306	to	_	
10-4	1307-1310	own	_	
10-5	1311-1313	vs	_	
10-6	1313-1314	.	_	
10-7	1315-1322	unknown	_	
10-8	1323-1329	infant	_	
10-9	1330-1335	cries	_	
10-10	1336-1339	did	_	
10-11	1340-1343	not	_	
10-12	1344-1357	significantly	_	
10-13	1358-1364	differ	_	
10-14	1365-1372	between	_	
10-15	1373-1388	substance-using	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	
10-16	1389-1392	and	_	
10-17	1393-1412	non-substance-using	_	
10-18	1413-1420	mothers	_	
10-19	1420-1421	.	_	

#Text=Conclusions.
11-1	1422-1433	Conclusions	_	
11-2	1433-1434	.	_	

#Text=Findings suggest overlapping cortical and subcortical brain regions implicated in responding to infant faces, with activation differences related to infant familiarity, emotional expression, and maternal substance use.
12-1	1435-1443	Findings	_	
12-2	1444-1451	suggest	_	
12-3	1452-1463	overlapping	_	
12-4	1464-1472	cortical	_	
12-5	1473-1476	and	_	
12-6	1477-1488	subcortical	_	
12-7	1489-1494	brain	_	
12-8	1495-1502	regions	_	
12-9	1503-1513	implicated	_	
12-10	1514-1516	in	_	
12-11	1517-1527	responding	_	
12-12	1528-1530	to	_	
12-13	1531-1537	infant	_	
12-14	1538-1543	faces	_	
12-15	1543-1544	,	_	
12-16	1545-1549	with	_	
12-17	1550-1560	activation	_	
12-18	1561-1572	differences	_	
12-19	1573-1580	related	_	
12-20	1581-1583	to	_	
12-21	1584-1590	infant	_	
12-22	1591-1602	familiarity	_	
12-23	1602-1603	,	_	
12-24	1604-1613	emotional	_	
12-25	1614-1624	expression	_	
12-26	1624-1625	,	_	
12-27	1626-1629	and	_	
12-28	1630-1638	maternal	_	
12-29	1639-1648	substance	_	
12-30	1649-1652	use	_	
12-31	1652-1653	.	_	

#Text=While prior work has focused on attenuated neural responses to infant cues, greater attention is needed toward understanding the increased reactivity to affective infant cues observed in substance-using mothers.
13-1	1654-1659	While	_	
13-2	1660-1665	prior	_	
13-3	1666-1670	work	_	
13-4	1671-1674	has	_	
13-5	1675-1682	focused	_	
13-6	1683-1685	on	_	
13-7	1686-1696	attenuated	_	
13-8	1697-1703	neural	_	
13-9	1704-1713	responses	_	
13-10	1714-1716	to	_	
13-11	1717-1723	infant	_	
13-12	1724-1728	cues	_	
13-13	1728-1729	,	_	
13-14	1730-1737	greater	_	
13-15	1738-1747	attention	_	
13-16	1748-1750	is	_	
13-17	1751-1757	needed	_	
13-18	1758-1764	toward	_	
13-19	1765-1778	understanding	_	
13-20	1779-1782	the	_	
13-21	1783-1792	increased	_	
13-22	1793-1803	reactivity	_	
13-23	1804-1806	to	_	
13-24	1807-1816	affective	_	
13-25	1817-1823	infant	_	
13-26	1824-1828	cues	_	
13-27	1829-1837	observed	_	
13-28	1838-1840	in	_	
13-29	1841-1856	substance-using	_	
13-30	1857-1864	mothers	_	
13-31	1864-1865	.	_	

#Text=Introduction
#Text=Maternal substance use remains a significant public health concern, with detrimental consequences extending to both mothers and developing children.
14-1	1866-1878	Introduction	_	
14-2	1879-1887	Maternal	_	
14-3	1888-1897	substance	_	
14-4	1898-1901	use	_	
14-5	1902-1909	remains	_	
14-6	1910-1911	a	_	
14-7	1912-1923	significant	_	
14-8	1924-1930	public	_	
14-9	1931-1937	health	_	
14-10	1938-1945	concern	_	
14-11	1945-1946	,	_	
14-12	1947-1951	with	_	
14-13	1952-1963	detrimental	_	
14-14	1964-1976	consequences	_	
14-15	1977-1986	extending	_	
14-16	1987-1989	to	_	
14-17	1990-1994	both	_	
14-18	1995-2002	mothers	_	
14-19	2003-2006	and	_	
14-20	2007-2017	developing	_	
14-21	2018-2026	children	_	
14-22	2026-2027	.	_	

#Text=In the United States, recent data suggest an increasing trend in prenatal past-month illicit drug, tobacco product, and alcohol use from 2016 to 2017.
15-1	2028-2030	In	_	
15-2	2031-2034	the	_	
15-3	2035-2041	United	_	
15-4	2042-2048	States	_	
15-5	2048-2049	,	_	
15-6	2050-2056	recent	_	
15-7	2057-2061	data	_	
15-8	2062-2069	suggest	_	
15-9	2070-2072	an	_	
15-10	2073-2083	increasing	_	
15-11	2084-2089	trend	_	
15-12	2090-2092	in	_	
15-13	2093-2101	prenatal	_	
15-14	2102-2112	past-month	_	
15-15	2113-2120	illicit	_	
15-16	2121-2125	drug	_	
15-17	2125-2126	,	_	
15-18	2127-2134	tobacco	_	
15-19	2135-2142	product	_	
15-20	2142-2143	,	_	
15-21	2144-2147	and	_	
15-22	2148-2155	alcohol	_	
15-23	2156-2159	use	_	
15-24	2160-2164	from	_	
15-25	2165-2169	2016	_	
15-26	2170-2172	to	_	
15-27	2173-2177	2017	_	
15-28	2177-2178	.	_	

#Text=Even for women able to abstain from substance use during pregnancy, most relapse within two years postpartum.
16-1	2179-2183	Even	_	
16-2	2184-2187	for	_	
16-3	2188-2193	women	_	
16-4	2194-2198	able	_	
16-5	2199-2201	to	_	
16-6	2202-2209	abstain	_	
16-7	2210-2214	from	_	
16-8	2215-2224	substance	_	
16-9	2225-2228	use	_	
16-10	2229-2235	during	_	
16-11	2236-2245	pregnancy	_	
16-12	2245-2246	,	_	
16-13	2247-2251	most	_	
16-14	2252-2259	relapse	_	
16-15	2260-2266	within	_	
16-16	2267-2270	two	_	
16-17	2271-2276	years	_	
16-18	2277-2287	postpartum	_	
16-19	2287-2288	.	_	

#Text=Substance use during pregnancy may exert teratogenic effects on fetal development and neonatal complications upon delivery.
17-1	2289-2298	Substance	_	
17-2	2299-2302	use	_	
17-3	2303-2309	during	_	
17-4	2310-2319	pregnancy	_	
17-5	2320-2323	may	_	
17-6	2324-2329	exert	_	
17-7	2330-2341	teratogenic	_	
17-8	2342-2349	effects	_	
17-9	2350-2352	on	_	
17-10	2353-2358	fetal	_	
17-11	2359-2370	development	_	
17-12	2371-2374	and	_	
17-13	2375-2383	neonatal	_	
17-14	2384-2397	complications	_	
17-15	2398-2402	upon	_	
17-16	2403-2411	delivery	_	
17-17	2411-2412	.	_	

#Text=Postpartum maternal substance use may also detrimentally impact child development.
18-1	2413-2423	Postpartum	_	
18-2	2424-2432	maternal	_	
18-3	2433-2442	substance	_	
18-4	2443-2446	use	_	
18-5	2447-2450	may	_	
18-6	2451-2455	also	_	
18-7	2456-2469	detrimentally	_	
18-8	2470-2476	impact	_	
18-9	2477-2482	child	_	
18-10	2483-2494	development	_	
18-11	2494-2495	.	_	

#Text=Substance-using mothers evidence less maternal sensitivity during interactions with their children as compared to non-substance-using mothers, interactions which can be marked by maternal disengagement as well as intrusiveness.
19-1	2496-2511	Substance-using	_	
19-2	2512-2519	mothers	_	
19-3	2520-2528	evidence	_	
19-4	2529-2533	less	_	
19-5	2534-2542	maternal	_	
19-6	2543-2554	sensitivity	_	
19-7	2555-2561	during	_	
19-8	2562-2574	interactions	_	
19-9	2575-2579	with	_	
19-10	2580-2585	their	_	
19-11	2586-2594	children	_	
19-12	2595-2597	as	_	
19-13	2598-2606	compared	_	
19-14	2607-2609	to	_	
19-15	2610-2629	non-substance-using	_	
19-16	2630-2637	mothers	_	
19-17	2637-2638	,	_	
19-18	2639-2651	interactions	_	
19-19	2652-2657	which	_	
19-20	2658-2661	can	_	
19-21	2662-2664	be	_	
19-22	2665-2671	marked	_	
19-23	2672-2674	by	_	
19-24	2675-2683	maternal	_	
19-25	2684-2697	disengagement	_	
19-26	2698-2700	as	_	
19-27	2701-2705	well	_	
19-28	2706-2708	as	_	
19-29	2709-2722	intrusiveness	_	
19-30	2722-2723	.	_	

#Text=Indeed, parental substance use is positively associated with child maltreatment and child welfare cases.
20-1	2724-2730	Indeed	_	
20-2	2730-2731	,	_	
20-3	2732-2740	parental	_	
20-4	2741-2750	substance	_	
20-5	2751-2754	use	_	
20-6	2755-2757	is	_	
20-7	2758-2768	positively	_	
20-8	2769-2779	associated	_	
20-9	2780-2784	with	_	
20-10	2785-2790	child	_	
20-11	2791-2803	maltreatment	_	
20-12	2804-2807	and	_	
20-13	2808-2813	child	_	
20-14	2814-2821	welfare	_	
20-15	2822-2827	cases	_	
20-16	2827-2828	.	_	

#Text=Critically, disrupted maternal care, specifically in the context of addiction, may increase children’s vulnerability for later substance use, abuse, and dependence, laying the foundation for the intergenerational transmission of addiction.
21-1	2829-2839	Critically	_	
21-2	2839-2840	,	_	
21-3	2841-2850	disrupted	_	
21-4	2851-2859	maternal	_	
21-5	2860-2864	care	_	
21-6	2864-2865	,	_	
21-7	2866-2878	specifically	_	
21-8	2879-2881	in	_	
21-9	2882-2885	the	_	
21-10	2886-2893	context	_	
21-11	2894-2896	of	_	
21-12	2897-2906	addiction	_	
21-13	2906-2907	,	_	
21-14	2908-2911	may	_	
21-15	2912-2920	increase	_	
21-16	2921-2929	children	_	
21-17	2929-2930	’	_	
21-18	2930-2931	s	_	
21-19	2932-2945	vulnerability	_	
21-20	2946-2949	for	_	
21-21	2950-2955	later	_	
21-22	2956-2965	substance	_	
21-23	2966-2969	use	_	
21-24	2969-2970	,	_	
21-25	2971-2976	abuse	_	
21-26	2976-2977	,	_	
21-27	2978-2981	and	_	
21-28	2982-2992	dependence	_	
21-29	2992-2993	,	_	
21-30	2994-3000	laying	_	
21-31	3001-3004	the	_	
21-32	3005-3015	foundation	_	
21-33	3016-3019	for	_	
21-34	3020-3023	the	_	
21-35	3024-3041	intergenerational	_	
21-36	3042-3054	transmission	_	
21-37	3055-3057	of	_	
21-38	3058-3067	addiction	_	
21-39	3067-3068	.	_	

#Text=Therefore it is of critical importance to understand mechanisms underscoring caregiving that may be impaired in mothers with substance use disorders.
22-1	3069-3078	Therefore	_	
22-2	3079-3081	it	_	
22-3	3082-3084	is	_	
22-4	3085-3087	of	_	
22-5	3088-3096	critical	_	
22-6	3097-3107	importance	_	
22-7	3108-3110	to	_	
22-8	3111-3121	understand	_	
22-9	3122-3132	mechanisms	_	
22-10	3133-3145	underscoring	_	
22-11	3146-3156	caregiving	_	
22-12	3157-3161	that	_	
22-13	3162-3165	may	_	
22-14	3166-3168	be	_	
22-15	3169-3177	impaired	_	
22-16	3178-3180	in	_	
22-17	3181-3188	mothers	_	
22-18	3189-3193	with	_	
22-19	3194-3203	substance	_	
22-20	3204-3207	use	_	
22-21	3208-3217	disorders	_	
22-22	3217-3218	.	_	

#Text=One approach to mechanistically probing variability in caregiving is at a neurobiological level through the measurement of neural responses to infant affective cues (e.g., infant faces and cries).
23-1	3219-3222	One	_	
23-2	3223-3231	approach	_	
23-3	3232-3234	to	_	
23-4	3235-3250	mechanistically	_	
23-5	3251-3258	probing	_	
23-6	3259-3270	variability	_	
23-7	3271-3273	in	_	
23-8	3274-3284	caregiving	_	
23-9	3285-3287	is	_	
23-10	3288-3290	at	_	
23-11	3291-3292	a	_	
23-12	3293-3308	neurobiological	_	
23-13	3309-3314	level	_	
23-14	3315-3322	through	_	
23-15	3323-3326	the	_	
23-16	3327-3338	measurement	_	
23-17	3339-3341	of	_	
23-18	3342-3348	neural	_	
23-19	3349-3358	responses	_	
23-20	3359-3361	to	_	
23-21	3362-3368	infant	_	
23-22	3369-3378	affective	_	
23-23	3379-3383	cues	_	
23-24	3384-3385	(	_	
23-25	3385-3388	e.g	_	
23-26	3388-3389	.	_	
23-27	3389-3390	,	_	
23-28	3391-3397	infant	_	
23-29	3398-3403	faces	_	
23-30	3404-3407	and	_	
23-31	3408-3413	cries	_	
23-32	3413-3414	)	_	
23-33	3414-3415	.	_	

#Text=This approach provides insight into the neural mechanisms that may mediate optimal caregiving and suggest new directions for interventions to support parents in their caregiving role.
24-1	3416-3420	This	_	
24-2	3421-3429	approach	_	
24-3	3430-3438	provides	_	
24-4	3439-3446	insight	_	
24-5	3447-3451	into	_	
24-6	3452-3455	the	_	
24-7	3456-3462	neural	_	
24-8	3463-3473	mechanisms	_	
24-9	3474-3478	that	_	
24-10	3479-3482	may	_	
24-11	3483-3490	mediate	_	
24-12	3491-3498	optimal	_	
24-13	3499-3509	caregiving	_	
24-14	3510-3513	and	_	
24-15	3514-3521	suggest	_	
24-16	3522-3525	new	_	
24-17	3526-3536	directions	_	
24-18	3537-3540	for	_	
24-19	3541-3554	interventions	_	
24-20	3555-3557	to	_	
24-21	3558-3565	support	_	
24-22	3566-3573	parents	_	
24-23	3574-3576	in	_	
24-24	3577-3582	their	_	
24-25	3583-3593	caregiving	_	
24-26	3594-3598	role	_	
24-27	3598-3599	.	_	

#Text=In particular, given the typically positively valenced nature of mother-infant interactions, attention has been focused on regions implicated in reward processing at cortical (e.g., prefrontal cortex, PFC) and subcortical (e.g., striatum) levels, particularly when mothers view photographs of their own infant’s emotional facial expressions.
25-1	3600-3602	In	_	
25-2	3603-3613	particular	_	
25-3	3613-3614	,	_	
25-4	3615-3620	given	_	
25-5	3621-3624	the	_	
25-6	3625-3634	typically	_	
25-7	3635-3645	positively	_	
25-8	3646-3654	valenced	_	
25-9	3655-3661	nature	_	
25-10	3662-3664	of	_	
25-11	3665-3678	mother-infant	_	
25-12	3679-3691	interactions	_	
25-13	3691-3692	,	_	
25-14	3693-3702	attention	_	
25-15	3703-3706	has	_	
25-16	3707-3711	been	_	
25-17	3712-3719	focused	_	
25-18	3720-3722	on	_	
25-19	3723-3730	regions	_	
25-20	3731-3741	implicated	_	
25-21	3742-3744	in	_	
25-22	3745-3751	reward	_	
25-23	3752-3762	processing	_	
25-24	3763-3765	at	_	
25-25	3766-3774	cortical	_	
25-26	3775-3776	(	_	
25-27	3776-3779	e.g	_	
25-28	3779-3780	.	_	
25-29	3780-3781	,	_	
25-30	3782-3792	prefrontal	_	
25-31	3793-3799	cortex	_	
25-32	3799-3800	,	_	
25-33	3801-3804	PFC	_	
25-34	3804-3805	)	_	
25-35	3806-3809	and	_	
25-36	3810-3821	subcortical	_	
25-37	3822-3823	(	_	
25-38	3823-3826	e.g	_	
25-39	3826-3827	.	_	
25-40	3827-3828	,	_	
25-41	3829-3837	striatum	_	
25-42	3837-3838	)	_	
25-43	3839-3845	levels	_	
25-44	3845-3846	,	_	
25-45	3847-3859	particularly	_	
25-46	3860-3864	when	_	
25-47	3865-3872	mothers	_	
25-48	3873-3877	view	_	
25-49	3878-3889	photographs	_	
25-50	3890-3892	of	_	
25-51	3893-3898	their	_	
25-52	3899-3902	own	_	
25-53	3903-3909	infant	_	
25-54	3909-3910	’	_	
25-55	3910-3911	s	_	
25-56	3912-3921	emotional	_	
25-57	3922-3928	facial	_	
25-58	3929-3940	expressions	_	
25-59	3940-3941	.	_	

#Text=For instance, in non-substance-using mothers, viewing their own infant’s face, as compared to an unknown infant’s face, multiple brain regions are activated, including the striatum, substantia nigra, prefrontal cortex (PFC), and insula.
26-1	3942-3945	For	_	
26-2	3946-3954	instance	_	
26-3	3954-3955	,	_	
26-4	3956-3958	in	_	
26-5	3959-3978	non-substance-using	_	
26-6	3979-3986	mothers	_	
26-7	3986-3987	,	_	
26-8	3988-3995	viewing	_	
26-9	3996-4001	their	_	
26-10	4002-4005	own	_	
26-11	4006-4012	infant	_	
26-12	4012-4013	’	_	
26-13	4013-4014	s	_	
26-14	4015-4019	face	_	
26-15	4019-4020	,	_	
26-16	4021-4023	as	_	
26-17	4024-4032	compared	_	
26-18	4033-4035	to	_	
26-19	4036-4038	an	_	
26-20	4039-4046	unknown	_	
26-21	4047-4053	infant	_	
26-22	4053-4054	’	_	
26-23	4054-4055	s	_	
26-24	4056-4060	face	_	
26-25	4060-4061	,	_	
26-26	4062-4070	multiple	_	
26-27	4071-4076	brain	_	
26-28	4077-4084	regions	_	
26-29	4085-4088	are	_	
26-30	4089-4098	activated	_	
26-31	4098-4099	,	_	
26-32	4100-4109	including	_	
26-33	4110-4113	the	_	
26-34	4114-4122	striatum	_	
26-35	4122-4123	,	_	
26-36	4124-4134	substantia	_	
26-37	4135-4140	nigra	_	
26-38	4140-4141	,	_	
26-39	4142-4152	prefrontal	_	
26-40	4153-4159	cortex	_	
26-41	4160-4161	(	_	
26-42	4161-4164	PFC	_	
26-43	4164-4165	)	_	
26-44	4165-4166	,	_	
26-45	4167-4170	and	_	
26-46	4171-4177	insula	_	
26-47	4177-4178	.	_	

#Text=Similarly, when listening to infant vocalizations, parents can be distinguished from non-parents by brain activation in the amygdala, ventral PFC, and insula, regions implicated in cognition and emotion.
27-1	4179-4188	Similarly	_	
27-2	4188-4189	,	_	
27-3	4190-4194	when	_	
27-4	4195-4204	listening	_	
27-5	4205-4207	to	_	
27-6	4208-4214	infant	_	
27-7	4215-4228	vocalizations	_	
27-8	4228-4229	,	_	
27-9	4230-4237	parents	_	
27-10	4238-4241	can	_	
27-11	4242-4244	be	_	
27-12	4245-4258	distinguished	_	
27-13	4259-4263	from	_	
27-14	4264-4275	non-parents	_	
27-15	4276-4278	by	_	
27-16	4279-4284	brain	_	
27-17	4285-4295	activation	_	
27-18	4296-4298	in	_	
27-19	4299-4302	the	_	
27-20	4303-4311	amygdala	_	
27-21	4311-4312	,	_	
27-22	4313-4320	ventral	_	
27-23	4321-4324	PFC	_	
27-24	4324-4325	,	_	
27-25	4326-4329	and	_	
27-26	4330-4336	insula	_	
27-27	4336-4337	,	_	
27-28	4338-4345	regions	_	
27-29	4346-4356	implicated	_	
27-30	4357-4359	in	_	
27-31	4360-4369	cognition	_	
27-32	4370-4373	and	_	
27-33	4374-4381	emotion	_	
27-34	4381-4382	.	_	

#Text=Thus, accumulating research indicates encoding of maternal responsiveness by corticolimbic brain regions.
28-1	4383-4387	Thus	_	
28-2	4387-4388	,	_	
28-3	4389-4401	accumulating	_	
28-4	4402-4410	research	_	
28-5	4411-4420	indicates	_	
28-6	4421-4429	encoding	_	
28-7	4430-4432	of	_	
28-8	4433-4441	maternal	_	
28-9	4442-4456	responsiveness	_	
28-10	4457-4459	by	_	
28-11	4460-4473	corticolimbic	_	
28-12	4474-4479	brain	_	
28-13	4480-4487	regions	_	
28-14	4487-4488	.	_	

#Text=However, brain regions engaged by these affective infant cues, particularly those implicated in reward and stress reactivity and regulation (e.g., ventral striatum, PFC, amygdala), are also affected by addiction.
29-1	4489-4496	However	_	
29-2	4496-4497	,	_	
29-3	4498-4503	brain	_	
29-4	4504-4511	regions	_	
29-5	4512-4519	engaged	_	
29-6	4520-4522	by	_	
29-7	4523-4528	these	_	
29-8	4529-4538	affective	_	
29-9	4539-4545	infant	_	
29-10	4546-4550	cues	_	
29-11	4550-4551	,	_	
29-12	4552-4564	particularly	_	
29-13	4565-4570	those	_	
29-14	4571-4581	implicated	_	
29-15	4582-4584	in	_	
29-16	4585-4591	reward	_	
29-17	4592-4595	and	_	
29-18	4596-4602	stress	_	
29-19	4603-4613	reactivity	_	
29-20	4614-4617	and	_	
29-21	4618-4628	regulation	_	
29-22	4629-4630	(	_	
29-23	4630-4633	e.g	_	
29-24	4633-4634	.	_	
29-25	4634-4635	,	_	
29-26	4636-4643	ventral	_	
29-27	4644-4652	striatum	_	
29-28	4652-4653	,	_	
29-29	4654-4657	PFC	_	
29-30	4657-4658	,	_	
29-31	4659-4667	amygdala	_	
29-32	4667-4668	)	_	
29-33	4668-4669	,	_	
29-34	4670-4673	are	_	
29-35	4674-4678	also	_	
29-36	4679-4687	affected	_	
29-37	4688-4690	by	_	
29-38	4691-4700	addiction	_	
29-39	4700-4701	.	_	

#Text=Therefore, it has been hypothesized that behavioral caregiving difficulties experienced by substance-using mothers may in part relate to dysregulation of these neural circuits in addiction, engendering caregiving to be less pleasurable and more stressful.
30-1	4702-4711	Therefore	_	
30-2	4711-4712	,	_	
30-3	4713-4715	it	_	
30-4	4716-4719	has	_	
30-5	4720-4724	been	_	
30-6	4725-4737	hypothesized	_	
30-7	4738-4742	that	_	
30-8	4743-4753	behavioral	_	
30-9	4754-4764	caregiving	_	
30-10	4765-4777	difficulties	_	
30-11	4778-4789	experienced	_	
30-12	4790-4792	by	_	
30-13	4793-4808	substance-using	_	
30-14	4809-4816	mothers	_	
30-15	4817-4820	may	_	
30-16	4821-4823	in	_	
30-17	4824-4828	part	_	
30-18	4829-4835	relate	_	
30-19	4836-4838	to	_	
30-20	4839-4852	dysregulation	_	
30-21	4853-4855	of	_	
30-22	4856-4861	these	_	
30-23	4862-4868	neural	_	
30-24	4869-4877	circuits	_	
30-25	4878-4880	in	_	
30-26	4881-4890	addiction	_	
30-27	4890-4891	,	_	
30-28	4892-4903	engendering	_	
30-29	4904-4914	caregiving	_	
30-30	4915-4917	to	_	
30-31	4918-4920	be	_	
30-32	4921-4925	less	_	
30-33	4926-4937	pleasurable	_	
30-34	4938-4941	and	_	
30-35	4942-4946	more	_	
30-36	4947-4956	stressful	_	
30-37	4956-4957	.	_	

#Text=Only two fMRI studies to date have specifically examined associations between maternal substance use and the neural correlates of the processing of infant cues to test this proposed reward-stress account of addiction and parenting. presented recent mothers with affective cues of unknown infants; specifically, happy, sad, and neutral infant faces as well as high- and low-distress infant cries.
31-1	4958-4962	Only	_	
31-2	4963-4966	two	_	
31-3	4967-4971	fMRI	_	
31-4	4972-4979	studies	_	
31-5	4980-4982	to	_	
31-6	4983-4987	date	_	
31-7	4988-4992	have	_	
31-8	4993-5005	specifically	_	
31-9	5006-5014	examined	_	
31-10	5015-5027	associations	_	
31-11	5028-5035	between	_	
31-12	5036-5044	maternal	_	
31-13	5045-5054	substance	_	
31-14	5055-5058	use	_	
31-15	5059-5062	and	_	
31-16	5063-5066	the	_	
31-17	5067-5073	neural	_	
31-18	5074-5084	correlates	_	
31-19	5085-5087	of	_	
31-20	5088-5091	the	_	
31-21	5092-5102	processing	_	
31-22	5103-5105	of	_	
31-23	5106-5112	infant	_	
31-24	5113-5117	cues	_	
31-25	5118-5120	to	_	
31-26	5121-5125	test	_	
31-27	5126-5130	this	_	
31-28	5131-5139	proposed	_	
31-29	5140-5153	reward-stress	_	
31-30	5154-5161	account	_	
31-31	5162-5164	of	_	
31-32	5165-5174	addiction	_	
31-33	5175-5178	and	_	
31-34	5179-5188	parenting	_	
31-35	5188-5189	.	_	
31-36	5190-5199	presented	_	
31-37	5200-5206	recent	_	
31-38	5207-5214	mothers	_	
31-39	5215-5219	with	_	
31-40	5220-5229	affective	_	
31-41	5230-5234	cues	_	
31-42	5235-5237	of	_	
31-43	5238-5245	unknown	_	
31-44	5246-5253	infants	_	
31-45	5253-5254	;	_	
31-46	5255-5267	specifically	_	
31-47	5267-5268	,	_	
31-48	5269-5274	happy	_	
31-49	5274-5275	,	_	
31-50	5276-5279	sad	_	
31-51	5279-5280	,	_	
31-52	5281-5284	and	_	
31-53	5285-5292	neutral	_	
31-54	5293-5299	infant	_	
31-55	5300-5305	faces	_	
31-56	5306-5308	as	_	
31-57	5309-5313	well	_	
31-58	5314-5316	as	_	
31-59	5317-5321	high	_	
31-60	5321-5322	-	_	
31-61	5323-5326	and	_	
31-62	5327-5339	low-distress	_	
31-63	5340-5346	infant	_	
31-64	5347-5352	cries	_	
31-65	5352-5353	.	_	

#Text=This investigation studied mothers with poly-substance use, which included use and abuse of licit and illicit drugs.
32-1	5354-5358	This	_	
32-2	5359-5372	investigation	_	
32-3	5373-5380	studied	_	
32-4	5381-5388	mothers	_	
32-5	5389-5393	with	_	
32-6	5394-5408	poly-substance	_	
32-7	5409-5412	use	_	
32-8	5412-5413	,	_	
32-9	5414-5419	which	_	
32-10	5420-5428	included	_	
32-11	5429-5432	use	_	
32-12	5433-5436	and	_	
32-13	5437-5442	abuse	_	
32-14	5443-5445	of	_	
32-15	5446-5451	licit	_	
32-16	5452-5455	and	_	
32-17	5456-5463	illicit	_	
32-18	5464-5469	drugs	_	
32-19	5469-5470	.	_	

#Text=Across all infant facial expressions, relative to non-substance-using mothers, substance-using mothers had decreased activation in the dorsolateral and ventromedial PFC, occipital lobes, and parahippocampus, and amygdala.
33-1	5471-5477	Across	_	
33-2	5478-5481	all	_	
33-3	5482-5488	infant	_	
33-4	5489-5495	facial	_	
33-5	5496-5507	expressions	_	
33-6	5507-5508	,	_	
33-7	5509-5517	relative	_	
33-8	5518-5520	to	_	
33-9	5521-5540	non-substance-using	_	
33-10	5541-5548	mothers	_	
33-11	5548-5549	,	_	
33-12	5550-5565	substance-using	_	
33-13	5566-5573	mothers	_	
33-14	5574-5577	had	_	
33-15	5578-5587	decreased	_	
33-16	5588-5598	activation	_	
33-17	5599-5601	in	_	
33-18	5602-5605	the	_	
33-19	5606-5618	dorsolateral	_	
33-20	5619-5622	and	_	
33-21	5623-5635	ventromedial	_	
33-22	5636-5639	PFC	_	
33-23	5639-5640	,	_	
33-24	5641-5650	occipital	_	
33-25	5651-5656	lobes	_	
33-26	5656-5657	,	_	
33-27	5658-5661	and	_	
33-28	5662-5677	parahippocampus	_	
33-29	5677-5678	,	_	
33-30	5679-5682	and	_	
33-31	5683-5691	amygdala	_	
33-32	5691-5692	.	_	

#Text=Maternal substance use was also associated with reduced activation in response to infant cries, again in prefrontal regions, auditory regions, insula, parahippocampus, and amygdala.
34-1	5693-5701	Maternal	_	
34-2	5702-5711	substance	_	
34-3	5712-5715	use	_	
34-4	5716-5719	was	_	
34-5	5720-5724	also	_	
34-6	5725-5735	associated	_	
34-7	5736-5740	with	_	
34-8	5741-5748	reduced	_	
34-9	5749-5759	activation	_	
34-10	5760-5762	in	_	
34-11	5763-5771	response	_	
34-12	5772-5774	to	_	
34-13	5775-5781	infant	_	
34-14	5782-5787	cries	_	
34-15	5787-5788	,	_	
34-16	5789-5794	again	_	
34-17	5795-5797	in	_	
34-18	5798-5808	prefrontal	_	
34-19	5809-5816	regions	_	
34-20	5816-5817	,	_	
34-21	5818-5826	auditory	_	
34-22	5827-5834	regions	_	
34-23	5834-5835	,	_	
34-24	5836-5842	insula	_	
34-25	5842-5843	,	_	
34-26	5844-5859	parahippocampus	_	
34-27	5859-5860	,	_	
34-28	5861-5864	and	_	
34-29	5865-5873	amygdala	_	
34-30	5873-5874	.	_	

#Text=Taken together, these findings converge with the notion that maternal substance use may be associated with unknown affective infant cues having decreased salience.
35-1	5875-5880	Taken	_	
35-2	5881-5889	together	_	
35-3	5889-5890	,	_	
35-4	5891-5896	these	_	
35-5	5897-5905	findings	_	
35-6	5906-5914	converge	_	
35-7	5915-5919	with	_	
35-8	5920-5923	the	_	
35-9	5924-5930	notion	_	
35-10	5931-5935	that	_	
35-11	5936-5944	maternal	_	
35-12	5945-5954	substance	_	
35-13	5955-5958	use	_	
35-14	5959-5962	may	_	
35-15	5963-5965	be	_	
35-16	5966-5976	associated	_	
35-17	5977-5981	with	_	
35-18	5982-5989	unknown	_	
35-19	5990-5999	affective	_	
35-20	6000-6006	infant	_	
35-21	6007-6011	cues	_	
35-22	6012-6018	having	_	
35-23	6019-6028	decreased	_	
35-24	6029-6037	salience	_	
35-25	6037-6038	.	_	

#Text=Building on this work, examined neural responses to emotional infant faces in mothers receiving inpatient treatment for substance-use disorders.
36-1	6039-6047	Building	_	
36-2	6048-6050	on	_	
36-3	6051-6055	this	_	
36-4	6056-6060	work	_	
36-5	6060-6061	,	_	
36-6	6062-6070	examined	_	
36-7	6071-6077	neural	_	
36-8	6078-6087	responses	_	
36-9	6088-6090	to	_	
36-10	6091-6100	emotional	_	
36-11	6101-6107	infant	_	
36-12	6108-6113	faces	_	
36-13	6114-6116	in	_	
36-14	6117-6124	mothers	_	
36-15	6125-6134	receiving	_	
36-16	6135-6144	inpatient	_	
36-17	6145-6154	treatment	_	
36-18	6155-6158	for	_	
36-19	6159-6172	substance-use	_	
36-20	6173-6182	disorders	_	
36-21	6182-6183	.	_	

#Text=Infant face stimuli presented to mothers were either their own infant’s face, or an unknown demographically matched infant’s face.
37-1	6184-6190	Infant	_	
37-2	6191-6195	face	_	
37-3	6196-6203	stimuli	_	
37-4	6204-6213	presented	_	
37-5	6214-6216	to	_	
37-6	6217-6224	mothers	_	
37-7	6225-6229	were	_	
37-8	6230-6236	either	_	
37-9	6237-6242	their	_	
37-10	6243-6246	own	_	
37-11	6247-6253	infant	_	
37-12	6253-6254	’	_	
37-13	6254-6255	s	_	
37-14	6256-6260	face	_	
37-15	6260-6261	,	_	
37-16	6262-6264	or	_	
37-17	6265-6267	an	_	
37-18	6268-6275	unknown	_	
37-19	6276-6291	demographically	_	
37-20	6292-6299	matched	_	
37-21	6300-6306	infant	_	
37-22	6306-6307	’	_	
37-23	6307-6308	s	_	
37-24	6309-6313	face	_	
37-25	6313-6314	.	_	

#Text=When viewing their own infant’s happy face, relative to the unknown infant’s happy face, decreased activation was observed in the ventromedial PFC, hypothalamus, and ventral striatum.
38-1	6315-6319	When	_	
38-2	6320-6327	viewing	_	
38-3	6328-6333	their	_	
38-4	6334-6337	own	_	
38-5	6338-6344	infant	_	
38-6	6344-6345	’	_	
38-7	6345-6346	s	_	
38-8	6347-6352	happy	_	
38-9	6353-6357	face	_	
38-10	6357-6358	,	_	
38-11	6359-6367	relative	_	
38-12	6368-6370	to	_	
38-13	6371-6374	the	_	
38-14	6375-6382	unknown	_	
38-15	6383-6389	infant	_	
38-16	6389-6390	’	_	
38-17	6390-6391	s	_	
38-18	6392-6397	happy	_	
38-19	6398-6402	face	_	
38-20	6402-6403	,	_	
38-21	6404-6413	decreased	_	
38-22	6414-6424	activation	_	
38-23	6425-6428	was	_	
38-24	6429-6437	observed	_	
38-25	6438-6440	in	_	
38-26	6441-6444	the	_	
38-27	6445-6457	ventromedial	_	
38-28	6458-6461	PFC	_	
38-29	6461-6462	,	_	
38-30	6463-6475	hypothalamus	_	
38-31	6475-6476	,	_	
38-32	6477-6480	and	_	
38-33	6481-6488	ventral	_	
38-34	6489-6497	striatum	_	
38-35	6497-6498	.	_	

#Text=However, increased activation to own, as compared to unknown, happy faces was observed across multiple regions, including in the amygdala, hippocampus, thalamus, cingulate, inferior frontal gyrus, insula, ventral premotor cortex, and cerebellum.
39-1	6499-6506	However	_	
39-2	6506-6507	,	_	
39-3	6508-6517	increased	_	
39-4	6518-6528	activation	_	
39-5	6529-6531	to	_	
39-6	6532-6535	own	_	
39-7	6535-6536	,	_	
39-8	6537-6539	as	_	
39-9	6540-6548	compared	_	
39-10	6549-6551	to	_	
39-11	6552-6559	unknown	_	
39-12	6559-6560	,	_	
39-13	6561-6566	happy	_	
39-14	6567-6572	faces	_	
39-15	6573-6576	was	_	
39-16	6577-6585	observed	_	
39-17	6586-6592	across	_	
39-18	6593-6601	multiple	_	
39-19	6602-6609	regions	_	
39-20	6609-6610	,	_	
39-21	6611-6620	including	_	
39-22	6621-6623	in	_	
39-23	6624-6627	the	_	
39-24	6628-6636	amygdala	_	
39-25	6636-6637	,	_	
39-26	6638-6649	hippocampus	_	
39-27	6649-6650	,	_	
39-28	6651-6659	thalamus	_	
39-29	6659-6660	,	_	
39-30	6661-6670	cingulate	_	
39-31	6670-6671	,	_	
39-32	6672-6680	inferior	_	
39-33	6681-6688	frontal	_	
39-34	6689-6694	gyrus	_	
39-35	6694-6695	,	_	
39-36	6696-6702	insula	_	
39-37	6702-6703	,	_	
39-38	6704-6711	ventral	_	
39-39	6712-6720	premotor	_	
39-40	6721-6727	cortex	_	
39-41	6727-6728	,	_	
39-42	6729-6732	and	_	
39-43	6733-6743	cerebellum	_	
39-44	6743-6744	.	_	

#Text=Finally, increased activation to own, as compared to unknown, sad infant faces was observed in overlapping regions responsive to happy infant faces, including the thalamus, cingulate, inferior frontal gyrus, and cerebellum.
40-1	6745-6752	Finally	_	
40-2	6752-6753	,	_	
40-3	6754-6763	increased	_	
40-4	6764-6774	activation	_	
40-5	6775-6777	to	_	
40-6	6778-6781	own	_	
40-7	6781-6782	,	_	
40-8	6783-6785	as	_	
40-9	6786-6794	compared	_	
40-10	6795-6797	to	_	
40-11	6798-6805	unknown	_	
40-12	6805-6806	,	_	
40-13	6807-6810	sad	_	
40-14	6811-6817	infant	_	
40-15	6818-6823	faces	_	
40-16	6824-6827	was	_	
40-17	6828-6836	observed	_	
40-18	6837-6839	in	_	
40-19	6840-6851	overlapping	_	
40-20	6852-6859	regions	_	
40-21	6860-6870	responsive	_	
40-22	6871-6873	to	_	
40-23	6874-6879	happy	_	
40-24	6880-6886	infant	_	
40-25	6887-6892	faces	_	
40-26	6892-6893	,	_	
40-27	6894-6903	including	_	
40-28	6904-6907	the	_	
40-29	6908-6916	thalamus	_	
40-30	6916-6917	,	_	
40-31	6918-6927	cingulate	_	
40-32	6927-6928	,	_	
40-33	6929-6937	inferior	_	
40-34	6938-6945	frontal	_	
40-35	6946-6951	gyrus	_	
40-36	6951-6952	,	_	
40-37	6953-6956	and	_	
40-38	6957-6967	cerebellum	_	
40-39	6967-6968	.	_	

#Text=In sum, mothers in treatment for addiction evidenced a decreased response to their own infant’s happy expressions in regions implicated in reward processing; however, increased activation towards own happy and sad expressions were also observed across regions implicated in emotional, motoric, and cognitive processes/functions.
41-1	6969-6971	In	_	
41-2	6972-6975	sum	_	
41-3	6975-6976	,	_	
41-4	6977-6984	mothers	_	
41-5	6985-6987	in	_	
41-6	6988-6997	treatment	_	
41-7	6998-7001	for	_	
41-8	7002-7011	addiction	_	
41-9	7012-7021	evidenced	_	
41-10	7022-7023	a	_	
41-11	7024-7033	decreased	_	
41-12	7034-7042	response	_	
41-13	7043-7045	to	_	
41-14	7046-7051	their	_	
41-15	7052-7055	own	_	
41-16	7056-7062	infant	_	
41-17	7062-7063	’	_	
41-18	7063-7064	s	_	
41-19	7065-7070	happy	_	
41-20	7071-7082	expressions	_	
41-21	7083-7085	in	_	
41-22	7086-7093	regions	_	
41-23	7094-7104	implicated	_	
41-24	7105-7107	in	_	
41-25	7108-7114	reward	_	
41-26	7115-7125	processing	_	
41-27	7125-7126	;	_	
41-28	7127-7134	however	_	
41-29	7134-7135	,	_	
41-30	7136-7145	increased	_	
41-31	7146-7156	activation	_	
41-32	7157-7164	towards	_	
41-33	7165-7168	own	_	
41-34	7169-7174	happy	_	
41-35	7175-7178	and	_	
41-36	7179-7182	sad	_	
41-37	7183-7194	expressions	_	
41-38	7195-7199	were	_	
41-39	7200-7204	also	_	
41-40	7205-7213	observed	_	
41-41	7214-7220	across	_	
41-42	7221-7228	regions	_	
41-43	7229-7239	implicated	_	
41-44	7240-7242	in	_	
41-45	7243-7252	emotional	_	
41-46	7252-7253	,	_	
41-47	7254-7261	motoric	_	
41-48	7261-7262	,	_	
41-49	7263-7266	and	_	
41-50	7267-7276	cognitive	_	
41-51	7277-7286	processes	_	
41-52	7286-7287	/	_	
41-53	7287-7296	functions	_	
41-54	7296-7297	.	_	

#Text=Consistent with neurobiological models of addiction and parenting, research suggests that maternal substance use and addiction may be associated with neural processing of affective infant cues.
42-1	7298-7308	Consistent	_	
42-2	7309-7313	with	_	
42-3	7314-7329	neurobiological	_	
42-4	7330-7336	models	_	
42-5	7337-7339	of	_	
42-6	7340-7349	addiction	_	
42-7	7350-7353	and	_	
42-8	7354-7363	parenting	_	
42-9	7363-7364	,	_	
42-10	7365-7373	research	_	
42-11	7374-7382	suggests	_	
42-12	7383-7387	that	_	
42-13	7388-7396	maternal	_	
42-14	7397-7406	substance	_	
42-15	7407-7410	use	_	
42-16	7411-7414	and	_	
42-17	7415-7424	addiction	_	
42-18	7425-7428	may	_	
42-19	7429-7431	be	_	
42-20	7432-7442	associated	_	
42-21	7443-7447	with	_	
42-22	7448-7454	neural	_	
42-23	7455-7465	processing	_	
42-24	7466-7468	of	_	
42-25	7469-7478	affective	_	
42-26	7479-7485	infant	_	
42-27	7486-7490	cues	_	
42-28	7490-7491	.	_	

#Text=However, no study to date has examined responding to own and unknown infant faces and cries in substance-using and non-substance-using mothers.
43-1	7492-7499	However	_	
43-2	7499-7500	,	_	
43-3	7501-7503	no	_	
43-4	7504-7509	study	_	
43-5	7510-7512	to	_	
43-6	7513-7517	date	_	
43-7	7518-7521	has	_	
43-8	7522-7530	examined	_	
43-9	7531-7541	responding	_	
43-10	7542-7544	to	_	
43-11	7545-7548	own	_	
43-12	7549-7552	and	_	
43-13	7553-7560	unknown	_	
43-14	7561-7567	infant	_	
43-15	7568-7573	faces	_	
43-16	7574-7577	and	_	
43-17	7578-7583	cries	_	
43-18	7584-7586	in	_	
43-19	7587-7602	substance-using	_	
43-20	7603-7606	and	_	
43-21	7607-7626	non-substance-using	_	
43-22	7627-7634	mothers	_	
43-23	7634-7635	.	_	

#Text=Incorporating own and unknown infant affective stimuli is particularly important to probe the interpersonal importance of maternal brain responding.
44-1	7636-7649	Incorporating	_	
44-2	7650-7653	own	_	
44-3	7654-7657	and	_	
44-4	7658-7665	unknown	_	
44-5	7666-7672	infant	_	
44-6	7673-7682	affective	_	
44-7	7683-7690	stimuli	_	
44-8	7691-7693	is	_	
44-9	7694-7706	particularly	_	
44-10	7707-7716	important	_	
44-11	7717-7719	to	_	
44-12	7720-7725	probe	_	
44-13	7726-7729	the	_	
44-14	7730-7743	interpersonal	_	
44-15	7744-7754	importance	_	
44-16	7755-7757	of	_	
44-17	7758-7766	maternal	_	
44-18	7767-7772	brain	_	
44-19	7773-7783	responding	_	
44-20	7783-7784	.	_	

#Text=Therefore, in the current study we presented mothers with happy and sad infant faces and cries from their own and an unknown infant and measured whether regional brain responses to these affective infant cues varied by maternal substance use status (present, absent).
45-1	7785-7794	Therefore	_	
45-2	7794-7795	,	_	
45-3	7796-7798	in	_	
45-4	7799-7802	the	_	
45-5	7803-7810	current	_	
45-6	7811-7816	study	_	
45-7	7817-7819	we	_	
45-8	7820-7829	presented	_	
45-9	7830-7837	mothers	_	
45-10	7838-7842	with	_	
45-11	7843-7848	happy	_	
45-12	7849-7852	and	_	
45-13	7853-7856	sad	_	
45-14	7857-7863	infant	_	
45-15	7864-7869	faces	_	
45-16	7870-7873	and	_	
45-17	7874-7879	cries	_	
45-18	7880-7884	from	_	
45-19	7885-7890	their	_	
45-20	7891-7894	own	_	
45-21	7895-7898	and	_	
45-22	7899-7901	an	_	
45-23	7902-7909	unknown	_	
45-24	7910-7916	infant	_	
45-25	7917-7920	and	_	
45-26	7921-7929	measured	_	
45-27	7930-7937	whether	_	
45-28	7938-7946	regional	_	
45-29	7947-7952	brain	_	
45-30	7953-7962	responses	_	
45-31	7963-7965	to	_	
45-32	7966-7971	these	_	
45-33	7972-7981	affective	_	
45-34	7982-7988	infant	_	
45-35	7989-7993	cues	_	
45-36	7994-8000	varied	_	
45-37	8001-8003	by	_	
45-38	8004-8012	maternal	_	
45-39	8013-8022	substance	_	
45-40	8023-8026	use	_	
45-41	8027-8033	status	_	
45-42	8034-8035	(	_	
45-43	8035-8042	present	_	
45-44	8042-8043	,	_	
45-45	8044-8050	absent	_	
45-46	8050-8051	)	_	
45-47	8051-8052	.	_	

#Text=Consistent with prior research, we hypothesized that, as compared to non-substance-using mothers, substance-using mothers would evidence: (1) decreased reactivity to affective cues from unknown infants across prefrontal, sensory, and limbic regions (i.e.,); and, (2) decreased reactivity to own as compared to unknown infant faces, particularly when happy in expression, in regions implicated in reward processing (i.e.,).
46-1	8053-8063	Consistent	_	
46-2	8064-8068	with	_	
46-3	8069-8074	prior	_	
46-4	8075-8083	research	_	
46-5	8083-8084	,	_	
46-6	8085-8087	we	_	
46-7	8088-8100	hypothesized	_	
46-8	8101-8105	that	_	
46-9	8105-8106	,	_	
46-10	8107-8109	as	_	
46-11	8110-8118	compared	_	
46-12	8119-8121	to	_	
46-13	8122-8141	non-substance-using	_	
46-14	8142-8149	mothers	_	
46-15	8149-8150	,	_	
46-16	8151-8166	substance-using	_	
46-17	8167-8174	mothers	_	
46-18	8175-8180	would	_	
46-19	8181-8189	evidence	_	
46-20	8189-8190	:	_	
46-21	8191-8192	(	_	
46-22	8192-8193	1	_	
46-23	8193-8194	)	_	
46-24	8195-8204	decreased	_	
46-25	8205-8215	reactivity	_	
46-26	8216-8218	to	_	
46-27	8219-8228	affective	_	
46-28	8229-8233	cues	_	
46-29	8234-8238	from	_	
46-30	8239-8246	unknown	_	
46-31	8247-8254	infants	_	
46-32	8255-8261	across	_	
46-33	8262-8272	prefrontal	_	
46-34	8272-8273	,	_	
46-35	8274-8281	sensory	_	
46-36	8281-8282	,	_	
46-37	8283-8286	and	_	
46-38	8287-8293	limbic	_	
46-39	8294-8301	regions	_	
46-40	8302-8303	(	_	
46-41	8303-8306	i.e	_	
46-42	8306-8307	.	_	
46-43	8307-8308	,	_	
46-44	8308-8309	)	_	
46-45	8309-8310	;	_	
46-46	8311-8314	and	_	
46-47	8314-8315	,	_	
46-48	8316-8317	(	_	
46-49	8317-8318	2	_	
46-50	8318-8319	)	_	
46-51	8320-8329	decreased	_	
46-52	8330-8340	reactivity	_	
46-53	8341-8343	to	_	
46-54	8344-8347	own	_	
46-55	8348-8350	as	_	
46-56	8351-8359	compared	_	
46-57	8360-8362	to	_	
46-58	8363-8370	unknown	_	
46-59	8371-8377	infant	_	
46-60	8378-8383	faces	_	
46-61	8383-8384	,	_	
46-62	8385-8397	particularly	_	
46-63	8398-8402	when	_	
46-64	8403-8408	happy	_	
46-65	8409-8411	in	_	
46-66	8412-8422	expression	_	
46-67	8422-8423	,	_	
46-68	8424-8426	in	_	
46-69	8427-8434	regions	_	
46-70	8435-8445	implicated	_	
46-71	8446-8448	in	_	
46-72	8449-8455	reward	_	
46-73	8456-8466	processing	_	
46-74	8467-8468	(	_	
46-75	8468-8471	i.e	_	
46-76	8471-8472	.	_	
46-77	8472-8473	,	_	
46-78	8473-8474	)	_	
46-79	8474-8475	.	_	

#Text=We also hypothesized that substance-using mothers, relative to the non-substance-using mothers, would evidence: (3) increased activation in response to own infant face and cry stimuli in regions implicated in emotional and cognitive processes, including the amygdala, cingulate, inferior frontal gyrus, and insula (i.e.,).
47-1	8476-8478	We	_	
47-2	8479-8483	also	_	
47-3	8484-8496	hypothesized	_	
47-4	8497-8501	that	_	
47-5	8502-8517	substance-using	_	
47-6	8518-8525	mothers	_	
47-7	8525-8526	,	_	
47-8	8527-8535	relative	_	
47-9	8536-8538	to	_	
47-10	8539-8542	the	_	
47-11	8543-8562	non-substance-using	_	
47-12	8563-8570	mothers	_	
47-13	8570-8571	,	_	
47-14	8572-8577	would	_	
47-15	8578-8586	evidence	_	
47-16	8586-8587	:	_	
47-17	8588-8589	(	_	
47-18	8589-8590	3	_	
47-19	8590-8591	)	_	
47-20	8592-8601	increased	_	
47-21	8602-8612	activation	_	
47-22	8613-8615	in	_	
47-23	8616-8624	response	_	
47-24	8625-8627	to	_	
47-25	8628-8631	own	_	
47-26	8632-8638	infant	_	
47-27	8639-8643	face	_	
47-28	8644-8647	and	_	
47-29	8648-8651	cry	_	
47-30	8652-8659	stimuli	_	
47-31	8660-8662	in	_	
47-32	8663-8670	regions	_	
47-33	8671-8681	implicated	_	
47-34	8682-8684	in	_	
47-35	8685-8694	emotional	_	
47-36	8695-8698	and	_	
47-37	8699-8708	cognitive	_	
47-38	8709-8718	processes	_	
47-39	8718-8719	,	_	
47-40	8720-8729	including	_	
47-41	8730-8733	the	_	
47-42	8734-8742	amygdala	_	
47-43	8742-8743	,	_	
47-44	8744-8753	cingulate	_	
47-45	8753-8754	,	_	
47-46	8755-8763	inferior	_	
47-47	8764-8771	frontal	_	
47-48	8772-8777	gyrus	_	
47-49	8777-8778	,	_	
47-50	8779-8782	and	_	
47-51	8783-8789	insula	_	
47-52	8790-8791	(	_	
47-53	8791-8794	i.e	_	
47-54	8794-8795	.	_	
47-55	8795-8796	,	_	
47-56	8796-8797	)	_	
47-57	8797-8798	.	_	

#Text=Materials and Methods
#Text=Participants
#Text=Yale School of Medicine’s Human Investigation Committee approved all procedures prior to recruitment.
48-1	8799-8808	Materials	http://www.case.edu/ProvCaRe/provcare#StudyMethod[1]	
48-2	8809-8812	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[1]	
48-3	8813-8820	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[1]	
48-4	8821-8833	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
48-5	8834-8838	Yale	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
48-6	8839-8845	School	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
48-7	8846-8848	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
48-8	8849-8857	Medicine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
48-9	8857-8858	’	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
48-10	8858-8859	s	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
48-11	8860-8865	Human	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
48-12	8866-8879	Investigation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
48-13	8880-8889	Committee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
48-14	8890-8898	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
48-15	8899-8902	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
48-16	8903-8913	procedures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
48-17	8914-8919	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
48-18	8920-8922	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
48-19	8923-8934	recruitment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
48-20	8934-8935	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	

#Text=Sixty-two mothers of infants (M=8 months; SD=2 months) were recruited from the local community as part of a larger study on parenting and addiction.
49-1	8936-8945	Sixty-two	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
49-2	8946-8953	mothers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
49-3	8954-8956	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
49-4	8957-8964	infants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
49-5	8965-8966	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
49-6	8966-8967	M	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
49-7	8967-8968	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
49-8	8968-8969	8	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
49-9	8970-8976	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
49-10	8976-8977	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
49-11	8978-8980	SD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
49-12	8980-8981	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
49-13	8981-8982	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
49-14	8983-8989	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
49-15	8989-8990	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
49-16	8991-8995	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
49-17	8996-9005	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
49-18	9006-9010	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
49-19	9011-9014	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
49-20	9015-9020	local	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
49-21	9021-9030	community	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
49-22	9031-9033	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
49-23	9034-9038	part	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
49-24	9039-9041	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
49-25	9042-9043	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
49-26	9044-9050	larger	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
49-27	9051-9056	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
49-28	9057-9059	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
49-29	9060-9069	parenting	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
49-30	9070-9073	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
49-31	9074-9083	addiction	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
49-32	9083-9084	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	

#Text=All mothers were compensated $80 for completing the MRI visit.
50-1	9085-9088	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
50-2	9089-9096	mothers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
50-3	9097-9101	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
50-4	9102-9113	compensated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
50-5	9114-9117	$80	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
50-6	9118-9121	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
50-7	9122-9132	completing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
50-8	9133-9136	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
50-9	9137-9140	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]|http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[4]	
50-10	9141-9146	visit	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
50-11	9146-9147	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	

#Text=Eight participants (4 substance-using; 4 healthy control) were excluded from analyses with excessive motion during the scan, described below, and the final sample consisted of 32 substance-using mothers and 22 healthy control mothers.
51-1	9148-9153	Eight	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
51-2	9154-9166	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
51-3	9167-9168	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
51-4	9168-9169	4	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
51-5	9170-9185	substance-using	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
51-6	9185-9186	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
51-7	9187-9188	4	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
51-8	9189-9196	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
51-9	9197-9204	control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
51-10	9204-9205	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
51-11	9206-9210	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
51-12	9211-9219	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
51-13	9220-9224	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
51-14	9225-9233	analyses	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
51-15	9234-9238	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
51-16	9239-9248	excessive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
51-17	9249-9255	motion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
51-18	9256-9262	during	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
51-19	9263-9266	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
51-20	9267-9271	scan	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
51-21	9271-9272	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
51-22	9273-9282	described	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
51-23	9283-9288	below	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
51-24	9288-9289	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
51-25	9290-9293	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
51-26	9294-9297	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
51-27	9298-9303	final	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
51-28	9304-9310	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
51-29	9311-9320	consisted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
51-30	9321-9323	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
51-31	9324-9326	32	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
51-32	9327-9342	substance-using	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[5]	
51-33	9343-9350	mothers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
51-34	9351-9354	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
51-35	9355-9357	22	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
51-36	9358-9365	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[6]	
51-37	9366-9373	control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[6]	
51-38	9374-9381	mothers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
51-39	9381-9382	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	

#Text=Demographic data for the final sample are presented in Table 1.
52-1	9383-9394	Demographic	_	
52-2	9395-9399	data	_	
52-3	9400-9403	for	_	
52-4	9404-9407	the	_	
52-5	9408-9413	final	_	
52-6	9414-9420	sample	_	
52-7	9421-9424	are	_	
52-8	9425-9434	presented	_	
52-9	9435-9437	in	_	
52-10	9438-9443	Table	_	
52-11	9444-9445	1	_	
52-12	9445-9446	.	_	

#Text=Mothers were included in the substance-using group if they met any of the following criteria: current or prior methadone maintenance, current or prior detoxification or treatment programs for substance use, current tobacco smoking with a nicotine dependence score of ≥5 as measured by the Fagerstrom Test for Nicotine Dependence (FTND), positive drug urine toxicology at the time of scan, reported past-year drug abuse and/or meeting drug abuse or dependence criteria on the Mini-International Neuropsychiatric Interview (MINI).
53-1	9447-9454	Mothers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-2	9455-9459	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-3	9460-9468	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-4	9469-9471	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-5	9472-9475	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-6	9476-9491	substance-using	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-7	9492-9497	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-8	9498-9500	if	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-9	9501-9505	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-10	9506-9509	met	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-11	9510-9513	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-12	9514-9516	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-13	9517-9520	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-14	9521-9530	following	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-15	9531-9539	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-16	9539-9540	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-17	9541-9548	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-18	9549-9551	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-19	9552-9557	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-20	9558-9567	methadone	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-21	9568-9579	maintenance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-22	9579-9580	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-23	9581-9588	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-24	9589-9591	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-25	9592-9597	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-26	9598-9612	detoxification	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-27	9613-9615	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-28	9616-9625	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-29	9626-9634	programs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-30	9635-9638	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-31	9639-9648	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-32	9649-9652	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-33	9652-9653	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-34	9654-9661	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-35	9662-9669	tobacco	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-36	9670-9677	smoking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-37	9678-9682	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-38	9683-9684	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-39	9685-9693	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-40	9694-9704	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-41	9705-9710	score	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-42	9711-9713	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-43	9714-9715	≥	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-44	9715-9716	5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-45	9717-9719	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-46	9720-9728	measured	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-47	9729-9731	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-48	9732-9735	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-49	9736-9746	Fagerstrom	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[8]	
53-50	9747-9751	Test	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[8]	
53-51	9752-9755	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[8]	
53-52	9756-9764	Nicotine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[8]	
53-53	9765-9775	Dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[8]	
53-54	9776-9777	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[8]	
53-55	9777-9781	FTND	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[8]	
53-56	9781-9782	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[8]	
53-57	9782-9783	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-58	9784-9792	positive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-59	9793-9797	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-60	9798-9803	urine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-61	9804-9814	toxicology	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-62	9815-9817	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-63	9818-9821	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-64	9822-9826	time	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-65	9827-9829	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-66	9830-9834	scan	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-67	9834-9835	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-68	9836-9844	reported	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-69	9845-9854	past-year	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-70	9855-9859	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-71	9860-9865	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-72	9866-9869	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-73	9869-9870	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-74	9870-9872	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-75	9873-9880	meeting	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-76	9881-9885	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-77	9886-9891	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-78	9892-9894	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-79	9895-9905	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-80	9906-9914	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-81	9915-9917	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-82	9918-9921	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-83	9922-9940	Mini-International	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-84	9941-9957	Neuropsychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-85	9958-9967	Interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-86	9968-9969	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-87	9969-9973	MINI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-88	9973-9974	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
53-89	9974-9975	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	

#Text=Details of maternal substance use are presented in Table 2.
54-1	9976-9983	Details	_	
54-2	9984-9986	of	_	
54-3	9987-9995	maternal	_	
54-4	9996-10005	substance	_	
54-5	10006-10009	use	_	
54-6	10010-10013	are	_	
54-7	10014-10023	presented	_	
54-8	10024-10026	in	_	
54-9	10027-10032	Table	_	
54-10	10033-10034	2	_	
54-11	10034-10035	.	_	

#Text=The healthy control mothers did not endorse substance use on any of these measures.
55-1	10036-10039	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
55-2	10040-10047	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[10]	
55-3	10048-10055	control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[10]	
55-4	10056-10063	mothers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
55-5	10064-10067	did	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
55-6	10068-10071	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
55-7	10072-10079	endorse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
55-8	10080-10089	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
55-9	10090-10093	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
55-10	10094-10096	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
55-11	10097-10100	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
55-12	10101-10103	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
55-13	10104-10109	these	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
55-14	10110-10118	measures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
55-15	10118-10119	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	

#Text=Experimental Task
#Text=All infant face and cry stimuli were presented pseudorandomly through E-Prime 1.2.
56-1	10120-10132	Experimental	_	
56-2	10133-10137	Task	_	
56-3	10138-10141	All	_	
56-4	10142-10148	infant	_	
56-5	10149-10153	face	_	
56-6	10154-10157	and	_	
56-7	10158-10161	cry	_	
56-8	10162-10169	stimuli	_	
56-9	10170-10174	were	_	
56-10	10175-10184	presented	_	
56-11	10185-10199	pseudorandomly	_	
56-12	10200-10207	through	_	
56-13	10208-10215	E-Prime	_	
56-14	10216-10219	1.2	_	
56-15	10219-10220	.	_	

#Text=Infant face stimuli consisted of 10 own-happy-, 10 own-sad-, 10 unknown-happy-, and 10 unknown-sad-face exemplars (40 unique faces in total).
57-1	10221-10227	Infant	_	
57-2	10228-10232	face	_	
57-3	10233-10240	stimuli	_	
57-4	10241-10250	consisted	_	
57-5	10251-10253	of	_	
57-6	10254-10256	10	_	
57-7	10257-10266	own-happy	_	
57-8	10266-10267	-	_	
57-9	10267-10268	,	_	
57-10	10269-10271	10	_	
57-11	10272-10279	own-sad	_	
57-12	10279-10280	-	_	
57-13	10280-10281	,	_	
57-14	10282-10284	10	_	
57-15	10285-10298	unknown-happy	_	
57-16	10298-10299	-	_	
57-17	10299-10300	,	_	
57-18	10301-10304	and	_	
57-19	10305-10307	10	_	
57-20	10308-10324	unknown-sad-face	_	
57-21	10325-10334	exemplars	_	
57-22	10335-10336	(	_	
57-23	10336-10338	40	_	
57-24	10339-10345	unique	_	
57-25	10346-10351	faces	_	
57-26	10352-10354	in	_	
57-27	10355-10360	total	_	
57-28	10360-10361	)	_	
57-29	10361-10362	.	_	

#Text=Infant cry stimuli consisted of 10 own-cry and 10 unknown-cry exemplars (20 unique cries in total).
58-1	10363-10369	Infant	_	
58-2	10370-10373	cry	_	
58-3	10374-10381	stimuli	_	
58-4	10382-10391	consisted	_	
58-5	10392-10394	of	_	
58-6	10395-10397	10	_	
58-7	10398-10405	own-cry	_	
58-8	10406-10409	and	_	
58-9	10410-10412	10	_	
58-10	10413-10424	unknown-cry	_	
58-11	10425-10434	exemplars	_	
58-12	10435-10436	(	_	
58-13	10436-10438	20	_	
58-14	10439-10445	unique	_	
58-15	10446-10451	cries	_	
58-16	10452-10454	in	_	
58-17	10455-10460	total	_	
58-18	10460-10461	)	_	
58-19	10461-10462	.	_	

#Text=Own-face and own-cry stimuli were collected as part of a prior study visit, where infant expressions were captured through filming and cries were audio recorded.
59-1	10463-10471	Own-face	_	
59-2	10472-10475	and	_	
59-3	10476-10483	own-cry	_	
59-4	10484-10491	stimuli	_	
59-5	10492-10496	were	_	
59-6	10497-10506	collected	_	
59-7	10507-10509	as	_	
59-8	10510-10514	part	_	
59-9	10515-10517	of	_	
59-10	10518-10519	a	_	
59-11	10520-10525	prior	_	
59-12	10526-10531	study	_	
59-13	10532-10537	visit	_	
59-14	10537-10538	,	_	
59-15	10539-10544	where	_	
59-16	10545-10551	infant	_	
59-17	10552-10563	expressions	_	
59-18	10564-10568	were	_	
59-19	10569-10577	captured	_	
59-20	10578-10585	through	_	
59-21	10586-10593	filming	_	
59-22	10594-10597	and	_	
59-23	10598-10603	cries	_	
59-24	10604-10608	were	_	
59-25	10609-10614	audio	_	
59-26	10615-10623	recorded	_	
59-27	10623-10624	.	_	

#Text=Own and unknown infant face stimuli were matched on race and affect intensity, with the latter coded by research staff trained to reliability (see for full details).
60-1	10625-10628	Own	_	
60-2	10629-10632	and	_	
60-3	10633-10640	unknown	_	
60-4	10641-10647	infant	_	
60-5	10648-10652	face	_	
60-6	10653-10660	stimuli	_	
60-7	10661-10665	were	_	
60-8	10666-10673	matched	_	
60-9	10674-10676	on	_	
60-10	10677-10681	race	_	
60-11	10682-10685	and	_	
60-12	10686-10692	affect	_	
60-13	10693-10702	intensity	_	
60-14	10702-10703	,	_	
60-15	10704-10708	with	_	
60-16	10709-10712	the	_	
60-17	10713-10719	latter	_	
60-18	10720-10725	coded	_	
60-19	10726-10728	by	_	
60-20	10729-10737	research	_	
60-21	10738-10743	staff	_	
60-22	10744-10751	trained	_	
60-23	10752-10754	to	_	
60-24	10755-10766	reliability	_	
60-25	10767-10768	(	_	
60-26	10768-10771	see	_	
60-27	10772-10775	for	_	
60-28	10776-10780	full	_	
60-29	10781-10788	details	_	
60-30	10788-10789	)	_	
60-31	10789-10790	.	_	

#Text=Own- and unknown-cry stimuli were matched according to cry intensity and cry type.
61-1	10791-10794	Own	_	
61-2	10794-10795	-	_	
61-3	10796-10799	and	_	
61-4	10800-10811	unknown-cry	_	
61-5	10812-10819	stimuli	_	
61-6	10820-10824	were	_	
61-7	10825-10832	matched	_	
61-8	10833-10842	according	_	
61-9	10843-10845	to	_	
61-10	10846-10849	cry	_	
61-11	10850-10859	intensity	_	
61-12	10860-10863	and	_	
61-13	10864-10867	cry	_	
61-14	10868-10872	type	_	
61-15	10872-10873	.	_	

#Text=Infant faces were centrally presented in color on a gray background for 2 seconds, and infant cries were presented through headphones for 2 seconds, with a blank visual display.
62-1	10874-10880	Infant	_	
62-2	10881-10886	faces	_	
62-3	10887-10891	were	_	
62-4	10892-10901	centrally	_	
62-5	10902-10911	presented	_	
62-6	10912-10914	in	_	
62-7	10915-10920	color	_	
62-8	10921-10923	on	_	
62-9	10924-10925	a	_	
62-10	10926-10930	gray	_	
62-11	10931-10941	background	_	
62-12	10942-10945	for	_	
62-13	10946-10947	2	_	
62-14	10948-10955	seconds	_	
62-15	10955-10956	,	_	
62-16	10957-10960	and	_	
62-17	10961-10967	infant	_	
62-18	10968-10973	cries	_	
62-19	10974-10978	were	_	
62-20	10979-10988	presented	_	
62-21	10989-10996	through	_	
62-22	10997-11007	headphones	_	
62-23	11008-11011	for	_	
62-24	11012-11013	2	_	
62-25	11014-11021	seconds	_	
62-26	11021-11022	,	_	
62-27	11023-11027	with	_	
62-28	11028-11029	a	_	
62-29	11030-11035	blank	_	
62-30	11036-11042	visual	_	
62-31	11043-11050	display	_	
62-32	11050-11051	.	_	

#Text=The inter-stimulus interval was jittered from 2–11 seconds.
63-1	11052-11055	The	_	
63-2	11056-11070	inter-stimulus	_	
63-3	11071-11079	interval	_	
63-4	11080-11083	was	_	
63-5	11084-11092	jittered	_	
63-6	11093-11097	from	_	
63-7	11098-11099	2	_	
63-8	11099-11100	–	_	
63-9	11100-11102	11	_	
63-10	11103-11110	seconds	_	
63-11	11110-11111	.	_	

#Text=For each condition (own-happy, own-sad, unknown-happy, unknown-sad, own-cry, unknown-cry), six trials were presented within a block, and there were 7 blocks of data collected, leading to a total of 42 trials per condition.
64-1	11112-11115	For	_	
64-2	11116-11120	each	_	
64-3	11121-11130	condition	_	
64-4	11131-11132	(	_	
64-5	11132-11141	own-happy	_	
64-6	11141-11142	,	_	
64-7	11143-11150	own-sad	_	
64-8	11150-11151	,	_	
64-9	11152-11165	unknown-happy	_	
64-10	11165-11166	,	_	
64-11	11167-11178	unknown-sad	_	
64-12	11178-11179	,	_	
64-13	11180-11187	own-cry	_	
64-14	11187-11188	,	_	
64-15	11189-11200	unknown-cry	_	
64-16	11200-11201	)	_	
64-17	11201-11202	,	_	
64-18	11203-11206	six	_	
64-19	11207-11213	trials	_	
64-20	11214-11218	were	_	
64-21	11219-11228	presented	_	
64-22	11229-11235	within	_	
64-23	11236-11237	a	_	
64-24	11238-11243	block	_	
64-25	11243-11244	,	_	
64-26	11245-11248	and	_	
64-27	11249-11254	there	_	
64-28	11255-11259	were	_	
64-29	11260-11261	7	_	
64-30	11262-11268	blocks	_	
64-31	11269-11271	of	_	
64-32	11272-11276	data	_	
64-33	11277-11286	collected	_	
64-34	11286-11287	,	_	
64-35	11288-11295	leading	_	
64-36	11296-11298	to	_	
64-37	11299-11300	a	_	
64-38	11301-11306	total	_	
64-39	11307-11309	of	_	
64-40	11310-11312	42	_	
64-41	11313-11319	trials	_	
64-42	11320-11323	per	_	
64-43	11324-11333	condition	_	
64-44	11333-11334	.	_	

#Text=After the fMRI, each own- and unknown-face and -cry stimulus was presented again to participants to rate them in terms of sadness and distress (sad faces and cries) and happiness (happy faces) employing a 1 (least) to 7 (most) likert scale for each measure.
#Text=fMRI Data Acquisition
#Text=Data were acquired with a Siemens Trio 3T MRI system employing a standard 12-channel head coil.
65-1	11335-11340	After	_	
65-2	11341-11344	the	_	
65-3	11345-11349	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
65-4	11349-11350	,	_	
65-5	11351-11355	each	_	
65-6	11356-11359	own	_	
65-7	11359-11360	-	_	
65-8	11361-11364	and	_	
65-9	11365-11377	unknown-face	_	
65-10	11378-11381	and	_	
65-11	11382-11383	-	_	
65-12	11383-11386	cry	_	
65-13	11387-11395	stimulus	_	
65-14	11396-11399	was	_	
65-15	11400-11409	presented	_	
65-16	11410-11415	again	_	
65-17	11416-11418	to	_	
65-18	11419-11431	participants	_	
65-19	11432-11434	to	_	
65-20	11435-11439	rate	_	
65-21	11440-11444	them	_	
65-22	11445-11447	in	_	
65-23	11448-11453	terms	_	
65-24	11454-11456	of	_	
65-25	11457-11464	sadness	_	
65-26	11465-11468	and	_	
65-27	11469-11477	distress	_	
65-28	11478-11479	(	_	
65-29	11479-11482	sad	_	
65-30	11483-11488	faces	_	
65-31	11489-11492	and	_	
65-32	11493-11498	cries	_	
65-33	11498-11499	)	_	
65-34	11500-11503	and	_	
65-35	11504-11513	happiness	_	
65-36	11514-11515	(	_	
65-37	11515-11520	happy	_	
65-38	11521-11526	faces	_	
65-39	11526-11527	)	_	
65-40	11528-11537	employing	_	
65-41	11538-11539	a	_	
65-42	11540-11541	1	_	
65-43	11542-11543	(	_	
65-44	11543-11548	least	_	
65-45	11548-11549	)	_	
65-46	11550-11552	to	_	
65-47	11553-11554	7	_	
65-48	11555-11556	(	_	
65-49	11556-11560	most	_	
65-50	11560-11561	)	_	
65-51	11562-11568	likert	_	
65-52	11569-11574	scale	_	
65-53	11575-11578	for	_	
65-54	11579-11583	each	_	
65-55	11584-11591	measure	_	
65-56	11591-11592	.	_	
65-57	11593-11597	fMRI	_	
65-58	11598-11602	Data	_	
65-59	11603-11614	Acquisition	_	
65-60	11615-11619	Data	_	
65-61	11620-11624	were	_	
65-62	11625-11633	acquired	_	
65-63	11634-11638	with	_	
65-64	11639-11640	a	_	
65-65	11641-11648	Siemens	_	
65-66	11649-11653	Trio	_	
65-67	11654-11656	3T	_	
65-68	11657-11660	MRI	_	
65-69	11661-11667	system	_	
65-70	11668-11677	employing	_	
65-71	11678-11679	a	_	
65-72	11680-11688	standard	_	
65-73	11689-11691	12	_	
65-74	11691-11692	-	_	
65-75	11692-11699	channel	_	
65-76	11700-11704	head	_	
65-77	11705-11709	coil	_	
65-78	11709-11710	.	_	

#Text=Functional data were collected with a gradient echo, echoplanar sequence: repetition time (TR) = 2000 ms, echotime (TE) = 30 ms, flip angle = 80°, field of view = 220 × 220 mm, matrix = 64 × 64, slice thickness = 4mm, and 32 slices.
#Text=fMRI Analyses
#Text=Data pre-processing, subject-level, and group level statistics were completed in SPM12.
66-1	11711-11721	Functional	_	
66-2	11722-11726	data	_	
66-3	11727-11731	were	_	
66-4	11732-11741	collected	_	
66-5	11742-11746	with	_	
66-6	11747-11748	a	_	
66-7	11749-11757	gradient	_	
66-8	11758-11762	echo	_	
66-9	11762-11763	,	_	
66-10	11764-11774	echoplanar	_	
66-11	11775-11783	sequence	_	
66-12	11783-11784	:	_	
66-13	11785-11795	repetition	_	
66-14	11796-11800	time	_	
66-15	11801-11802	(	_	
66-16	11802-11804	TR	_	
66-17	11804-11805	)	_	
66-18	11806-11807	=	_	
66-19	11808-11812	2000	_	
66-20	11813-11815	ms	_	
66-21	11815-11816	,	_	
66-22	11817-11825	echotime	_	
66-23	11826-11827	(	_	
66-24	11827-11829	TE	_	
66-25	11829-11830	)	_	
66-26	11831-11832	=	_	
66-27	11833-11835	30	_	
66-28	11836-11838	ms	_	
66-29	11838-11839	,	_	
66-30	11840-11844	flip	_	
66-31	11845-11850	angle	_	
66-32	11851-11852	=	_	
66-33	11853-11855	80	_	
66-34	11855-11856	°	_	
66-35	11856-11857	,	_	
66-36	11858-11863	field	_	
66-37	11864-11866	of	_	
66-38	11867-11871	view	_	
66-39	11872-11873	=	_	
66-40	11874-11877	220	_	
66-41	11878-11879	×	_	
66-42	11880-11883	220	_	
66-43	11884-11886	mm	_	
66-44	11886-11887	,	_	
66-45	11888-11894	matrix	_	
66-46	11895-11896	=	_	
66-47	11897-11899	64	_	
66-48	11900-11901	×	_	
66-49	11902-11904	64	_	
66-50	11904-11905	,	_	
66-51	11906-11911	slice	_	
66-52	11912-11921	thickness	_	
66-53	11922-11923	=	_	
66-54	11924-11927	4mm	_	
66-55	11927-11928	,	_	
66-56	11929-11932	and	_	
66-57	11933-11935	32	_	
66-58	11936-11942	slices	_	
66-59	11942-11943	.	_	
66-60	11944-11948	fMRI	_	
66-61	11949-11957	Analyses	_	
66-62	11958-11962	Data	_	
66-63	11963-11977	pre-processing	_	
66-64	11977-11978	,	_	
66-65	11979-11992	subject-level	_	
66-66	11992-11993	,	_	
66-67	11994-11997	and	_	
66-68	11998-12003	group	_	
66-69	12004-12009	level	_	
66-70	12010-12020	statistics	_	
66-71	12021-12025	were	_	
66-72	12026-12035	completed	_	
66-73	12036-12038	in	_	
66-74	12039-12044	SPM12	_	
66-75	12044-12045	.	_	

#Text=Functional images were aligned prior to normalization to Montreal Neurological Institute space.
67-1	12046-12056	Functional	_	
67-2	12057-12063	images	_	
67-3	12064-12068	were	_	
67-4	12069-12076	aligned	_	
67-5	12077-12082	prior	_	
67-6	12083-12085	to	_	
67-7	12086-12099	normalization	_	
67-8	12100-12102	to	_	
67-9	12103-12111	Montreal	_	
67-10	12112-12124	Neurological	_	
67-11	12125-12134	Institute	_	
67-12	12135-12140	space	_	
67-13	12140-12141	.	_	

#Text=Functional runs where participant motion was in excess of 3 mm or degrees were excluded.
68-1	12142-12152	Functional	_	
68-2	12153-12157	runs	_	
68-3	12158-12163	where	_	
68-4	12164-12175	participant	_	
68-5	12176-12182	motion	_	
68-6	12183-12186	was	_	
68-7	12187-12189	in	_	
68-8	12190-12196	excess	_	
68-9	12197-12199	of	_	
68-10	12200-12201	3	_	
68-11	12202-12204	mm	_	
68-12	12205-12207	or	_	
68-13	12208-12215	degrees	_	
68-14	12216-12220	were	_	
68-15	12221-12229	excluded	_	
68-16	12229-12230	.	_	

#Text=To be included in the analysis, participants needed at least four functional runs to be motion-free (i.e., < 3 mm or degrees).
69-1	12231-12233	To	_	
69-2	12234-12236	be	_	
69-3	12237-12245	included	_	
69-4	12246-12248	in	_	
69-5	12249-12252	the	_	
69-6	12253-12261	analysis	_	
69-7	12261-12262	,	_	
69-8	12263-12275	participants	_	
69-9	12276-12282	needed	_	
69-10	12283-12285	at	_	
69-11	12286-12291	least	_	
69-12	12292-12296	four	_	
69-13	12297-12307	functional	_	
69-14	12308-12312	runs	_	
69-15	12313-12315	to	_	
69-16	12316-12318	be	_	
69-17	12319-12330	motion-free	_	
69-18	12331-12332	(	_	
69-19	12332-12335	i.e	_	
69-20	12335-12336	.	_	
69-21	12336-12337	,	_	
69-22	12338-12339	<	_	
69-23	12340-12341	3	_	
69-24	12342-12344	mm	_	
69-25	12345-12347	or	_	
69-26	12348-12355	degrees	_	
69-27	12355-12356	)	_	
69-28	12356-12357	.	_	

#Text=Data were smoothed using a 6mm full-width-half-maximum (FWHM) Gaussian kernel.
70-1	12358-12362	Data	_	
70-2	12363-12367	were	_	
70-3	12368-12376	smoothed	_	
70-4	12377-12382	using	_	
70-5	12383-12384	a	_	
70-6	12385-12388	6mm	_	
70-7	12389-12412	full-width-half-maximum	_	
70-8	12413-12414	(	_	
70-9	12414-12418	FWHM	_	
70-10	12418-12419	)	_	
70-11	12420-12428	Gaussian	_	
70-12	12429-12435	kernel	_	
70-13	12435-12436	.	_	

#Text=Face- and cry-stimulus onsets were convolved with the hemodynamic response function and modeled with temporal derivatives.
71-1	12437-12441	Face	_	
71-2	12441-12442	-	_	
71-3	12443-12446	and	_	
71-4	12447-12459	cry-stimulus	_	
71-5	12460-12466	onsets	_	
71-6	12467-12471	were	_	
71-7	12472-12481	convolved	_	
71-8	12482-12486	with	_	
71-9	12487-12490	the	_	
71-10	12491-12502	hemodynamic	_	
71-11	12503-12511	response	_	
71-12	12512-12520	function	_	
71-13	12521-12524	and	_	
71-14	12525-12532	modeled	_	
71-15	12533-12537	with	_	
71-16	12538-12546	temporal	_	
71-17	12547-12558	derivatives	_	
71-18	12558-12559	.	_	

#Text=High-pass filtering (128 s) was applied to all models, and motion parameters from realignment were included as regressors of no interest in the final analyses.
72-1	12560-12569	High-pass	_	
72-2	12570-12579	filtering	_	
72-3	12580-12581	(	_	
72-4	12581-12584	128	_	
72-5	12585-12586	s	_	
72-6	12586-12587	)	_	
72-7	12588-12591	was	_	
72-8	12592-12599	applied	_	
72-9	12600-12602	to	_	
72-10	12603-12606	all	_	
72-11	12607-12613	models	_	
72-12	12613-12614	,	_	
72-13	12615-12618	and	_	
72-14	12619-12625	motion	_	
72-15	12626-12636	parameters	_	
72-16	12637-12641	from	_	
72-17	12642-12653	realignment	_	
72-18	12654-12658	were	_	
72-19	12659-12667	included	_	
72-20	12668-12670	as	_	
72-21	12671-12681	regressors	_	
72-22	12682-12684	of	_	
72-23	12685-12687	no	_	
72-24	12688-12696	interest	_	
72-25	12697-12699	in	_	
72-26	12700-12703	the	_	
72-27	12704-12709	final	_	
72-28	12710-12718	analyses	_	
72-29	12718-12719	.	_	

#Text=Group effects were assessed using the full and flexible factorial modules in SPM12.
73-1	12720-12725	Group	_	
73-2	12726-12733	effects	_	
73-3	12734-12738	were	_	
73-4	12739-12747	assessed	_	
73-5	12748-12753	using	_	
73-6	12754-12757	the	_	
73-7	12758-12762	full	_	
73-8	12763-12766	and	_	
73-9	12767-12775	flexible	_	
73-10	12776-12785	factorial	_	
73-11	12786-12793	modules	_	
73-12	12794-12796	in	_	
73-13	12797-12802	SPM12	_	
73-14	12802-12803	.	_	

#Text=For face and cry functional data, main effects of group (substance-using, non-substance-using) were assessed using a full factorial design.
74-1	12804-12807	For	_	
74-2	12808-12812	face	_	
74-3	12813-12816	and	_	
74-4	12817-12820	cry	_	
74-5	12821-12831	functional	_	
74-6	12832-12836	data	_	
74-7	12836-12837	,	_	
74-8	12838-12842	main	_	
74-9	12843-12850	effects	_	
74-10	12851-12853	of	_	
74-11	12854-12859	group	_	
74-12	12860-12861	(	_	
74-13	12861-12876	substance-using	_	
74-14	12876-12877	,	_	
74-15	12878-12897	non-substance-using	_	
74-16	12897-12898	)	_	
74-17	12899-12903	were	_	
74-18	12904-12912	assessed	_	
74-19	12913-12918	using	_	
74-20	12919-12920	a	_	
74-21	12921-12925	full	_	
74-22	12926-12935	factorial	_	
74-23	12936-12942	design	_	
74-24	12942-12943	.	_	

#Text=For face data, we examined, using a flexible factorial design, interactions relating to familiarity (own, unknown) by substance-use group and emotional expression (happy, sad) by substance-use group.
75-1	12944-12947	For	_	
75-2	12948-12952	face	_	
75-3	12953-12957	data	_	
75-4	12957-12958	,	_	
75-5	12959-12961	we	_	
75-6	12962-12970	examined	_	
75-7	12970-12971	,	_	
75-8	12972-12977	using	_	
75-9	12978-12979	a	_	
75-10	12980-12988	flexible	_	
75-11	12989-12998	factorial	_	
75-12	12999-13005	design	_	
75-13	13005-13006	,	_	
75-14	13007-13019	interactions	_	
75-15	13020-13028	relating	_	
75-16	13029-13031	to	_	
75-17	13032-13043	familiarity	_	
75-18	13044-13045	(	_	
75-19	13045-13048	own	_	
75-20	13048-13049	,	_	
75-21	13050-13057	unknown	_	
75-22	13057-13058	)	_	
75-23	13059-13061	by	_	
75-24	13062-13075	substance-use	_	
75-25	13076-13081	group	_	
75-26	13082-13085	and	_	
75-27	13086-13095	emotional	_	
75-28	13096-13106	expression	_	
75-29	13107-13108	(	_	
75-30	13108-13113	happy	_	
75-31	13113-13114	,	_	
75-32	13115-13118	sad	_	
75-33	13118-13119	)	_	
75-34	13120-13122	by	_	
75-35	13123-13136	substance-use	_	
75-36	13137-13142	group	_	
75-37	13142-13143	.	_	

#Text=For these analyses, all face stimuli (own-happy, own-unhappy, unknown-happy, unknown-sad) were included as within-subjects factors.
76-1	13144-13147	For	_	
76-2	13148-13153	these	_	
76-3	13154-13162	analyses	_	
76-4	13162-13163	,	_	
76-5	13164-13167	all	_	
76-6	13168-13172	face	_	
76-7	13173-13180	stimuli	_	
76-8	13181-13182	(	_	
76-9	13182-13191	own-happy	_	
76-10	13191-13192	,	_	
76-11	13193-13204	own-unhappy	_	
76-12	13204-13205	,	_	
76-13	13206-13219	unknown-happy	_	
76-14	13219-13220	,	_	
76-15	13221-13232	unknown-sad	_	
76-16	13232-13233	)	_	
76-17	13234-13238	were	_	
76-18	13239-13247	included	_	
76-19	13248-13250	as	_	
76-20	13251-13266	within-subjects	_	
76-21	13267-13274	factors	_	
76-22	13274-13275	.	_	

#Text=For cries, we similarly examined interactions involving familiarity (own, unknown) by substance-use group.
77-1	13276-13279	For	_	
77-2	13280-13285	cries	_	
77-3	13285-13286	,	_	
77-4	13287-13289	we	_	
77-5	13290-13299	similarly	_	
77-6	13300-13308	examined	_	
77-7	13309-13321	interactions	_	
77-8	13322-13331	involving	_	
77-9	13332-13343	familiarity	_	
77-10	13344-13345	(	_	
77-11	13345-13348	own	_	
77-12	13348-13349	,	_	
77-13	13350-13357	unknown	_	
77-14	13357-13358	)	_	
77-15	13359-13361	by	_	
77-16	13362-13375	substance-use	_	
77-17	13376-13381	group	_	
77-18	13381-13382	.	_	

#Text=Main effects of group were assessed using full factorial designs.
78-1	13383-13387	Main	_	
78-2	13388-13395	effects	_	
78-3	13396-13398	of	_	
78-4	13399-13404	group	_	
78-5	13405-13409	were	_	
78-6	13410-13418	assessed	_	
78-7	13419-13424	using	_	
78-8	13425-13429	full	_	
78-9	13430-13439	factorial	_	
78-10	13440-13447	designs	_	
78-11	13447-13448	.	_	

#Text=Consistent with current recommendations, whole-brain statistical maps were voxel-level thresholded at p<.001 and family-wise-error-corrected (FWE) at pFWE<.05.
79-1	13449-13459	Consistent	_	
79-2	13460-13464	with	_	
79-3	13465-13472	current	_	
79-4	13473-13488	recommendations	_	
79-5	13488-13489	,	_	
79-6	13490-13501	whole-brain	_	
79-7	13502-13513	statistical	_	
79-8	13514-13518	maps	_	
79-9	13519-13523	were	_	
79-10	13524-13535	voxel-level	_	
79-11	13536-13547	thresholded	_	
79-12	13548-13550	at	_	
79-13	13551-13552	p	_	
79-14	13552-13553	<	_	
79-15	13553-13557	.001	_	
79-16	13558-13561	and	_	
79-17	13562-13589	family-wise-error-corrected	_	
79-18	13590-13591	(	_	
79-19	13591-13594	FWE	_	
79-20	13594-13595	)	_	
79-21	13596-13598	at	_	
79-22	13599-13603	pFWE	_	
79-23	13603-13604	<	_	
79-24	13604-13607	.05	_	
79-25	13607-13608	.	_	

#Text=Post-Scan Infant Face and Cry Ratings
#Text=For sad infant faces and cries, repeated-measures ANOVAs specifying familiarity (own, unknown), rated negative emotion (sad, distress), and substance-use group (substance-using, non-substance-using) were conducted.
80-1	13609-13618	Post-Scan	_	
80-2	13619-13625	Infant	_	
80-3	13626-13630	Face	_	
80-4	13631-13634	and	_	
80-5	13635-13638	Cry	_	
80-6	13639-13646	Ratings	_	
80-7	13647-13650	For	_	
80-8	13651-13654	sad	_	
80-9	13655-13661	infant	_	
80-10	13662-13667	faces	_	
80-11	13668-13671	and	_	
80-12	13672-13677	cries	_	
80-13	13677-13678	,	_	
80-14	13679-13696	repeated-measures	_	
80-15	13697-13703	ANOVAs	_	
80-16	13704-13714	specifying	_	
80-17	13715-13726	familiarity	_	
80-18	13727-13728	(	_	
80-19	13728-13731	own	_	
80-20	13731-13732	,	_	
80-21	13733-13740	unknown	_	
80-22	13740-13741	)	_	
80-23	13741-13742	,	_	
80-24	13743-13748	rated	_	
80-25	13749-13757	negative	_	
80-26	13758-13765	emotion	_	
80-27	13766-13767	(	_	
80-28	13767-13770	sad	_	
80-29	13770-13771	,	_	
80-30	13772-13780	distress	_	
80-31	13780-13781	)	_	
80-32	13781-13782	,	_	
80-33	13783-13786	and	_	
80-34	13787-13800	substance-use	_	
80-35	13801-13806	group	_	
80-36	13807-13808	(	_	
80-37	13808-13823	substance-using	_	
80-38	13823-13824	,	_	
80-39	13825-13844	non-substance-using	_	
80-40	13844-13845	)	_	
80-41	13846-13850	were	_	
80-42	13851-13860	conducted	_	
80-43	13860-13861	.	_	

#Text=For happy infant faces, a repeated-measures ANOVA specifying familiarity (own, unknown) and substance-use group (substance-using, non-substance-using) was conducted.
81-1	13862-13865	For	_	
81-2	13866-13871	happy	_	
81-3	13872-13878	infant	_	
81-4	13879-13884	faces	_	
81-5	13884-13885	,	_	
81-6	13886-13887	a	_	
81-7	13888-13905	repeated-measures	_	
81-8	13906-13911	ANOVA	_	
81-9	13912-13922	specifying	_	
81-10	13923-13934	familiarity	_	
81-11	13935-13936	(	_	
81-12	13936-13939	own	_	
81-13	13939-13940	,	_	
81-14	13941-13948	unknown	_	
81-15	13948-13949	)	_	
81-16	13950-13953	and	_	
81-17	13954-13967	substance-use	_	
81-18	13968-13973	group	_	
81-19	13974-13975	(	_	
81-20	13975-13990	substance-using	_	
81-21	13990-13991	,	_	
81-22	13992-14011	non-substance-using	_	
81-23	14011-14012	)	_	
81-24	14013-14016	was	_	
81-25	14017-14026	conducted	_	
81-26	14026-14027	.	_	

#Text=Correlations between face and cry ratings with activation to infant face and cry regions identified as significant in whole-brain analyses were also conducted.
82-1	14028-14040	Correlations	_	
82-2	14041-14048	between	_	
82-3	14049-14053	face	_	
82-4	14054-14057	and	_	
82-5	14058-14061	cry	_	
82-6	14062-14069	ratings	_	
82-7	14070-14074	with	_	
82-8	14075-14085	activation	_	
82-9	14086-14088	to	_	
82-10	14089-14095	infant	_	
82-11	14096-14100	face	_	
82-12	14101-14104	and	_	
82-13	14105-14108	cry	_	
82-14	14109-14116	regions	_	
82-15	14117-14127	identified	_	
82-16	14128-14130	as	_	
82-17	14131-14142	significant	_	
82-18	14143-14145	in	_	
82-19	14146-14157	whole-brain	_	
82-20	14158-14166	analyses	_	
82-21	14167-14171	were	_	
82-22	14172-14176	also	_	
82-23	14177-14186	conducted	_	
82-24	14186-14187	.	_	

#Text=Results
#Text=Ratings Data
#Text=Data were missing from one substance-using mother and one non-substance-using mother.
83-1	14188-14195	Results	_	
83-2	14196-14203	Ratings	_	
83-3	14204-14208	Data	_	
83-4	14209-14213	Data	_	
83-5	14214-14218	were	_	
83-6	14219-14226	missing	_	
83-7	14227-14231	from	_	
83-8	14232-14235	one	_	
83-9	14236-14251	substance-using	_	
83-10	14252-14258	mother	_	
83-11	14259-14262	and	_	
83-12	14263-14266	one	_	
83-13	14267-14286	non-substance-using	_	
83-14	14287-14293	mother	_	
83-15	14293-14294	.	_	

#Text=For sad-face ratings, while there was no maternal substance-use between-group effect contributing to face ratings for sadness and distress scales, F(1,50)=2.15,p=.15,ηp2 =.041, there was a main effect of infant familiarity, F(1,50)=8.29,p=.006,ηp2 =.142.
84-1	14295-14298	For	_	
84-2	14299-14307	sad-face	_	
84-3	14308-14315	ratings	_	
84-4	14315-14316	,	_	
84-5	14317-14322	while	_	
84-6	14323-14328	there	_	
84-7	14329-14332	was	_	
84-8	14333-14335	no	_	
84-9	14336-14344	maternal	_	
84-10	14345-14358	substance-use	_	
84-11	14359-14372	between-group	_	
84-12	14373-14379	effect	_	
84-13	14380-14392	contributing	_	
84-14	14393-14395	to	_	
84-15	14396-14400	face	_	
84-16	14401-14408	ratings	_	
84-17	14409-14412	for	_	
84-18	14413-14420	sadness	_	
84-19	14421-14424	and	_	
84-20	14425-14433	distress	_	
84-21	14434-14440	scales	_	
84-22	14440-14441	,	_	
84-23	14442-14443	F	_	
84-24	14443-14444	(	_	
84-25	14444-14448	1,50	_	
84-26	14448-14449	)	_	
84-27	14449-14450	=	_	
84-28	14450-14454	2.15	_	
84-29	14454-14455	,	_	
84-30	14455-14456	p	_	
84-31	14456-14457	=	_	
84-32	14457-14460	.15	_	
84-33	14460-14461	,	_	
84-34	14461-14464	ηp2	_	
84-35	14465-14466	=	_	
84-36	14466-14470	.041	_	
84-37	14470-14471	,	_	
84-38	14472-14477	there	_	
84-39	14478-14481	was	_	
84-40	14482-14483	a	_	
84-41	14484-14488	main	_	
84-42	14489-14495	effect	_	
84-43	14496-14498	of	_	
84-44	14499-14505	infant	_	
84-45	14506-14517	familiarity	_	
84-46	14517-14518	,	_	
84-47	14519-14520	F	_	
84-48	14520-14521	(	_	
84-49	14521-14525	1,50	_	
84-50	14525-14526	)	_	
84-51	14526-14527	=	_	
84-52	14527-14531	8.29	_	
84-53	14531-14532	,	_	
84-54	14532-14533	p	_	
84-55	14533-14534	=	_	
84-56	14534-14538	.006	_	
84-57	14538-14539	,	_	
84-58	14539-14542	ηp2	_	
84-59	14543-14544	=	_	
84-60	14544-14548	.142	_	
84-61	14548-14549	.	_	

#Text=Mothers rated their own infant (M=7.05; SD=1.54) as feeling more negative emotions than the unknown infant (M=6.57; SD=1.58).
85-1	14550-14557	Mothers	_	
85-2	14558-14563	rated	_	
85-3	14564-14569	their	_	
85-4	14570-14573	own	_	
85-5	14574-14580	infant	_	
85-6	14581-14582	(	_	
85-7	14582-14583	M	_	
85-8	14583-14584	=	_	
85-9	14584-14588	7.05	_	
85-10	14588-14589	;	_	
85-11	14590-14592	SD	_	
85-12	14592-14593	=	_	
85-13	14593-14597	1.54	_	
85-14	14597-14598	)	_	
85-15	14599-14601	as	_	
85-16	14602-14609	feeling	_	
85-17	14610-14614	more	_	
85-18	14615-14623	negative	_	
85-19	14624-14632	emotions	_	
85-20	14633-14637	than	_	
85-21	14638-14641	the	_	
85-22	14642-14649	unknown	_	
85-23	14650-14656	infant	_	
85-24	14657-14658	(	_	
85-25	14658-14659	M	_	
85-26	14659-14660	=	_	
85-27	14660-14664	6.57	_	
85-28	14664-14665	;	_	
85-29	14666-14668	SD	_	
85-30	14668-14669	=	_	
85-31	14669-14673	1.58	_	
85-32	14673-14674	)	_	
85-33	14674-14675	.	_	

#Text=The main effect of infant negative emotion (rating sadness or distress) did not reach statistical significance, F(1,50)=3.52,p=.067,ηp2 =.066, and there were no other interactions between these variables.
86-1	14676-14679	The	_	
86-2	14680-14684	main	_	
86-3	14685-14691	effect	_	
86-4	14692-14694	of	_	
86-5	14695-14701	infant	_	
86-6	14702-14710	negative	_	
86-7	14711-14718	emotion	_	
86-8	14719-14720	(	_	
86-9	14720-14726	rating	_	
86-10	14727-14734	sadness	_	
86-11	14735-14737	or	_	
86-12	14738-14746	distress	_	
86-13	14746-14747	)	_	
86-14	14748-14751	did	_	
86-15	14752-14755	not	_	
86-16	14756-14761	reach	_	
86-17	14762-14773	statistical	_	
86-18	14774-14786	significance	_	
86-19	14786-14787	,	_	
86-20	14788-14789	F	_	
86-21	14789-14790	(	_	
86-22	14790-14794	1,50	_	
86-23	14794-14795	)	_	
86-24	14795-14796	=	_	
86-25	14796-14800	3.52	_	
86-26	14800-14801	,	_	
86-27	14801-14802	p	_	
86-28	14802-14803	=	_	
86-29	14803-14807	.067	_	
86-30	14807-14808	,	_	
86-31	14808-14811	ηp2	_	
86-32	14812-14813	=	_	
86-33	14813-14817	.066	_	
86-34	14817-14818	,	_	
86-35	14819-14822	and	_	
86-36	14823-14828	there	_	
86-37	14829-14833	were	_	
86-38	14834-14836	no	_	
86-39	14837-14842	other	_	
86-40	14843-14855	interactions	_	
86-41	14856-14863	between	_	
86-42	14864-14869	these	_	
86-43	14870-14879	variables	_	
86-44	14879-14880	.	_	

#Text=For happy-face ratings, there was no effect of maternal substance-use status, F<1, though all mothers rated their own infant (M=7.74; SD=1.06) as feeling happier than the unknown infant (M=6.98; SD=1.26), F(1,50)=40.10, p<.001,ηp2 =.445.
87-1	14881-14884	For	_	
87-2	14885-14895	happy-face	_	
87-3	14896-14903	ratings	_	
87-4	14903-14904	,	_	
87-5	14905-14910	there	_	
87-6	14911-14914	was	_	
87-7	14915-14917	no	_	
87-8	14918-14924	effect	_	
87-9	14925-14927	of	_	
87-10	14928-14936	maternal	_	
87-11	14937-14950	substance-use	_	
87-12	14951-14957	status	_	
87-13	14957-14958	,	_	
87-14	14959-14960	F	_	
87-15	14960-14961	<	_	
87-16	14961-14962	1	_	
87-17	14962-14963	,	_	
87-18	14964-14970	though	_	
87-19	14971-14974	all	_	
87-20	14975-14982	mothers	_	
87-21	14983-14988	rated	_	
87-22	14989-14994	their	_	
87-23	14995-14998	own	_	
87-24	14999-15005	infant	_	
87-25	15006-15007	(	_	
87-26	15007-15008	M	_	
87-27	15008-15009	=	_	
87-28	15009-15013	7.74	_	
87-29	15013-15014	;	_	
87-30	15015-15017	SD	_	
87-31	15017-15018	=	_	
87-32	15018-15022	1.06	_	
87-33	15022-15023	)	_	
87-34	15024-15026	as	_	
87-35	15027-15034	feeling	_	
87-36	15035-15042	happier	_	
87-37	15043-15047	than	_	
87-38	15048-15051	the	_	
87-39	15052-15059	unknown	_	
87-40	15060-15066	infant	_	
87-41	15067-15068	(	_	
87-42	15068-15069	M	_	
87-43	15069-15070	=	_	
87-44	15070-15074	6.98	_	
87-45	15074-15075	;	_	
87-46	15076-15078	SD	_	
87-47	15078-15079	=	_	
87-48	15079-15083	1.26	_	
87-49	15083-15084	)	_	
87-50	15084-15085	,	_	
87-51	15086-15087	F	_	
87-52	15087-15088	(	_	
87-53	15088-15092	1,50	_	
87-54	15092-15093	)	_	
87-55	15093-15094	=	_	
87-56	15094-15099	40.10	_	
87-57	15099-15100	,	_	
87-58	15101-15102	p	_	
87-59	15102-15103	<	_	
87-60	15103-15107	.001	_	
87-61	15107-15108	,	_	
87-62	15108-15111	ηp2	_	
87-63	15112-15113	=	_	
87-64	15113-15117	.445	_	
87-65	15117-15118	.	_	

#Text=Maternal substance-use status affected infant cry ratings, F(1,50)=4.34, p=.042,ηp2 =.080, with substance-using mothers rating all infants as less sad (M=5.75; SD=1.71 vs M=6.69; SD=1.15) and less distressed (M=5.83; SD=1.69 vs M=6.65; SD=1.24) than non-substance-using mothers.
88-1	15119-15127	Maternal	_	
88-2	15128-15141	substance-use	_	
88-3	15142-15148	status	_	
88-4	15149-15157	affected	_	
88-5	15158-15164	infant	_	
88-6	15165-15168	cry	_	
88-7	15169-15176	ratings	_	
88-8	15176-15177	,	_	
88-9	15178-15179	F	_	
88-10	15179-15180	(	_	
88-11	15180-15184	1,50	_	
88-12	15184-15185	)	_	
88-13	15185-15186	=	_	
88-14	15186-15190	4.34	_	
88-15	15190-15191	,	_	
88-16	15192-15193	p	_	
88-17	15193-15194	=	_	
88-18	15194-15198	.042	_	
88-19	15198-15199	,	_	
88-20	15199-15202	ηp2	_	
88-21	15203-15204	=	_	
88-22	15204-15208	.080	_	
88-23	15208-15209	,	_	
88-24	15210-15214	with	_	
88-25	15215-15230	substance-using	_	
88-26	15231-15238	mothers	_	
88-27	15239-15245	rating	_	
88-28	15246-15249	all	_	
88-29	15250-15257	infants	_	
88-30	15258-15260	as	_	
88-31	15261-15265	less	_	
88-32	15266-15269	sad	_	
88-33	15270-15271	(	_	
88-34	15271-15272	M	_	
88-35	15272-15273	=	_	
88-36	15273-15277	5.75	_	
88-37	15277-15278	;	_	
88-38	15279-15281	SD	_	
88-39	15281-15282	=	_	
88-40	15282-15286	1.71	_	
88-41	15287-15289	vs	_	
88-42	15290-15291	M	_	
88-43	15291-15292	=	_	
88-44	15292-15296	6.69	_	
88-45	15296-15297	;	_	
88-46	15298-15300	SD	_	
88-47	15300-15301	=	_	
88-48	15301-15305	1.15	_	
88-49	15305-15306	)	_	
88-50	15307-15310	and	_	
88-51	15311-15315	less	_	
88-52	15316-15326	distressed	_	
88-53	15327-15328	(	_	
88-54	15328-15329	M	_	
88-55	15329-15330	=	_	
88-56	15330-15334	5.83	_	
88-57	15334-15335	;	_	
88-58	15336-15338	SD	_	
88-59	15338-15339	=	_	
88-60	15339-15343	1.69	_	
88-61	15344-15346	vs	_	
88-62	15347-15348	M	_	
88-63	15348-15349	=	_	
88-64	15349-15353	6.65	_	
88-65	15353-15354	;	_	
88-66	15355-15357	SD	_	
88-67	15357-15358	=	_	
88-68	15358-15362	1.24	_	
88-69	15362-15363	)	_	
88-70	15364-15368	than	_	
88-71	15369-15388	non-substance-using	_	
88-72	15389-15396	mothers	_	
88-73	15396-15397	.	_	

#Text=There was also a main effect of infant familiarity, F(1,50)=9.31, p=.004,ηp2 =.157.
89-1	15398-15403	There	_	
89-2	15404-15407	was	_	
89-3	15408-15412	also	_	
89-4	15413-15414	a	_	
89-5	15415-15419	main	_	
89-6	15420-15426	effect	_	
89-7	15427-15429	of	_	
89-8	15430-15436	infant	_	
89-9	15437-15448	familiarity	_	
89-10	15448-15449	,	_	
89-11	15450-15451	F	_	
89-12	15451-15452	(	_	
89-13	15452-15456	1,50	_	
89-14	15456-15457	)	_	
89-15	15457-15458	=	_	
89-16	15458-15462	9.31	_	
89-17	15462-15463	,	_	
89-18	15464-15465	p	_	
89-19	15465-15466	=	_	
89-20	15466-15470	.004	_	
89-21	15470-15471	,	_	
89-22	15471-15474	ηp2	_	
89-23	15475-15476	=	_	
89-24	15476-15480	.157	_	
89-25	15480-15481	.	_	

#Text=Mothers rated their own infants (M=6.38; SD=1.61) as sadder and more distressed than unknown infants (M=5.91; SD=1.68).
90-1	15482-15489	Mothers	_	
90-2	15490-15495	rated	_	
90-3	15496-15501	their	_	
90-4	15502-15505	own	_	
90-5	15506-15513	infants	_	
90-6	15514-15515	(	_	
90-7	15515-15516	M	_	
90-8	15516-15517	=	_	
90-9	15517-15521	6.38	_	
90-10	15521-15522	;	_	
90-11	15523-15525	SD	_	
90-12	15525-15526	=	_	
90-13	15526-15530	1.61	_	
90-14	15530-15531	)	_	
90-15	15532-15534	as	_	
90-16	15535-15541	sadder	_	
90-17	15542-15545	and	_	
90-18	15546-15550	more	_	
90-19	15551-15561	distressed	_	
90-20	15562-15566	than	_	
90-21	15567-15574	unknown	_	
90-22	15575-15582	infants	_	
90-23	15583-15584	(	_	
90-24	15584-15585	M	_	
90-25	15585-15586	=	_	
90-26	15586-15590	5.91	_	
90-27	15590-15591	;	_	
90-28	15592-15594	SD	_	
90-29	15594-15595	=	_	
90-30	15595-15599	1.68	_	
90-31	15599-15600	)	_	
90-32	15600-15601	.	_	

#Text=There were no interactions between these variables.
91-1	15602-15607	There	_	
91-2	15608-15612	were	_	
91-3	15613-15615	no	_	
91-4	15616-15628	interactions	_	
91-5	15629-15636	between	_	
91-6	15637-15642	these	_	
91-7	15643-15652	variables	_	
91-8	15652-15653	.	_	

#Text=Taken together, self-reported ratings evidenced (1) maternal substance-use status affected how mothers perceived the feelings of infants when listening to their cries but not when processing their faces; and, (2) infant familiarity increased the strength of emotions mothers reported their children feeling when rating face and cry stimuli.
92-1	15654-15659	Taken	_	
92-2	15660-15668	together	_	
92-3	15668-15669	,	_	
92-4	15670-15683	self-reported	_	
92-5	15684-15691	ratings	_	
92-6	15692-15701	evidenced	_	
92-7	15702-15703	(	_	
92-8	15703-15704	1	_	
92-9	15704-15705	)	_	
92-10	15706-15714	maternal	_	
92-11	15715-15728	substance-use	_	
92-12	15729-15735	status	_	
92-13	15736-15744	affected	_	
92-14	15745-15748	how	_	
92-15	15749-15756	mothers	_	
92-16	15757-15766	perceived	_	
92-17	15767-15770	the	_	
92-18	15771-15779	feelings	_	
92-19	15780-15782	of	_	
92-20	15783-15790	infants	_	
92-21	15791-15795	when	_	
92-22	15796-15805	listening	_	
92-23	15806-15808	to	_	
92-24	15809-15814	their	_	
92-25	15815-15820	cries	_	
92-26	15821-15824	but	_	
92-27	15825-15828	not	_	
92-28	15829-15833	when	_	
92-29	15834-15844	processing	_	
92-30	15845-15850	their	_	
92-31	15851-15856	faces	_	
92-32	15856-15857	;	_	
92-33	15858-15861	and	_	
92-34	15861-15862	,	_	
92-35	15863-15864	(	_	
92-36	15864-15865	2	_	
92-37	15865-15866	)	_	
92-38	15867-15873	infant	_	
92-39	15874-15885	familiarity	_	
92-40	15886-15895	increased	_	
92-41	15896-15899	the	_	
92-42	15900-15908	strength	_	
92-43	15909-15911	of	_	
92-44	15912-15920	emotions	_	
92-45	15921-15928	mothers	_	
92-46	15929-15937	reported	_	
92-47	15938-15943	their	_	
92-48	15944-15952	children	_	
92-49	15953-15960	feeling	_	
92-50	15961-15965	when	_	
92-51	15966-15972	rating	_	
92-52	15973-15977	face	_	
92-53	15978-15981	and	_	
92-54	15982-15985	cry	_	
92-55	15986-15993	stimuli	_	
92-56	15993-15994	.	_	

#Text=Neuroimaging Data
#Text=Whole-brain analyses identified a significant infant-familiarity-by-maternal-substance-use-group interaction during infant face processing.
93-1	15995-16007	Neuroimaging	_	
93-2	16008-16012	Data	_	
93-3	16013-16024	Whole-brain	_	
93-4	16025-16033	analyses	_	
93-5	16034-16044	identified	_	
93-6	16045-16046	a	_	
93-7	16047-16058	significant	_	
93-8	16059-16109	infant-familiarity-by-maternal-substance-use-group	_	
93-9	16110-16121	interaction	_	
93-10	16122-16128	during	_	
93-11	16129-16135	infant	_	
93-12	16136-16140	face	_	
93-13	16141-16151	processing	_	
93-14	16151-16152	.	_	

#Text=Specifically, while substance-using mothers had greater activation to their own infants’ faces as compared to unknown faces, non-substance-using mothers evidenced a greater activation to unknown infants’ faces as compared to their own infants’ faces (Figure 1).
94-1	16153-16165	Specifically	_	
94-2	16165-16166	,	_	
94-3	16167-16172	while	_	
94-4	16173-16188	substance-using	_	
94-5	16189-16196	mothers	_	
94-6	16197-16200	had	_	
94-7	16201-16208	greater	_	
94-8	16209-16219	activation	_	
94-9	16220-16222	to	_	
94-10	16223-16228	their	_	
94-11	16229-16232	own	_	
94-12	16233-16240	infants	_	
94-13	16240-16241	’	_	
94-14	16242-16247	faces	_	
94-15	16248-16250	as	_	
94-16	16251-16259	compared	_	
94-17	16260-16262	to	_	
94-18	16263-16270	unknown	_	
94-19	16271-16276	faces	_	
94-20	16276-16277	,	_	
94-21	16278-16297	non-substance-using	_	
94-22	16298-16305	mothers	_	
94-23	16306-16315	evidenced	_	
94-24	16316-16317	a	_	
94-25	16318-16325	greater	_	
94-26	16326-16336	activation	_	
94-27	16337-16339	to	_	
94-28	16340-16347	unknown	_	
94-29	16348-16355	infants	_	
94-30	16355-16356	’	_	
94-31	16357-16362	faces	_	
94-32	16363-16365	as	_	
94-33	16366-16374	compared	_	
94-34	16375-16377	to	_	
94-35	16378-16383	their	_	
94-36	16384-16387	own	_	
94-37	16388-16395	infants	_	
94-38	16395-16396	’	_	
94-39	16397-16402	faces	_	
94-40	16403-16404	(	_	
94-41	16404-16410	Figure	_	
94-42	16411-16412	1	_	
94-43	16412-16413	)	_	
94-44	16413-16414	.	_	

#Text=Regions identified in the interaction included a superior medial frontal cluster extending into the supplementary motor area, left and right inferior parietal clusters extending into the insula, and a left middle temporal cluster extending into the occipital cortex, cuneus, and lingual gyrus (Table 3).
95-1	16415-16422	Regions	_	
95-2	16423-16433	identified	_	
95-3	16434-16436	in	_	
95-4	16437-16440	the	_	
95-5	16441-16452	interaction	_	
95-6	16453-16461	included	_	
95-7	16462-16463	a	_	
95-8	16464-16472	superior	_	
95-9	16473-16479	medial	_	
95-10	16480-16487	frontal	_	
95-11	16488-16495	cluster	_	
95-12	16496-16505	extending	_	
95-13	16506-16510	into	_	
95-14	16511-16514	the	_	
95-15	16515-16528	supplementary	_	
95-16	16529-16534	motor	_	
95-17	16535-16539	area	_	
95-18	16539-16540	,	_	
95-19	16541-16545	left	_	
95-20	16546-16549	and	_	
95-21	16550-16555	right	_	
95-22	16556-16564	inferior	_	
95-23	16565-16573	parietal	_	
95-24	16574-16582	clusters	_	
95-25	16583-16592	extending	_	
95-26	16593-16597	into	_	
95-27	16598-16601	the	_	
95-28	16602-16608	insula	_	
95-29	16608-16609	,	_	
95-30	16610-16613	and	_	
95-31	16614-16615	a	_	
95-32	16616-16620	left	_	
95-33	16621-16627	middle	_	
95-34	16628-16636	temporal	_	
95-35	16637-16644	cluster	_	
95-36	16645-16654	extending	_	
95-37	16655-16659	into	_	
95-38	16660-16663	the	_	
95-39	16664-16673	occipital	_	
95-40	16674-16680	cortex	_	
95-41	16680-16681	,	_	
95-42	16682-16688	cuneus	_	
95-43	16688-16689	,	_	
95-44	16690-16693	and	_	
95-45	16694-16701	lingual	_	
95-46	16702-16707	gyrus	_	
95-47	16708-16709	(	_	
95-48	16709-16714	Table	_	
95-49	16715-16716	3	_	
95-50	16716-16717	)	_	
95-51	16717-16718	.	_	

#Text=Whole-brain analyses also identified a significant main effect of maternal substance-use status on processing of sad infant faces within the ventral striatum, involving decreased activity among substance-using versus non-substance-using mothers (Table 3; Figure 2).
96-1	16719-16730	Whole-brain	_	
96-2	16731-16739	analyses	_	
96-3	16740-16744	also	_	
96-4	16745-16755	identified	_	
96-5	16756-16757	a	_	
96-6	16758-16769	significant	_	
96-7	16770-16774	main	_	
96-8	16775-16781	effect	_	
96-9	16782-16784	of	_	
96-10	16785-16793	maternal	_	
96-11	16794-16807	substance-use	_	
96-12	16808-16814	status	_	
96-13	16815-16817	on	_	
96-14	16818-16828	processing	_	
96-15	16829-16831	of	_	
96-16	16832-16835	sad	_	
96-17	16836-16842	infant	_	
96-18	16843-16848	faces	_	
96-19	16849-16855	within	_	
96-20	16856-16859	the	_	
96-21	16860-16867	ventral	_	
96-22	16868-16876	striatum	_	
96-23	16876-16877	,	_	
96-24	16878-16887	involving	_	
96-25	16888-16897	decreased	_	
96-26	16898-16906	activity	_	
96-27	16907-16912	among	_	
96-28	16913-16928	substance-using	_	
96-29	16929-16935	versus	_	
96-30	16936-16955	non-substance-using	_	
96-31	16956-16963	mothers	_	
96-32	16964-16965	(	_	
96-33	16965-16970	Table	_	
96-34	16971-16972	3	_	
96-35	16972-16973	;	_	
96-36	16974-16980	Figure	_	
96-37	16981-16982	2	_	
96-38	16982-16983	)	_	
96-39	16983-16984	.	_	

#Text=Primary findings were relatively unchanged in follow-up analyses of the extracted cluster values that included demographic factors that differentiated the two maternal groups (i.e., maternal education, parity, and breastfeeding status) as covariates (see supplementary materials).
97-1	16985-16992	Primary	_	
97-2	16993-17001	findings	_	
97-3	17002-17006	were	_	
97-4	17007-17017	relatively	_	
97-5	17018-17027	unchanged	_	
97-6	17028-17030	in	_	
97-7	17031-17040	follow-up	_	
97-8	17041-17049	analyses	_	
97-9	17050-17052	of	_	
97-10	17053-17056	the	_	
97-11	17057-17066	extracted	_	
97-12	17067-17074	cluster	_	
97-13	17075-17081	values	_	
97-14	17082-17086	that	_	
97-15	17087-17095	included	_	
97-16	17096-17107	demographic	_	
97-17	17108-17115	factors	_	
97-18	17116-17120	that	_	
97-19	17121-17135	differentiated	_	
97-20	17136-17139	the	_	
97-21	17140-17143	two	_	
97-22	17144-17152	maternal	_	
97-23	17153-17159	groups	_	
97-24	17160-17161	(	_	
97-25	17161-17164	i.e	_	
97-26	17164-17165	.	_	
97-27	17165-17166	,	_	
97-28	17167-17175	maternal	_	
97-29	17176-17185	education	_	
97-30	17185-17186	,	_	
97-31	17187-17193	parity	_	
97-32	17193-17194	,	_	
97-33	17195-17198	and	_	
97-34	17199-17212	breastfeeding	_	
97-35	17213-17219	status	_	
97-36	17219-17220	)	_	
97-37	17221-17223	as	_	
97-38	17224-17234	covariates	_	
97-39	17235-17236	(	_	
97-40	17236-17239	see	_	
97-41	17240-17253	supplementary	_	
97-42	17254-17263	materials	_	
97-43	17263-17264	)	_	
97-44	17264-17265	.	_	

#Text=Maternal substance-use status did not interact with infant facial emotional expression or infant familiarity for cry trials.
98-1	17266-17274	Maternal	_	
98-2	17275-17288	substance-use	_	
98-3	17289-17295	status	_	
98-4	17296-17299	did	_	
98-5	17300-17303	not	_	
98-6	17304-17312	interact	_	
98-7	17313-17317	with	_	
98-8	17318-17324	infant	_	
98-9	17325-17331	facial	_	
98-10	17332-17341	emotional	_	
98-11	17342-17352	expression	_	
98-12	17353-17355	or	_	
98-13	17356-17362	infant	_	
98-14	17363-17374	familiarity	_	
98-15	17375-17378	for	_	
98-16	17379-17382	cry	_	
98-17	17383-17389	trials	_	
98-18	17389-17390	.	_	

#Text=There was also no main effect of maternal substance-use status across infant face and cry data.
99-1	17391-17396	There	_	
99-2	17397-17400	was	_	
99-3	17401-17405	also	_	
99-4	17406-17408	no	_	
99-5	17409-17413	main	_	
99-6	17414-17420	effect	_	
99-7	17421-17423	of	_	
99-8	17424-17432	maternal	_	
99-9	17433-17446	substance-use	_	
99-10	17447-17453	status	_	
99-11	17454-17460	across	_	
99-12	17461-17467	infant	_	
99-13	17468-17472	face	_	
99-14	17473-17476	and	_	
99-15	17477-17480	cry	_	
99-16	17481-17485	data	_	
99-17	17485-17486	.	_	

#Text=Neuroimaging and Ratings Data
#Text=Substance-using mothers’ responses to own-infant faces in the right lingual gyrus and bilateral cuneus cluster were positively correlated with rating their own infant’s face with respect to distress, r=.41, p=.021, and ratings of sadness, r=.44, p=.013.
100-1	17487-17499	Neuroimaging	_	
100-2	17500-17503	and	_	
100-3	17504-17511	Ratings	_	
100-4	17512-17516	Data	_	
100-5	17517-17532	Substance-using	_	
100-6	17533-17540	mothers	_	
100-7	17540-17541	’	_	
100-8	17542-17551	responses	_	
100-9	17552-17554	to	_	
100-10	17555-17565	own-infant	_	
100-11	17566-17571	faces	_	
100-12	17572-17574	in	_	
100-13	17575-17578	the	_	
100-14	17579-17584	right	_	
100-15	17585-17592	lingual	_	
100-16	17593-17598	gyrus	_	
100-17	17599-17602	and	_	
100-18	17603-17612	bilateral	_	
100-19	17613-17619	cuneus	_	
100-20	17620-17627	cluster	_	
100-21	17628-17632	were	_	
100-22	17633-17643	positively	_	
100-23	17644-17654	correlated	_	
100-24	17655-17659	with	_	
100-25	17660-17666	rating	_	
100-26	17667-17672	their	_	
100-27	17673-17676	own	_	
100-28	17677-17683	infant	_	
100-29	17683-17684	’	_	
100-30	17684-17685	s	_	
100-31	17686-17690	face	_	
100-32	17691-17695	with	_	
100-33	17696-17703	respect	_	
100-34	17704-17706	to	_	
100-35	17707-17715	distress	_	
100-36	17715-17716	,	_	
100-37	17717-17718	r	_	
100-38	17718-17719	=	_	
100-39	17719-17722	.41	_	
100-40	17722-17723	,	_	
100-41	17724-17725	p	_	
100-42	17725-17726	=	_	
100-43	17726-17730	.021	_	
100-44	17730-17731	,	_	
100-45	17732-17735	and	_	
100-46	17736-17743	ratings	_	
100-47	17744-17746	of	_	
100-48	17747-17754	sadness	_	
100-49	17754-17755	,	_	
100-50	17756-17757	r	_	
100-51	17757-17758	=	_	
100-52	17758-17761	.44	_	
100-53	17761-17762	,	_	
100-54	17763-17764	p	_	
100-55	17764-17765	=	_	
100-56	17765-17769	.013	_	
100-57	17769-17770	.	_	

#Text=Similarly, substance-using mothers’ ratings were positively correlated with BOLD responses to unknown-infant faces in this cluster when rating an unknown infant’s feelings of distress, r=.41, p=.020, sadness, r=.37, p=.040, and happiness, r=.36, p=.046.
101-1	17771-17780	Similarly	_	
101-2	17780-17781	,	_	
101-3	17782-17797	substance-using	_	
101-4	17798-17805	mothers	_	
101-5	17805-17806	’	_	
101-6	17807-17814	ratings	_	
101-7	17815-17819	were	_	
101-8	17820-17830	positively	_	
101-9	17831-17841	correlated	_	
101-10	17842-17846	with	_	
101-11	17847-17851	BOLD	_	
101-12	17852-17861	responses	_	
101-13	17862-17864	to	_	
101-14	17865-17879	unknown-infant	_	
101-15	17880-17885	faces	_	
101-16	17886-17888	in	_	
101-17	17889-17893	this	_	
101-18	17894-17901	cluster	_	
101-19	17902-17906	when	_	
101-20	17907-17913	rating	_	
101-21	17914-17916	an	_	
101-22	17917-17924	unknown	_	
101-23	17925-17931	infant	_	
101-24	17931-17932	’	_	
101-25	17932-17933	s	_	
101-26	17934-17942	feelings	_	
101-27	17943-17945	of	_	
101-28	17946-17954	distress	_	
101-29	17954-17955	,	_	
101-30	17956-17957	r	_	
101-31	17957-17958	=	_	
101-32	17958-17961	.41	_	
101-33	17961-17962	,	_	
101-34	17963-17964	p	_	
101-35	17964-17965	=	_	
101-36	17965-17969	.020	_	
101-37	17969-17970	,	_	
101-38	17971-17978	sadness	_	
101-39	17978-17979	,	_	
101-40	17980-17981	r	_	
101-41	17981-17982	=	_	
101-42	17982-17985	.37	_	
101-43	17985-17986	,	_	
101-44	17987-17988	p	_	
101-45	17988-17989	=	_	
101-46	17989-17993	.040	_	
101-47	17993-17994	,	_	
101-48	17995-17998	and	_	
101-49	17999-18008	happiness	_	
101-50	18008-18009	,	_	
101-51	18010-18011	r	_	
101-52	18011-18012	=	_	
101-53	18012-18015	.36	_	
101-54	18015-18016	,	_	
101-55	18017-18018	p	_	
101-56	18018-18019	=	_	
101-57	18019-18023	.046	_	
101-58	18023-18024	.	_	

#Text=There were no statistically significant associations between brain activations and ratings in the non-substance-using maternal group.
102-1	18025-18030	There	_	
102-2	18031-18035	were	_	
102-3	18036-18038	no	_	
102-4	18039-18052	statistically	_	
102-5	18053-18064	significant	_	
102-6	18065-18077	associations	_	
102-7	18078-18085	between	_	
102-8	18086-18091	brain	_	
102-9	18092-18103	activations	_	
102-10	18104-18107	and	_	
102-11	18108-18115	ratings	_	
102-12	18116-18118	in	_	
102-13	18119-18122	the	_	
102-14	18123-18142	non-substance-using	_	
102-15	18143-18151	maternal	_	
102-16	18152-18157	group	_	
102-17	18157-18158	.	_	

#Text=Activations in the ventral striatum cluster to sad infant faces were also not associated with maternal ratings of these faces.
103-1	18159-18170	Activations	_	
103-2	18171-18173	in	_	
103-3	18174-18177	the	_	
103-4	18178-18185	ventral	_	
103-5	18186-18194	striatum	_	
103-6	18195-18202	cluster	_	
103-7	18203-18205	to	_	
103-8	18206-18209	sad	_	
103-9	18210-18216	infant	_	
103-10	18217-18222	faces	_	
103-11	18223-18227	were	_	
103-12	18228-18232	also	_	
103-13	18233-18236	not	_	
103-14	18237-18247	associated	_	
103-15	18248-18252	with	_	
103-16	18253-18261	maternal	_	
103-17	18262-18269	ratings	_	
103-18	18270-18272	of	_	
103-19	18273-18278	these	_	
103-20	18279-18284	faces	_	
103-21	18284-18285	.	_	

#Text=Discussion
#Text=In the current study, we examined relationships between maternal substance-use status and the processing of affective cues from own and unknown infants.
104-1	18286-18296	Discussion	_	
104-2	18297-18299	In	_	
104-3	18300-18303	the	_	
104-4	18304-18311	current	_	
104-5	18312-18317	study	_	
104-6	18317-18318	,	_	
104-7	18319-18321	we	_	
104-8	18322-18330	examined	_	
104-9	18331-18344	relationships	_	
104-10	18345-18352	between	_	
104-11	18353-18361	maternal	_	
104-12	18362-18375	substance-use	_	
104-13	18376-18382	status	_	
104-14	18383-18386	and	_	
104-15	18387-18390	the	_	
104-16	18391-18401	processing	_	
104-17	18402-18404	of	_	
104-18	18405-18414	affective	_	
104-19	18415-18419	cues	_	
104-20	18420-18424	from	_	
104-21	18425-18428	own	_	
104-22	18429-18432	and	_	
104-23	18433-18440	unknown	_	
104-24	18441-18448	infants	_	
104-25	18448-18449	.	_	

#Text=We found that relative to non-substance-using mothers, substance-using mothers evidenced greater activation to own, as compared to unknown, infant faces in superior medial frontal, inferior parietal, and middle temporal regions, extending into the occipital cortex.
105-1	18450-18452	We	_	
105-2	18453-18458	found	_	
105-3	18459-18463	that	_	
105-4	18464-18472	relative	_	
105-5	18473-18475	to	_	
105-6	18476-18495	non-substance-using	_	
105-7	18496-18503	mothers	_	
105-8	18503-18504	,	_	
105-9	18505-18520	substance-using	_	
105-10	18521-18528	mothers	_	
105-11	18529-18538	evidenced	_	
105-12	18539-18546	greater	_	
105-13	18547-18557	activation	_	
105-14	18558-18560	to	_	
105-15	18561-18564	own	_	
105-16	18564-18565	,	_	
105-17	18566-18568	as	_	
105-18	18569-18577	compared	_	
105-19	18578-18580	to	_	
105-20	18581-18588	unknown	_	
105-21	18588-18589	,	_	
105-22	18590-18596	infant	_	
105-23	18597-18602	faces	_	
105-24	18603-18605	in	_	
105-25	18606-18614	superior	_	
105-26	18615-18621	medial	_	
105-27	18622-18629	frontal	_	
105-28	18629-18630	,	_	
105-29	18631-18639	inferior	_	
105-30	18640-18648	parietal	_	
105-31	18648-18649	,	_	
105-32	18650-18653	and	_	
105-33	18654-18660	middle	_	
105-34	18661-18669	temporal	_	
105-35	18670-18677	regions	_	
105-36	18677-18678	,	_	
105-37	18679-18688	extending	_	
105-38	18689-18693	into	_	
105-39	18694-18697	the	_	
105-40	18698-18707	occipital	_	
105-41	18708-18714	cortex	_	
105-42	18714-18715	.	_	

#Text=In contrast, non-substance-using mothers evidenced greater activation to an unknown, as compared to their own, infant’s face across the same brain areas.
106-1	18716-18718	In	_	
106-2	18719-18727	contrast	_	
106-3	18727-18728	,	_	
106-4	18729-18748	non-substance-using	_	
106-5	18749-18756	mothers	_	
106-6	18757-18766	evidenced	_	
106-7	18767-18774	greater	_	
106-8	18775-18785	activation	_	
106-9	18786-18788	to	_	
106-10	18789-18791	an	_	
106-11	18792-18799	unknown	_	
106-12	18799-18800	,	_	
106-13	18801-18803	as	_	
106-14	18804-18812	compared	_	
106-15	18813-18815	to	_	
106-16	18816-18821	their	_	
106-17	18822-18825	own	_	
106-18	18825-18826	,	_	
106-19	18827-18833	infant	_	
106-20	18833-18834	’	_	
106-21	18834-18835	s	_	
106-22	18836-18840	face	_	
106-23	18841-18847	across	_	
106-24	18848-18851	the	_	
106-25	18852-18856	same	_	
106-26	18857-18862	brain	_	
106-27	18863-18868	areas	_	
106-28	18868-18869	.	_	

#Text=Furthermore, we also found that, as compared to the substance-using mothers, non-substance-using mothers had a heightened response to infant sad faces (own and unknown) in the ventral striatum.
107-1	18870-18881	Furthermore	_	
107-2	18881-18882	,	_	
107-3	18883-18885	we	_	
107-4	18886-18890	also	_	
107-5	18891-18896	found	_	
107-6	18897-18901	that	_	
107-7	18901-18902	,	_	
107-8	18903-18905	as	_	
107-9	18906-18914	compared	_	
107-10	18915-18917	to	_	
107-11	18918-18921	the	_	
107-12	18922-18937	substance-using	_	
107-13	18938-18945	mothers	_	
107-14	18945-18946	,	_	
107-15	18947-18966	non-substance-using	_	
107-16	18967-18974	mothers	_	
107-17	18975-18978	had	_	
107-18	18979-18980	a	_	
107-19	18981-18991	heightened	_	
107-20	18992-19000	response	_	
107-21	19001-19003	to	_	
107-22	19004-19010	infant	_	
107-23	19011-19014	sad	_	
107-24	19015-19020	faces	_	
107-25	19021-19022	(	_	
107-26	19022-19025	own	_	
107-27	19026-19029	and	_	
107-28	19030-19037	unknown	_	
107-29	19037-19038	)	_	
107-30	19039-19041	in	_	
107-31	19042-19045	the	_	
107-32	19046-19053	ventral	_	
107-33	19054-19062	striatum	_	
107-34	19062-19063	.	_	

#Text=Importantly, there were no group differences in processing own or unknown infant cries.
108-1	19064-19075	Importantly	_	
108-2	19075-19076	,	_	
108-3	19077-19082	there	_	
108-4	19083-19087	were	_	
108-5	19088-19090	no	_	
108-6	19091-19096	group	_	
108-7	19097-19108	differences	_	
108-8	19109-19111	in	_	
108-9	19112-19122	processing	_	
108-10	19123-19126	own	_	
108-11	19127-19129	or	_	
108-12	19130-19137	unknown	_	
108-13	19138-19144	infant	_	
108-14	19145-19150	cries	_	
108-15	19150-19151	.	_	

#Text=Taken together, these findings suggest that maternal substance use may be associated with altered reactivity to infant affective cues, specifically processing of infant faces.
109-1	19152-19157	Taken	_	
109-2	19158-19166	together	_	
109-3	19166-19167	,	_	
109-4	19168-19173	these	_	
109-5	19174-19182	findings	_	
109-6	19183-19190	suggest	_	
109-7	19191-19195	that	_	
109-8	19196-19204	maternal	_	
109-9	19205-19214	substance	_	
109-10	19215-19218	use	_	
109-11	19219-19222	may	_	
109-12	19223-19225	be	_	
109-13	19226-19236	associated	_	
109-14	19237-19241	with	_	
109-15	19242-19249	altered	_	
109-16	19250-19260	reactivity	_	
109-17	19261-19263	to	_	
109-18	19264-19270	infant	_	
109-19	19271-19280	affective	_	
109-20	19281-19285	cues	_	
109-21	19285-19286	,	_	
109-22	19287-19299	specifically	_	
109-23	19300-19310	processing	_	
109-24	19311-19313	of	_	
109-25	19314-19320	infant	_	
109-26	19321-19326	faces	_	
109-27	19326-19327	.	_	

#Text=Neurobiological models of addiction and parenting propose that neural circuits implicated in parenting are compromised by addiction.
110-1	19328-19343	Neurobiological	_	
110-2	19344-19350	models	_	
110-3	19351-19353	of	_	
110-4	19354-19363	addiction	_	
110-5	19364-19367	and	_	
110-6	19368-19377	parenting	_	
110-7	19378-19385	propose	_	
110-8	19386-19390	that	_	
110-9	19391-19397	neural	_	
110-10	19398-19406	circuits	_	
110-11	19407-19417	implicated	_	
110-12	19418-19420	in	_	
110-13	19421-19430	parenting	_	
110-14	19431-19434	are	_	
110-15	19435-19446	compromised	_	
110-16	19447-19449	by	_	
110-17	19450-19459	addiction	_	
110-18	19459-19460	.	_	

#Text=Specifically, dysregulation of stress and reward neural circuits are hypothesized to lead to decreased reward and motivation for caregiving, with infant affective cues instead being more stress-provoking in mothers with substance-use disorders as compared to non-substance-using mothers.
111-1	19461-19473	Specifically	_	
111-2	19473-19474	,	_	
111-3	19475-19488	dysregulation	_	
111-4	19489-19491	of	_	
111-5	19492-19498	stress	_	
111-6	19499-19502	and	_	
111-7	19503-19509	reward	_	
111-8	19510-19516	neural	_	
111-9	19517-19525	circuits	_	
111-10	19526-19529	are	_	
111-11	19530-19542	hypothesized	_	
111-12	19543-19545	to	_	
111-13	19546-19550	lead	_	
111-14	19551-19553	to	_	
111-15	19554-19563	decreased	_	
111-16	19564-19570	reward	_	
111-17	19571-19574	and	_	
111-18	19575-19585	motivation	_	
111-19	19586-19589	for	_	
111-20	19590-19600	caregiving	_	
111-21	19600-19601	,	_	
111-22	19602-19606	with	_	
111-23	19607-19613	infant	_	
111-24	19614-19623	affective	_	
111-25	19624-19628	cues	_	
111-26	19629-19636	instead	_	
111-27	19637-19642	being	_	
111-28	19643-19647	more	_	
111-29	19648-19664	stress-provoking	_	
111-30	19665-19667	in	_	
111-31	19668-19675	mothers	_	
111-32	19676-19680	with	_	
111-33	19681-19694	substance-use	_	
111-34	19695-19704	disorders	_	
111-35	19705-19707	as	_	
111-36	19708-19716	compared	_	
111-37	19717-19719	to	_	
111-38	19720-19739	non-substance-using	_	
111-39	19740-19747	mothers	_	
111-40	19747-19748	.	_	

#Text=Consistent with this notion, non-substance-using mothers had a greater response to sad infant faces in the ventral striatum relative to the substance-using mothers.
112-1	19749-19759	Consistent	_	
112-2	19760-19764	with	_	
112-3	19765-19769	this	_	
112-4	19770-19776	notion	_	
112-5	19776-19777	,	_	
112-6	19778-19797	non-substance-using	_	
112-7	19798-19805	mothers	_	
112-8	19806-19809	had	_	
112-9	19810-19811	a	_	
112-10	19812-19819	greater	_	
112-11	19820-19828	response	_	
112-12	19829-19831	to	_	
112-13	19832-19835	sad	_	
112-14	19836-19842	infant	_	
112-15	19843-19848	faces	_	
112-16	19849-19851	in	_	
112-17	19852-19855	the	_	
112-18	19856-19863	ventral	_	
112-19	19864-19872	striatum	_	
112-20	19873-19881	relative	_	
112-21	19882-19884	to	_	
112-22	19885-19888	the	_	
112-23	19889-19904	substance-using	_	
112-24	19905-19912	mothers	_	
112-25	19912-19913	.	_	

#Text=The ventral striatum has previously been implicated in maternal neural responses to infant faces, and is a region more generally implicated in reward and motivation.
113-1	19914-19917	The	_	
113-2	19918-19925	ventral	_	
113-3	19926-19934	striatum	_	
113-4	19935-19938	has	_	
113-5	19939-19949	previously	_	
113-6	19950-19954	been	_	
113-7	19955-19965	implicated	_	
113-8	19966-19968	in	_	
113-9	19969-19977	maternal	_	
113-10	19978-19984	neural	_	
113-11	19985-19994	responses	_	
113-12	19995-19997	to	_	
113-13	19998-20004	infant	_	
113-14	20005-20010	faces	_	
113-15	20010-20011	,	_	
113-16	20012-20015	and	_	
113-17	20016-20018	is	_	
113-18	20019-20020	a	_	
113-19	20021-20027	region	_	
113-20	20028-20032	more	_	
113-21	20033-20042	generally	_	
113-22	20043-20053	implicated	_	
113-23	20054-20056	in	_	
113-24	20057-20063	reward	_	
113-25	20064-20067	and	_	
113-26	20068-20078	motivation	_	
113-27	20078-20079	.	_	

#Text=Notably, dopaminergic projections connect multiple brain regions underscoring brain responses to rewards with activity in the ventral striatum proposed to drive responding toward rewards.
114-1	20080-20087	Notably	_	
114-2	20087-20088	,	_	
114-3	20089-20101	dopaminergic	_	
114-4	20102-20113	projections	_	
114-5	20114-20121	connect	_	
114-6	20122-20130	multiple	_	
114-7	20131-20136	brain	_	
114-8	20137-20144	regions	_	
114-9	20145-20157	underscoring	_	
114-10	20158-20163	brain	_	
114-11	20164-20173	responses	_	
114-12	20174-20176	to	_	
114-13	20177-20184	rewards	_	
114-14	20185-20189	with	_	
114-15	20190-20198	activity	_	
114-16	20199-20201	in	_	
114-17	20202-20205	the	_	
114-18	20206-20213	ventral	_	
114-19	20214-20222	striatum	_	
114-20	20223-20231	proposed	_	
114-21	20232-20234	to	_	
114-22	20235-20240	drive	_	
114-23	20241-20251	responding	_	
114-24	20252-20258	toward	_	
114-25	20259-20266	rewards	_	
114-26	20266-20267	.	_	

#Text=Thus, the increased activation to sad infant faces observed in the non-substance-using mothers in the current study may suggest an increased motivation towards the sad infant faces to provide care and the relief of the infant’s distress.
115-1	20268-20272	Thus	_	
115-2	20272-20273	,	_	
115-3	20274-20277	the	_	
115-4	20278-20287	increased	_	
115-5	20288-20298	activation	_	
115-6	20299-20301	to	_	
115-7	20302-20305	sad	_	
115-8	20306-20312	infant	_	
115-9	20313-20318	faces	_	
115-10	20319-20327	observed	_	
115-11	20328-20330	in	_	
115-12	20331-20334	the	_	
115-13	20335-20354	non-substance-using	_	
115-14	20355-20362	mothers	_	
115-15	20363-20365	in	_	
115-16	20366-20369	the	_	
115-17	20370-20377	current	_	
115-18	20378-20383	study	_	
115-19	20384-20387	may	_	
115-20	20388-20395	suggest	_	
115-21	20396-20398	an	_	
115-22	20399-20408	increased	_	
115-23	20409-20419	motivation	_	
115-24	20420-20427	towards	_	
115-25	20428-20431	the	_	
115-26	20432-20435	sad	_	
115-27	20436-20442	infant	_	
115-28	20443-20448	faces	_	
115-29	20449-20451	to	_	
115-30	20452-20459	provide	_	
115-31	20460-20464	care	_	
115-32	20465-20468	and	_	
115-33	20469-20472	the	_	
115-34	20473-20479	relief	_	
115-35	20480-20482	of	_	
115-36	20483-20486	the	_	
115-37	20487-20493	infant	_	
115-38	20493-20494	’	_	
115-39	20494-20495	s	_	
115-40	20496-20504	distress	_	
115-41	20504-20505	.	_	

#Text=Indeed, similar reactivity has also been observed in the ventral striatum when mothers listened to infant cry recordings.
116-1	20506-20512	Indeed	_	
116-2	20512-20513	,	_	
116-3	20514-20521	similar	_	
116-4	20522-20532	reactivity	_	
116-5	20533-20536	has	_	
116-6	20537-20541	also	_	
116-7	20542-20546	been	_	
116-8	20547-20555	observed	_	
116-9	20556-20558	in	_	
116-10	20559-20562	the	_	
116-11	20563-20570	ventral	_	
116-12	20571-20579	striatum	_	
116-13	20580-20584	when	_	
116-14	20585-20592	mothers	_	
116-15	20593-20601	listened	_	
116-16	20602-20604	to	_	
116-17	20605-20611	infant	_	
116-18	20612-20615	cry	_	
116-19	20616-20626	recordings	_	
116-20	20626-20627	.	_	

#Text=The attenuated response in the substance-using mothers may reflect the decreased motivational salience of infant affective cues secondary to addiction, although longitudinal research is needed to fully explore this notion.
117-1	20628-20631	The	_	
117-2	20632-20642	attenuated	_	
117-3	20643-20651	response	_	
117-4	20652-20654	in	_	
117-5	20655-20658	the	_	
117-6	20659-20674	substance-using	_	
117-7	20675-20682	mothers	_	
117-8	20683-20686	may	_	
117-9	20687-20694	reflect	_	
117-10	20695-20698	the	_	
117-11	20699-20708	decreased	_	
117-12	20709-20721	motivational	_	
117-13	20722-20730	salience	_	
117-14	20731-20733	of	_	
117-15	20734-20740	infant	_	
117-16	20741-20750	affective	_	
117-17	20751-20755	cues	_	
117-18	20756-20765	secondary	_	
117-19	20766-20768	to	_	
117-20	20769-20778	addiction	_	
117-21	20778-20779	,	_	
117-22	20780-20788	although	_	
117-23	20789-20801	longitudinal	_	
117-24	20802-20810	research	_	
117-25	20811-20813	is	_	
117-26	20814-20820	needed	_	
117-27	20821-20823	to	_	
117-28	20824-20829	fully	_	
117-29	20830-20837	explore	_	
117-30	20838-20842	this	_	
117-31	20843-20849	notion	_	
117-32	20849-20850	.	_	

#Text=Notably, decreased responses to sad infant faces in the ventral striatum have also been observed in mothers with insecure patterns of attachment as compared to mothers with secure patterns of attachment.
118-1	20851-20858	Notably	_	
118-2	20858-20859	,	_	
118-3	20860-20869	decreased	_	
118-4	20870-20879	responses	_	
118-5	20880-20882	to	_	
118-6	20883-20886	sad	_	
118-7	20887-20893	infant	_	
118-8	20894-20899	faces	_	
118-9	20900-20902	in	_	
118-10	20903-20906	the	_	
118-11	20907-20914	ventral	_	
118-12	20915-20923	striatum	_	
118-13	20924-20928	have	_	
118-14	20929-20933	also	_	
118-15	20934-20938	been	_	
118-16	20939-20947	observed	_	
118-17	20948-20950	in	_	
118-18	20951-20958	mothers	_	
118-19	20959-20963	with	_	
118-20	20964-20972	insecure	_	
118-21	20973-20981	patterns	_	
118-22	20982-20984	of	_	
118-23	20985-20995	attachment	_	
118-24	20996-20998	as	_	
118-25	20999-21007	compared	_	
118-26	21008-21010	to	_	
118-27	21011-21018	mothers	_	
118-28	21019-21023	with	_	
118-29	21024-21030	secure	_	
118-30	21031-21039	patterns	_	
118-31	21040-21042	of	_	
118-32	21043-21053	attachment	_	
118-33	21053-21054	.	_	

#Text=Given that attachment insecurity has been implicated in developmental models of addiction (e.g.,), future research incorporating measures of attachment patterns could provide mechanistic insight into our understanding of aberrant processing of infant cues in substance-using mothers.
119-1	21055-21060	Given	_	
119-2	21061-21065	that	_	
119-3	21066-21076	attachment	_	
119-4	21077-21087	insecurity	_	
119-5	21088-21091	has	_	
119-6	21092-21096	been	_	
119-7	21097-21107	implicated	_	
119-8	21108-21110	in	_	
119-9	21111-21124	developmental	_	
119-10	21125-21131	models	_	
119-11	21132-21134	of	_	
119-12	21135-21144	addiction	_	
119-13	21145-21146	(	_	
119-14	21146-21149	e.g	_	
119-15	21149-21150	.	_	
119-16	21150-21151	,	_	
119-17	21151-21152	)	_	
119-18	21152-21153	,	_	
119-19	21154-21160	future	_	
119-20	21161-21169	research	_	
119-21	21170-21183	incorporating	_	
119-22	21184-21192	measures	_	
119-23	21193-21195	of	_	
119-24	21196-21206	attachment	_	
119-25	21207-21215	patterns	_	
119-26	21216-21221	could	_	
119-27	21222-21229	provide	_	
119-28	21230-21241	mechanistic	_	
119-29	21242-21249	insight	_	
119-30	21250-21254	into	_	
119-31	21255-21258	our	_	
119-32	21259-21272	understanding	_	
119-33	21273-21275	of	_	
119-34	21276-21284	aberrant	_	
119-35	21285-21295	processing	_	
119-36	21296-21298	of	_	
119-37	21299-21305	infant	_	
119-38	21306-21310	cues	_	
119-39	21311-21313	in	_	
119-40	21314-21329	substance-using	_	
119-41	21330-21337	mothers	_	
119-42	21337-21338	.	_	

#Text=Unlike prior work, we did not observe a decreased neural response to own, as compared to unknown, happy infant faces in regions implicated in reward processing, including the ventromedial PFC and ventral striatum when specified as regions of interest (i.e.,).
120-1	21339-21345	Unlike	_	
120-2	21346-21351	prior	_	
120-3	21352-21356	work	_	
120-4	21356-21357	,	_	
120-5	21358-21360	we	_	
120-6	21361-21364	did	_	
120-7	21365-21368	not	_	
120-8	21369-21376	observe	_	
120-9	21377-21378	a	_	
120-10	21379-21388	decreased	_	
120-11	21389-21395	neural	_	
120-12	21396-21404	response	_	
120-13	21405-21407	to	_	
120-14	21408-21411	own	_	
120-15	21411-21412	,	_	
120-16	21413-21415	as	_	
120-17	21416-21424	compared	_	
120-18	21425-21427	to	_	
120-19	21428-21435	unknown	_	
120-20	21435-21436	,	_	
120-21	21437-21442	happy	_	
120-22	21443-21449	infant	_	
120-23	21450-21455	faces	_	
120-24	21456-21458	in	_	
120-25	21459-21466	regions	_	
120-26	21467-21477	implicated	_	
120-27	21478-21480	in	_	
120-28	21481-21487	reward	_	
120-29	21488-21498	processing	_	
120-30	21498-21499	,	_	
120-31	21500-21509	including	_	
120-32	21510-21513	the	_	
120-33	21514-21526	ventromedial	_	
120-34	21527-21530	PFC	_	
120-35	21531-21534	and	_	
120-36	21535-21542	ventral	_	
120-37	21543-21551	striatum	_	
120-38	21552-21556	when	_	
120-39	21557-21566	specified	_	
120-40	21567-21569	as	_	
120-41	21570-21577	regions	_	
120-42	21578-21580	of	_	
120-43	21581-21589	interest	_	
120-44	21590-21591	(	_	
120-45	21591-21594	i.e	_	
120-46	21594-21595	.	_	
120-47	21595-21596	,	_	
120-48	21596-21597	)	_	
120-49	21597-21598	.	_	

#Text=Further, we did not observe an overall between-group effect wherein substance-using mothers had an attenuated response relative to non-substance-using mothers to infant face stimuli (i.e.,).
121-1	21599-21606	Further	_	
121-2	21606-21607	,	_	
121-3	21608-21610	we	_	
121-4	21611-21614	did	_	
121-5	21615-21618	not	_	
121-6	21619-21626	observe	_	
121-7	21627-21629	an	_	
121-8	21630-21637	overall	_	
121-9	21638-21651	between-group	_	
121-10	21652-21658	effect	_	
121-11	21659-21666	wherein	_	
121-12	21667-21682	substance-using	_	
121-13	21683-21690	mothers	_	
121-14	21691-21694	had	_	
121-15	21695-21697	an	_	
121-16	21698-21708	attenuated	_	
121-17	21709-21717	response	_	
121-18	21718-21726	relative	_	
121-19	21727-21729	to	_	
121-20	21730-21749	non-substance-using	_	
121-21	21750-21757	mothers	_	
121-22	21758-21760	to	_	
121-23	21761-21767	infant	_	
121-24	21768-21772	face	_	
121-25	21773-21780	stimuli	_	
121-26	21781-21782	(	_	
121-27	21782-21785	i.e	_	
121-28	21785-21786	.	_	
121-29	21786-21787	,	_	
121-30	21787-21788	)	_	
121-31	21788-21789	.	_	

#Text=Instead, we found that substance-using mothers had increased reactivity to own, as compared to unknown, infant faces across multiple cortical regions.
122-1	21790-21797	Instead	_	
122-2	21797-21798	,	_	
122-3	21799-21801	we	_	
122-4	21802-21807	found	_	
122-5	21808-21812	that	_	
122-6	21813-21828	substance-using	_	
122-7	21829-21836	mothers	_	
122-8	21837-21840	had	_	
122-9	21841-21850	increased	_	
122-10	21851-21861	reactivity	_	
122-11	21862-21864	to	_	
122-12	21865-21868	own	_	
122-13	21868-21869	,	_	
122-14	21870-21872	as	_	
122-15	21873-21881	compared	_	
122-16	21882-21884	to	_	
122-17	21885-21892	unknown	_	
122-18	21892-21893	,	_	
122-19	21894-21900	infant	_	
122-20	21901-21906	faces	_	
122-21	21907-21913	across	_	
122-22	21914-21922	multiple	_	
122-23	21923-21931	cortical	_	
122-24	21932-21939	regions	_	
122-25	21939-21940	.	_	

#Text=Consistent with our finding, also reported increased activation to own, as compared to unknown, infant faces in mothers receiving inpatient treatment for substance-use disorders in the cingulate, insula, precuneus, and precentral and postcentral gyrus – regions overlapping with those reported here.
123-1	21941-21951	Consistent	_	
123-2	21952-21956	with	_	
123-3	21957-21960	our	_	
123-4	21961-21968	finding	_	
123-5	21968-21969	,	_	
123-6	21970-21974	also	_	
123-7	21975-21983	reported	_	
123-8	21984-21993	increased	_	
123-9	21994-22004	activation	_	
123-10	22005-22007	to	_	
123-11	22008-22011	own	_	
123-12	22011-22012	,	_	
123-13	22013-22015	as	_	
123-14	22016-22024	compared	_	
123-15	22025-22027	to	_	
123-16	22028-22035	unknown	_	
123-17	22035-22036	,	_	
123-18	22037-22043	infant	_	
123-19	22044-22049	faces	_	
123-20	22050-22052	in	_	
123-21	22053-22060	mothers	_	
123-22	22061-22070	receiving	_	
123-23	22071-22080	inpatient	_	
123-24	22081-22090	treatment	_	
123-25	22091-22094	for	_	
123-26	22095-22108	substance-use	_	
123-27	22109-22118	disorders	_	
123-28	22119-22121	in	_	
123-29	22122-22125	the	_	
123-30	22126-22135	cingulate	_	
123-31	22135-22136	,	_	
123-32	22137-22143	insula	_	
123-33	22143-22144	,	_	
123-34	22145-22154	precuneus	_	
123-35	22154-22155	,	_	
123-36	22156-22159	and	_	
123-37	22160-22170	precentral	_	
123-38	22171-22174	and	_	
123-39	22175-22186	postcentral	_	
123-40	22187-22192	gyrus	_	
123-41	22193-22194	–	_	
123-42	22195-22202	regions	_	
123-43	22203-22214	overlapping	_	
123-44	22215-22219	with	_	
123-45	22220-22225	those	_	
123-46	22226-22234	reported	_	
123-47	22235-22239	here	_	
123-48	22239-22240	.	_	

#Text=In contrast, mothers not currently using substances evidenced the opposite pattern of responding: greater reactivity to unknown, as compared to own, infant faces.
124-1	22241-22243	In	_	
124-2	22244-22252	contrast	_	
124-3	22252-22253	,	_	
124-4	22254-22261	mothers	_	
124-5	22262-22265	not	_	
124-6	22266-22275	currently	_	
124-7	22276-22281	using	_	
124-8	22282-22292	substances	_	
124-9	22293-22302	evidenced	_	
124-10	22303-22306	the	_	
124-11	22307-22315	opposite	_	
124-12	22316-22323	pattern	_	
124-13	22324-22326	of	_	
124-14	22327-22337	responding	_	
124-15	22337-22338	:	_	
124-16	22339-22346	greater	_	
124-17	22347-22357	reactivity	_	
124-18	22358-22360	to	_	
124-19	22361-22368	unknown	_	
124-20	22368-22369	,	_	
124-21	22370-22372	as	_	
124-22	22373-22381	compared	_	
124-23	22382-22384	to	_	
124-24	22385-22388	own	_	
124-25	22388-22389	,	_	
124-26	22390-22396	infant	_	
124-27	22397-22402	faces	_	
124-28	22402-22403	.	_	

#Text=Nevertheless, there was convergence in findings between the current and prior work.
125-1	22404-22416	Nevertheless	_	
125-2	22416-22417	,	_	
125-3	22418-22423	there	_	
125-4	22424-22427	was	_	
125-5	22428-22439	convergence	_	
125-6	22440-22442	in	_	
125-7	22443-22451	findings	_	
125-8	22452-22459	between	_	
125-9	22460-22463	the	_	
125-10	22464-22471	current	_	
125-11	22472-22475	and	_	
125-12	22476-22481	prior	_	
125-13	22482-22486	work	_	
125-14	22486-22487	.	_	

#Text=Specifically, evidenced a decreased response to unknown infant faces in substance-using mothers as compared to non-substance-using mothers.
126-1	22488-22500	Specifically	_	
126-2	22500-22501	,	_	
126-3	22502-22511	evidenced	_	
126-4	22512-22513	a	_	
126-5	22514-22523	decreased	_	
126-6	22524-22532	response	_	
126-7	22533-22535	to	_	
126-8	22536-22543	unknown	_	
126-9	22544-22550	infant	_	
126-10	22551-22556	faces	_	
126-11	22557-22559	in	_	
126-12	22560-22575	substance-using	_	
126-13	22576-22583	mothers	_	
126-14	22584-22586	as	_	
126-15	22587-22595	compared	_	
126-16	22596-22598	to	_	
126-17	22599-22618	non-substance-using	_	
126-18	22619-22626	mothers	_	
126-19	22626-22627	.	_	

#Text=When viewing the comparable unknown infant face findings in Figure 1, we also observed a descriptively decreased response to unknown infant faces in the maternal substance-using group as compared to the non-substance-using group.
127-1	22628-22632	When	_	
127-2	22633-22640	viewing	_	
127-3	22641-22644	the	_	
127-4	22645-22655	comparable	_	
127-5	22656-22663	unknown	_	
127-6	22664-22670	infant	_	
127-7	22671-22675	face	_	
127-8	22676-22684	findings	_	
127-9	22685-22687	in	_	
127-10	22688-22694	Figure	_	
127-11	22695-22696	1	_	
127-12	22696-22697	,	_	
127-13	22698-22700	we	_	
127-14	22701-22705	also	_	
127-15	22706-22714	observed	_	
127-16	22715-22716	a	_	
127-17	22717-22730	descriptively	_	
127-18	22731-22740	decreased	_	
127-19	22741-22749	response	_	
127-20	22750-22752	to	_	
127-21	22753-22760	unknown	_	
127-22	22761-22767	infant	_	
127-23	22768-22773	faces	_	
127-24	22774-22776	in	_	
127-25	22777-22780	the	_	
127-26	22781-22789	maternal	_	
127-27	22790-22805	substance-using	_	
127-28	22806-22811	group	_	
127-29	22812-22814	as	_	
127-30	22815-22823	compared	_	
127-31	22824-22826	to	_	
127-32	22827-22830	the	_	
127-33	22831-22850	non-substance-using	_	
127-34	22851-22856	group	_	
127-35	22856-22857	.	_	

#Text=Why might maternal substance use be associated with increased reactivity to own, as compared to unknown, emotional infant faces?
128-1	22858-22861	Why	_	
128-2	22862-22867	might	_	
128-3	22868-22876	maternal	_	
128-4	22877-22886	substance	_	
128-5	22887-22890	use	_	
128-6	22891-22893	be	_	
128-7	22894-22904	associated	_	
128-8	22905-22909	with	_	
128-9	22910-22919	increased	_	
128-10	22920-22930	reactivity	_	
128-11	22931-22933	to	_	
128-12	22934-22937	own	_	
128-13	22937-22938	,	_	
128-14	22939-22941	as	_	
128-15	22942-22950	compared	_	
128-16	22951-22953	to	_	
128-17	22954-22961	unknown	_	
128-18	22961-22962	,	_	
128-19	22963-22972	emotional	_	
128-20	22973-22979	infant	_	
128-21	22980-22985	faces	_	
128-22	22985-22986	?	_	

#Text=Consistent with neurobiological models of parenting and addiction, this increased responsiveness to own-infant cues may relate to heightened arousal or reactivity to infant facial cues of affect in substance-using mothers.
129-1	22987-22997	Consistent	_	
129-2	22998-23002	with	_	
129-3	23003-23018	neurobiological	_	
129-4	23019-23025	models	_	
129-5	23026-23028	of	_	
129-6	23029-23038	parenting	_	
129-7	23039-23042	and	_	
129-8	23043-23052	addiction	_	
129-9	23052-23053	,	_	
129-10	23054-23058	this	_	
129-11	23059-23068	increased	_	
129-12	23069-23083	responsiveness	_	
129-13	23084-23086	to	_	
129-14	23087-23097	own-infant	_	
129-15	23098-23102	cues	_	
129-16	23103-23106	may	_	
129-17	23107-23113	relate	_	
129-18	23114-23116	to	_	
129-19	23117-23127	heightened	_	
129-20	23128-23135	arousal	_	
129-21	23136-23138	or	_	
129-22	23139-23149	reactivity	_	
129-23	23150-23152	to	_	
129-24	23153-23159	infant	_	
129-25	23160-23166	facial	_	
129-26	23167-23171	cues	_	
129-27	23172-23174	of	_	
129-28	23175-23181	affect	_	
129-29	23182-23184	in	_	
129-30	23185-23200	substance-using	_	
129-31	23201-23208	mothers	_	
129-32	23208-23209	.	_	

#Text=Prior research in non-parents has also evidenced increased activation in the occipital gyrus, and right inferior and superior parietal lobule, to emotional as compared to neutral pictures, with more arousing pictures (positive and negative) being associated with more widespread activity in these areas.
130-1	23210-23215	Prior	_	
130-2	23216-23224	research	_	
130-3	23225-23227	in	_	
130-4	23228-23239	non-parents	_	
130-5	23240-23243	has	_	
130-6	23244-23248	also	_	
130-7	23249-23258	evidenced	_	
130-8	23259-23268	increased	_	
130-9	23269-23279	activation	_	
130-10	23280-23282	in	_	
130-11	23283-23286	the	_	
130-12	23287-23296	occipital	_	
130-13	23297-23302	gyrus	_	
130-14	23302-23303	,	_	
130-15	23304-23307	and	_	
130-16	23308-23313	right	_	
130-17	23314-23322	inferior	_	
130-18	23323-23326	and	_	
130-19	23327-23335	superior	_	
130-20	23336-23344	parietal	_	
130-21	23345-23351	lobule	_	
130-22	23351-23352	,	_	
130-23	23353-23355	to	_	
130-24	23356-23365	emotional	_	
130-25	23366-23368	as	_	
130-26	23369-23377	compared	_	
130-27	23378-23380	to	_	
130-28	23381-23388	neutral	_	
130-29	23389-23397	pictures	_	
130-30	23397-23398	,	_	
130-31	23399-23403	with	_	
130-32	23404-23408	more	_	
130-33	23409-23417	arousing	_	
130-34	23418-23426	pictures	_	
130-35	23427-23428	(	_	
130-36	23428-23436	positive	_	
130-37	23437-23440	and	_	
130-38	23441-23449	negative	_	
130-39	23449-23450	)	_	
130-40	23451-23456	being	_	
130-41	23457-23467	associated	_	
130-42	23468-23472	with	_	
130-43	23473-23477	more	_	
130-44	23478-23488	widespread	_	
130-45	23489-23497	activity	_	
130-46	23498-23500	in	_	
130-47	23501-23506	these	_	
130-48	23507-23512	areas	_	
130-49	23512-23513	.	_	

#Text=Furthermore, ratings collected from substance-using mothers after the scanning protocol indicate that, in the cluster incorporating the right lingual gyrus and bilateral cuneus, increased activities to infant face stimuli were associated with increased ratings of affective intensities of the faces.
131-1	23514-23525	Furthermore	_	
131-2	23525-23526	,	_	
131-3	23527-23534	ratings	_	
131-4	23535-23544	collected	_	
131-5	23545-23549	from	_	
131-6	23550-23565	substance-using	_	
131-7	23566-23573	mothers	_	
131-8	23574-23579	after	_	
131-9	23580-23583	the	_	
131-10	23584-23592	scanning	_	
131-11	23593-23601	protocol	_	
131-12	23602-23610	indicate	_	
131-13	23611-23615	that	_	
131-14	23615-23616	,	_	
131-15	23617-23619	in	_	
131-16	23620-23623	the	_	
131-17	23624-23631	cluster	_	
131-18	23632-23645	incorporating	_	
131-19	23646-23649	the	_	
131-20	23650-23655	right	_	
131-21	23656-23663	lingual	_	
131-22	23664-23669	gyrus	_	
131-23	23670-23673	and	_	
131-24	23674-23683	bilateral	_	
131-25	23684-23690	cuneus	_	
131-26	23690-23691	,	_	
131-27	23692-23701	increased	_	
131-28	23702-23712	activities	_	
131-29	23713-23715	to	_	
131-30	23716-23722	infant	_	
131-31	23723-23727	face	_	
131-32	23728-23735	stimuli	_	
131-33	23736-23740	were	_	
131-34	23741-23751	associated	_	
131-35	23752-23756	with	_	
131-36	23757-23766	increased	_	
131-37	23767-23774	ratings	_	
131-38	23775-23777	of	_	
131-39	23778-23787	affective	_	
131-40	23788-23799	intensities	_	
131-41	23800-23802	of	_	
131-42	23803-23806	the	_	
131-43	23807-23812	faces	_	
131-44	23812-23813	.	_	

#Text=Finally, increased activation to own-infant sad faces as compared to unknown-infant sad faces has previously been shown in the insula in mothers with attachment insecurity.
132-1	23814-23821	Finally	_	
132-2	23821-23822	,	_	
132-3	23823-23832	increased	_	
132-4	23833-23843	activation	_	
132-5	23844-23846	to	_	
132-6	23847-23857	own-infant	_	
132-7	23858-23861	sad	_	
132-8	23862-23867	faces	_	
132-9	23868-23870	as	_	
132-10	23871-23879	compared	_	
132-11	23880-23882	to	_	
132-12	23883-23897	unknown-infant	_	
132-13	23898-23901	sad	_	
132-14	23902-23907	faces	_	
132-15	23908-23911	has	_	
132-16	23912-23922	previously	_	
132-17	23923-23927	been	_	
132-18	23928-23933	shown	_	
132-19	23934-23936	in	_	
132-20	23937-23940	the	_	
132-21	23941-23947	insula	_	
132-22	23948-23950	in	_	
132-23	23951-23958	mothers	_	
132-24	23959-23963	with	_	
132-25	23964-23974	attachment	_	
132-26	23975-23985	insecurity	_	
132-27	23985-23986	.	_	

#Text=The insula has been associated with emotional experiences and may be involved in higher-level representation of emotional states.
133-1	23987-23990	The	_	
133-2	23991-23997	insula	_	
133-3	23998-24001	has	_	
133-4	24002-24006	been	_	
133-5	24007-24017	associated	_	
133-6	24018-24022	with	_	
133-7	24023-24032	emotional	_	
133-8	24033-24044	experiences	_	
133-9	24045-24048	and	_	
133-10	24049-24052	may	_	
133-11	24053-24055	be	_	
133-12	24056-24064	involved	_	
133-13	24065-24067	in	_	
133-14	24068-24080	higher-level	_	
133-15	24081-24095	representation	_	
133-16	24096-24098	of	_	
133-17	24099-24108	emotional	_	
133-18	24109-24115	states	_	
133-19	24115-24116	.	_	

#Text=Furthermore, insula activity elicited by negatively valenced stimuli can be down-regulated by cognitive reappraisal.
134-1	24117-24128	Furthermore	_	
134-2	24128-24129	,	_	
134-3	24130-24136	insula	_	
134-4	24137-24145	activity	_	
134-5	24146-24154	elicited	_	
134-6	24155-24157	by	_	
134-7	24158-24168	negatively	_	
134-8	24169-24177	valenced	_	
134-9	24178-24185	stimuli	_	
134-10	24186-24189	can	_	
134-11	24190-24192	be	_	
134-12	24193-24207	down-regulated	_	
134-13	24208-24210	by	_	
134-14	24211-24220	cognitive	_	
134-15	24221-24232	reappraisal	_	
134-16	24232-24233	.	_	

#Text=Therefore, one explanation of the current findings may be that substance-using mothers evidence increased reactivity to own-infant cues akin to an arousal or an affective/stress response.
135-1	24234-24243	Therefore	_	
135-2	24243-24244	,	_	
135-3	24245-24248	one	_	
135-4	24249-24260	explanation	_	
135-5	24261-24263	of	_	
135-6	24264-24267	the	_	
135-7	24268-24275	current	_	
135-8	24276-24284	findings	_	
135-9	24285-24288	may	_	
135-10	24289-24291	be	_	
135-11	24292-24296	that	_	
135-12	24297-24312	substance-using	_	
135-13	24313-24320	mothers	_	
135-14	24321-24329	evidence	_	
135-15	24330-24339	increased	_	
135-16	24340-24350	reactivity	_	
135-17	24351-24353	to	_	
135-18	24354-24364	own-infant	_	
135-19	24365-24369	cues	_	
135-20	24370-24374	akin	_	
135-21	24375-24377	to	_	
135-22	24378-24380	an	_	
135-23	24381-24388	arousal	_	
135-24	24389-24391	or	_	
135-25	24392-24394	an	_	
135-26	24395-24404	affective	_	
135-27	24404-24405	/	_	
135-28	24405-24411	stress	_	
135-29	24412-24420	response	_	
135-30	24420-24421	.	_	

#Text=Consideration is also warranted for why non-substance-using mothers may have a greater neural response to unknown, as compared to own, infant faces across these same cortical regions.
136-1	24422-24435	Consideration	_	
136-2	24436-24438	is	_	
136-3	24439-24443	also	_	
136-4	24444-24453	warranted	_	
136-5	24454-24457	for	_	
136-6	24458-24461	why	_	
136-7	24462-24481	non-substance-using	_	
136-8	24482-24489	mothers	_	
136-9	24490-24493	may	_	
136-10	24494-24498	have	_	
136-11	24499-24500	a	_	
136-12	24501-24508	greater	_	
136-13	24509-24515	neural	_	
136-14	24516-24524	response	_	
136-15	24525-24527	to	_	
136-16	24528-24535	unknown	_	
136-17	24535-24536	,	_	
136-18	24537-24539	as	_	
136-19	24540-24548	compared	_	
136-20	24549-24551	to	_	
136-21	24552-24555	own	_	
136-22	24555-24556	,	_	
136-23	24557-24563	infant	_	
136-24	24564-24569	faces	_	
136-25	24570-24576	across	_	
136-26	24577-24582	these	_	
136-27	24583-24587	same	_	
136-28	24588-24596	cortical	_	
136-29	24597-24604	regions	_	
136-30	24604-24605	.	_	

#Text=An attenuated response may suggest potential habituation to these presumably salient infant affective stimuli, possibly related to non-substance-using mothers spending more time with their infants.
137-1	24606-24608	An	_	
137-2	24609-24619	attenuated	_	
137-3	24620-24628	response	_	
137-4	24629-24632	may	_	
137-5	24633-24640	suggest	_	
137-6	24641-24650	potential	_	
137-7	24651-24662	habituation	_	
137-8	24663-24665	to	_	
137-9	24666-24671	these	_	
137-10	24672-24682	presumably	_	
137-11	24683-24690	salient	_	
137-12	24691-24697	infant	_	
137-13	24698-24707	affective	_	
137-14	24708-24715	stimuli	_	
137-15	24715-24716	,	_	
137-16	24717-24725	possibly	_	
137-17	24726-24733	related	_	
137-18	24734-24736	to	_	
137-19	24737-24756	non-substance-using	_	
137-20	24757-24764	mothers	_	
137-21	24765-24773	spending	_	
137-22	24774-24778	more	_	
137-23	24779-24783	time	_	
137-24	24784-24788	with	_	
137-25	24789-24794	their	_	
137-26	24795-24802	infants	_	
137-27	24802-24803	.	_	

#Text=However, contrary to this, substance-using and non-substance-using mothers in this study were fairly comparable in the durations spent away from their child.
138-1	24804-24811	However	_	
138-2	24811-24812	,	_	
138-3	24813-24821	contrary	_	
138-4	24822-24824	to	_	
138-5	24825-24829	this	_	
138-6	24829-24830	,	_	
138-7	24831-24846	substance-using	_	
138-8	24847-24850	and	_	
138-9	24851-24870	non-substance-using	_	
138-10	24871-24878	mothers	_	
138-11	24879-24881	in	_	
138-12	24882-24886	this	_	
138-13	24887-24892	study	_	
138-14	24893-24897	were	_	
138-15	24898-24904	fairly	_	
138-16	24905-24915	comparable	_	
138-17	24916-24918	in	_	
138-18	24919-24922	the	_	
138-19	24923-24932	durations	_	
138-20	24933-24938	spent	_	
138-21	24939-24943	away	_	
138-22	24944-24948	from	_	
138-23	24949-24954	their	_	
138-24	24955-24960	child	_	
138-25	24960-24961	.	_	

#Text=However, substance-using mothers had shorter durations of breastfeeding with more women reporting not breastfeeding at all, relative to the non-substance-using mothers.
139-1	24962-24969	However	_	
139-2	24969-24970	,	_	
139-3	24971-24986	substance-using	_	
139-4	24987-24994	mothers	_	
139-5	24995-24998	had	_	
139-6	24999-25006	shorter	_	
139-7	25007-25016	durations	_	
139-8	25017-25019	of	_	
139-9	25020-25033	breastfeeding	_	
139-10	25034-25038	with	_	
139-11	25039-25043	more	_	
139-12	25044-25049	women	_	
139-13	25050-25059	reporting	_	
139-14	25060-25063	not	_	
139-15	25064-25077	breastfeeding	_	
139-16	25078-25080	at	_	
139-17	25081-25084	all	_	
139-18	25084-25085	,	_	
139-19	25086-25094	relative	_	
139-20	25095-25097	to	_	
139-21	25098-25101	the	_	
139-22	25102-25121	non-substance-using	_	
139-23	25122-25129	mothers	_	
139-24	25129-25130	.	_	

#Text=Although we did not measure maternal oxytocin levels in the current study, oxytocin is implicated in breastfeeding and mothers with insecure patterns of attachment have evidenced a decreased oxytocin response during interactions with their infants, perhaps implicating a role for the oxytocinergic and attachment systems in our current findings.
140-1	25131-25139	Although	_	
140-2	25140-25142	we	_	
140-3	25143-25146	did	_	
140-4	25147-25150	not	_	
140-5	25151-25158	measure	_	
140-6	25159-25167	maternal	_	
140-7	25168-25176	oxytocin	_	
140-8	25177-25183	levels	_	
140-9	25184-25186	in	_	
140-10	25187-25190	the	_	
140-11	25191-25198	current	_	
140-12	25199-25204	study	_	
140-13	25204-25205	,	_	
140-14	25206-25214	oxytocin	_	
140-15	25215-25217	is	_	
140-16	25218-25228	implicated	_	
140-17	25229-25231	in	_	
140-18	25232-25245	breastfeeding	_	
140-19	25246-25249	and	_	
140-20	25250-25257	mothers	_	
140-21	25258-25262	with	_	
140-22	25263-25271	insecure	_	
140-23	25272-25280	patterns	_	
140-24	25281-25283	of	_	
140-25	25284-25294	attachment	_	
140-26	25295-25299	have	_	
140-27	25300-25309	evidenced	_	
140-28	25310-25311	a	_	
140-29	25312-25321	decreased	_	
140-30	25322-25330	oxytocin	_	
140-31	25331-25339	response	_	
140-32	25340-25346	during	_	
140-33	25347-25359	interactions	_	
140-34	25360-25364	with	_	
140-35	25365-25370	their	_	
140-36	25371-25378	infants	_	
140-37	25378-25379	,	_	
140-38	25380-25387	perhaps	_	
140-39	25388-25399	implicating	_	
140-40	25400-25401	a	_	
140-41	25402-25406	role	_	
140-42	25407-25410	for	_	
140-43	25411-25414	the	_	
140-44	25415-25428	oxytocinergic	_	
140-45	25429-25432	and	_	
140-46	25433-25443	attachment	_	
140-47	25444-25451	systems	_	
140-48	25452-25454	in	_	
140-49	25455-25458	our	_	
140-50	25459-25466	current	_	
140-51	25467-25475	findings	_	
140-52	25475-25476	.	_	

#Text=Alternatively, reactivity to own-infant cues may be tempered in non-substance-using mothers, given greater tendencies to understand and interpret their infant’s affective bids, and thus not become overwhelmed by these emotional cues, a capacity that is often compromised in mothers with addictions.
141-1	25477-25490	Alternatively	_	
141-2	25490-25491	,	_	
141-3	25492-25502	reactivity	_	
141-4	25503-25505	to	_	
141-5	25506-25516	own-infant	_	
141-6	25517-25521	cues	_	
141-7	25522-25525	may	_	
141-8	25526-25528	be	_	
141-9	25529-25537	tempered	_	
141-10	25538-25540	in	_	
141-11	25541-25560	non-substance-using	_	
141-12	25561-25568	mothers	_	
141-13	25568-25569	,	_	
141-14	25570-25575	given	_	
141-15	25576-25583	greater	_	
141-16	25584-25594	tendencies	_	
141-17	25595-25597	to	_	
141-18	25598-25608	understand	_	
141-19	25609-25612	and	_	
141-20	25613-25622	interpret	_	
141-21	25623-25628	their	_	
141-22	25629-25635	infant	_	
141-23	25635-25636	’	_	
141-24	25636-25637	s	_	
141-25	25638-25647	affective	_	
141-26	25648-25652	bids	_	
141-27	25652-25653	,	_	
141-28	25654-25657	and	_	
141-29	25658-25662	thus	_	
141-30	25663-25666	not	_	
141-31	25667-25673	become	_	
141-32	25674-25685	overwhelmed	_	
141-33	25686-25688	by	_	
141-34	25689-25694	these	_	
141-35	25695-25704	emotional	_	
141-36	25705-25709	cues	_	
141-37	25709-25710	,	_	
141-38	25711-25712	a	_	
141-39	25713-25721	capacity	_	
141-40	25722-25726	that	_	
141-41	25727-25729	is	_	
141-42	25730-25735	often	_	
141-43	25736-25747	compromised	_	
141-44	25748-25750	in	_	
141-45	25751-25758	mothers	_	
141-46	25759-25763	with	_	
141-47	25764-25774	addictions	_	
141-48	25774-25775	.	_	

#Text=Thus, future studies developing this line of research should incorporate more precise measures of the quality and quantity of mother-infant interactions, including levels of oxytocin and attachment security, alongside measures that provide an indication of the capacity to respond and interpret affective signals from infants to inform our understanding of maternal brain findings.
142-1	25776-25780	Thus	_	
142-2	25780-25781	,	_	
142-3	25782-25788	future	_	
142-4	25789-25796	studies	_	
142-5	25797-25807	developing	_	
142-6	25808-25812	this	_	
142-7	25813-25817	line	_	
142-8	25818-25820	of	_	
142-9	25821-25829	research	_	
142-10	25830-25836	should	_	
142-11	25837-25848	incorporate	_	
142-12	25849-25853	more	_	
142-13	25854-25861	precise	_	
142-14	25862-25870	measures	_	
142-15	25871-25873	of	_	
142-16	25874-25877	the	_	
142-17	25878-25885	quality	_	
142-18	25886-25889	and	_	
142-19	25890-25898	quantity	_	
142-20	25899-25901	of	_	
142-21	25902-25915	mother-infant	_	
142-22	25916-25928	interactions	_	
142-23	25928-25929	,	_	
142-24	25930-25939	including	_	
142-25	25940-25946	levels	_	
142-26	25947-25949	of	_	
142-27	25950-25958	oxytocin	_	
142-28	25959-25962	and	_	
142-29	25963-25973	attachment	_	
142-30	25974-25982	security	_	
142-31	25982-25983	,	_	
142-32	25984-25993	alongside	_	
142-33	25994-26002	measures	_	
142-34	26003-26007	that	_	
142-35	26008-26015	provide	_	
142-36	26016-26018	an	_	
142-37	26019-26029	indication	_	
142-38	26030-26032	of	_	
142-39	26033-26036	the	_	
142-40	26037-26045	capacity	_	
142-41	26046-26048	to	_	
142-42	26049-26056	respond	_	
142-43	26057-26060	and	_	
142-44	26061-26070	interpret	_	
142-45	26071-26080	affective	_	
142-46	26081-26088	signals	_	
142-47	26089-26093	from	_	
142-48	26094-26101	infants	_	
142-49	26102-26104	to	_	
142-50	26105-26111	inform	_	
142-51	26112-26115	our	_	
142-52	26116-26129	understanding	_	
142-53	26130-26132	of	_	
142-54	26133-26141	maternal	_	
142-55	26142-26147	brain	_	
142-56	26148-26156	findings	_	
142-57	26156-26157	.	_	

#Text=We found no evidence for alterations in neural processing of infant cries as a function of maternal substance use.
143-1	26158-26160	We	_	
143-2	26161-26166	found	_	
143-3	26167-26169	no	_	
143-4	26170-26178	evidence	_	
143-5	26179-26182	for	_	
143-6	26183-26194	alterations	_	
143-7	26195-26197	in	_	
143-8	26198-26204	neural	_	
143-9	26205-26215	processing	_	
143-10	26216-26218	of	_	
143-11	26219-26225	infant	_	
143-12	26226-26231	cries	_	
143-13	26232-26234	as	_	
143-14	26235-26236	a	_	
143-15	26237-26245	function	_	
143-16	26246-26248	of	_	
143-17	26249-26257	maternal	_	
143-18	26258-26267	substance	_	
143-19	26268-26271	use	_	
143-20	26271-26272	.	_	

#Text=This contrasts with prior work, employing unknown infant cries, that evidenced a decreased response to infant cries in substance-using, as compared to non-substance-using, mothers.
144-1	26273-26277	This	_	
144-2	26278-26287	contrasts	_	
144-3	26288-26292	with	_	
144-4	26293-26298	prior	_	
144-5	26299-26303	work	_	
144-6	26303-26304	,	_	
144-7	26305-26314	employing	_	
144-8	26315-26322	unknown	_	
144-9	26323-26329	infant	_	
144-10	26330-26335	cries	_	
144-11	26335-26336	,	_	
144-12	26337-26341	that	_	
144-13	26342-26351	evidenced	_	
144-14	26352-26353	a	_	
144-15	26354-26363	decreased	_	
144-16	26364-26372	response	_	
144-17	26373-26375	to	_	
144-18	26376-26382	infant	_	
144-19	26383-26388	cries	_	
144-20	26389-26391	in	_	
144-21	26392-26407	substance-using	_	
144-22	26407-26408	,	_	
144-23	26409-26411	as	_	
144-24	26412-26420	compared	_	
144-25	26421-26423	to	_	
144-26	26424-26443	non-substance-using	_	
144-27	26443-26444	,	_	
144-28	26445-26452	mothers	_	
144-29	26452-26453	.	_	

#Text=Other studies have shown differential sensitivity to infant cries in clinical groups, including mothers with and without depression.
145-1	26454-26459	Other	_	
145-2	26460-26467	studies	_	
145-3	26468-26472	have	_	
145-4	26473-26478	shown	_	
145-5	26479-26491	differential	_	
145-6	26492-26503	sensitivity	_	
145-7	26504-26506	to	_	
145-8	26507-26513	infant	_	
145-9	26514-26519	cries	_	
145-10	26520-26522	in	_	
145-11	26523-26531	clinical	_	
145-12	26532-26538	groups	_	
145-13	26538-26539	,	_	
145-14	26540-26549	including	_	
145-15	26550-26557	mothers	_	
145-16	26558-26562	with	_	
145-17	26563-26566	and	_	
145-18	26567-26574	without	_	
145-19	26575-26585	depression	_	
145-20	26585-26586	.	_	

#Text=Furthermore, experimental instructions relating to cry perception and parenting characteristics are associated with changing responses to cries at neurobiological levels.
146-1	26587-26598	Furthermore	_	
146-2	26598-26599	,	_	
146-3	26600-26612	experimental	_	
146-4	26613-26625	instructions	_	
146-5	26626-26634	relating	_	
146-6	26635-26637	to	_	
146-7	26638-26641	cry	_	
146-8	26642-26652	perception	_	
146-9	26653-26656	and	_	
146-10	26657-26666	parenting	_	
146-11	26667-26682	characteristics	_	
146-12	26683-26686	are	_	
146-13	26687-26697	associated	_	
146-14	26698-26702	with	_	
146-15	26703-26711	changing	_	
146-16	26712-26721	responses	_	
146-17	26722-26724	to	_	
146-18	26725-26730	cries	_	
146-19	26731-26733	at	_	
146-20	26734-26749	neurobiological	_	
146-21	26750-26756	levels	_	
146-22	26756-26757	.	_	

#Text=These latter studies have employed cry recordings longer in duration than the two-second cries employed here, perhaps explaining this discrepancy.
147-1	26758-26763	These	_	
147-2	26764-26770	latter	_	
147-3	26771-26778	studies	_	
147-4	26779-26783	have	_	
147-5	26784-26792	employed	_	
147-6	26793-26796	cry	_	
147-7	26797-26807	recordings	_	
147-8	26808-26814	longer	_	
147-9	26815-26817	in	_	
147-10	26818-26826	duration	_	
147-11	26827-26831	than	_	
147-12	26832-26835	the	_	
147-13	26836-26846	two-second	_	
147-14	26847-26852	cries	_	
147-15	26853-26861	employed	_	
147-16	26862-26866	here	_	
147-17	26866-26867	,	_	
147-18	26868-26875	perhaps	_	
147-19	26876-26886	explaining	_	
147-20	26887-26891	this	_	
147-21	26892-26903	discrepancy	_	
147-22	26903-26904	.	_	

#Text=Thus, our null findings of maternal substance-use status and familiarity may in part be attributable to these differences in cry parameters.
148-1	26905-26909	Thus	_	
148-2	26909-26910	,	_	
148-3	26911-26914	our	_	
148-4	26915-26919	null	_	
148-5	26920-26928	findings	_	
148-6	26929-26931	of	_	
148-7	26932-26940	maternal	_	
148-8	26941-26954	substance-use	_	
148-9	26955-26961	status	_	
148-10	26962-26965	and	_	
148-11	26966-26977	familiarity	_	
148-12	26978-26981	may	_	
148-13	26982-26984	in	_	
148-14	26985-26989	part	_	
148-15	26990-26992	be	_	
148-16	26993-27005	attributable	_	
148-17	27006-27008	to	_	
148-18	27009-27014	these	_	
148-19	27015-27026	differences	_	
148-20	27027-27029	in	_	
148-21	27030-27033	cry	_	
148-22	27034-27044	parameters	_	
148-23	27044-27045	.	_	

#Text=That being said, it is worth noting differences in self-reported measures of cries that occurred after the scanning protocol wherein substance-using mothers rated the cry stimuli (own and unknown) as less sad and distressed than non-substance-using mothers.
149-1	27046-27050	That	_	
149-2	27051-27056	being	_	
149-3	27057-27061	said	_	
149-4	27061-27062	,	_	
149-5	27063-27065	it	_	
149-6	27066-27068	is	_	
149-7	27069-27074	worth	_	
149-8	27075-27081	noting	_	
149-9	27082-27093	differences	_	
149-10	27094-27096	in	_	
149-11	27097-27110	self-reported	_	
149-12	27111-27119	measures	_	
149-13	27120-27122	of	_	
149-14	27123-27128	cries	_	
149-15	27129-27133	that	_	
149-16	27134-27142	occurred	_	
149-17	27143-27148	after	_	
149-18	27149-27152	the	_	
149-19	27153-27161	scanning	_	
149-20	27162-27170	protocol	_	
149-21	27171-27178	wherein	_	
149-22	27179-27194	substance-using	_	
149-23	27195-27202	mothers	_	
149-24	27203-27208	rated	_	
149-25	27209-27212	the	_	
149-26	27213-27216	cry	_	
149-27	27217-27224	stimuli	_	
149-28	27225-27226	(	_	
149-29	27226-27229	own	_	
149-30	27230-27233	and	_	
149-31	27234-27241	unknown	_	
149-32	27241-27242	)	_	
149-33	27243-27245	as	_	
149-34	27246-27250	less	_	
149-35	27251-27254	sad	_	
149-36	27255-27258	and	_	
149-37	27259-27269	distressed	_	
149-38	27270-27274	than	_	
149-39	27275-27294	non-substance-using	_	
149-40	27295-27302	mothers	_	
149-41	27302-27303	.	_	

#Text=Furthermore, across the sample, mothers rated their own infant’s cries as sadder and more distressed than the unknown infant’s cries.
150-1	27304-27315	Furthermore	_	
150-2	27315-27316	,	_	
150-3	27317-27323	across	_	
150-4	27324-27327	the	_	
150-5	27328-27334	sample	_	
150-6	27334-27335	,	_	
150-7	27336-27343	mothers	_	
150-8	27344-27349	rated	_	
150-9	27350-27355	their	_	
150-10	27356-27359	own	_	
150-11	27360-27366	infant	_	
150-12	27366-27367	’	_	
150-13	27367-27368	s	_	
150-14	27369-27374	cries	_	
150-15	27375-27377	as	_	
150-16	27378-27384	sadder	_	
150-17	27385-27388	and	_	
150-18	27389-27393	more	_	
150-19	27394-27404	distressed	_	
150-20	27405-27409	than	_	
150-21	27410-27413	the	_	
150-22	27414-27421	unknown	_	
150-23	27422-27428	infant	_	
150-24	27428-27429	’	_	
150-25	27429-27430	s	_	
150-26	27431-27436	cries	_	
150-27	27436-27437	.	_	

#Text=Therefore, at a self-report level, maternal substance-use and familiarity effects emerge, but we do not see this same distinction at the level of neural function.
151-1	27438-27447	Therefore	_	
151-2	27447-27448	,	_	
151-3	27449-27451	at	_	
151-4	27452-27453	a	_	
151-5	27454-27465	self-report	_	
151-6	27466-27471	level	_	
151-7	27471-27472	,	_	
151-8	27473-27481	maternal	_	
151-9	27482-27495	substance-use	_	
151-10	27496-27499	and	_	
151-11	27500-27511	familiarity	_	
151-12	27512-27519	effects	_	
151-13	27520-27526	emerge	_	
151-14	27526-27527	,	_	
151-15	27528-27531	but	_	
151-16	27532-27534	we	_	
151-17	27535-27537	do	_	
151-18	27538-27541	not	_	
151-19	27542-27545	see	_	
151-20	27546-27550	this	_	
151-21	27551-27555	same	_	
151-22	27556-27567	distinction	_	
151-23	27568-27570	at	_	
151-24	27571-27574	the	_	
151-25	27575-27580	level	_	
151-26	27581-27583	of	_	
151-27	27584-27590	neural	_	
151-28	27591-27599	function	_	
151-29	27599-27600	.	_	

#Text=This divergence in brain and behavioral measures might reflect a response bias, a limitation of subjective measures, or a decrease in salience in response to repeated exposure to the cries across the scanning protocol.
152-1	27601-27605	This	_	
152-2	27606-27616	divergence	_	
152-3	27617-27619	in	_	
152-4	27620-27625	brain	_	
152-5	27626-27629	and	_	
152-6	27630-27640	behavioral	_	
152-7	27641-27649	measures	_	
152-8	27650-27655	might	_	
152-9	27656-27663	reflect	_	
152-10	27664-27665	a	_	
152-11	27666-27674	response	_	
152-12	27675-27679	bias	_	
152-13	27679-27680	,	_	
152-14	27681-27682	a	_	
152-15	27683-27693	limitation	_	
152-16	27694-27696	of	_	
152-17	27697-27707	subjective	_	
152-18	27708-27716	measures	_	
152-19	27716-27717	,	_	
152-20	27718-27720	or	_	
152-21	27721-27722	a	_	
152-22	27723-27731	decrease	_	
152-23	27732-27734	in	_	
152-24	27735-27743	salience	_	
152-25	27744-27746	in	_	
152-26	27747-27755	response	_	
152-27	27756-27758	to	_	
152-28	27759-27767	repeated	_	
152-29	27768-27776	exposure	_	
152-30	27777-27779	to	_	
152-31	27780-27783	the	_	
152-32	27784-27789	cries	_	
152-33	27790-27796	across	_	
152-34	27797-27800	the	_	
152-35	27801-27809	scanning	_	
152-36	27810-27818	protocol	_	
152-37	27818-27819	.	_	

#Text=The strengths of our study included the well-characterized sample of substance-using and non-substance-using mothers and our simultaneous assessment of infant face and infant cry familiarity effects.
153-1	27820-27823	The	_	
153-2	27824-27833	strengths	_	
153-3	27834-27836	of	_	
153-4	27837-27840	our	_	
153-5	27841-27846	study	_	
153-6	27847-27855	included	_	
153-7	27856-27859	the	_	
153-8	27860-27878	well-characterized	_	
153-9	27879-27885	sample	_	
153-10	27886-27888	of	_	
153-11	27889-27904	substance-using	_	
153-12	27905-27908	and	_	
153-13	27909-27928	non-substance-using	_	
153-14	27929-27936	mothers	_	
153-15	27937-27940	and	_	
153-16	27941-27944	our	_	
153-17	27945-27957	simultaneous	_	
153-18	27958-27968	assessment	_	
153-19	27969-27971	of	_	
153-20	27972-27978	infant	_	
153-21	27979-27983	face	_	
153-22	27984-27987	and	_	
153-23	27988-27994	infant	_	
153-24	27995-27998	cry	_	
153-25	27999-28010	familiarity	_	
153-26	28011-28018	effects	_	
153-27	28018-28019	.	_	

#Text=However, important limitations and directions for future research should be noted.
154-1	28020-28027	However	_	
154-2	28027-28028	,	_	
154-3	28029-28038	important	_	
154-4	28039-28050	limitations	_	
154-5	28051-28054	and	_	
154-6	28055-28065	directions	_	
154-7	28066-28069	for	_	
154-8	28070-28076	future	_	
154-9	28077-28085	research	_	
154-10	28086-28092	should	_	
154-11	28093-28095	be	_	
154-12	28096-28101	noted	_	
154-13	28101-28102	.	_	

#Text=Importantly, this was a cross-sectional design, preventing causal inference regarding the potential impact of maternal substance use on neural responses to infant affective cues.
155-1	28103-28114	Importantly	_	
155-2	28114-28115	,	_	
155-3	28116-28120	this	_	
155-4	28121-28124	was	_	
155-5	28125-28126	a	_	
155-6	28127-28142	cross-sectional	_	
155-7	28143-28149	design	_	
155-8	28149-28150	,	_	
155-9	28151-28161	preventing	_	
155-10	28162-28168	causal	_	
155-11	28169-28178	inference	_	
155-12	28179-28188	regarding	_	
155-13	28189-28192	the	_	
155-14	28193-28202	potential	_	
155-15	28203-28209	impact	_	
155-16	28210-28212	of	_	
155-17	28213-28221	maternal	_	
155-18	28222-28231	substance	_	
155-19	28232-28235	use	_	
155-20	28236-28238	on	_	
155-21	28239-28245	neural	_	
155-22	28246-28255	responses	_	
155-23	28256-28258	to	_	
155-24	28259-28265	infant	_	
155-25	28266-28275	affective	_	
155-26	28276-28280	cues	_	
155-27	28280-28281	.	_	

#Text=Instead these findings are best viewed as associations between mothers with and without current substance use and their neural response to infant cues, rather than as evidence of substance use leading to changing neural responses to infant cues.
156-1	28282-28289	Instead	_	
156-2	28290-28295	these	_	
156-3	28296-28304	findings	_	
156-4	28305-28308	are	_	
156-5	28309-28313	best	_	
156-6	28314-28320	viewed	_	
156-7	28321-28323	as	_	
156-8	28324-28336	associations	_	
156-9	28337-28344	between	_	
156-10	28345-28352	mothers	_	
156-11	28353-28357	with	_	
156-12	28358-28361	and	_	
156-13	28362-28369	without	_	
156-14	28370-28377	current	_	
156-15	28378-28387	substance	_	
156-16	28388-28391	use	_	
156-17	28392-28395	and	_	
156-18	28396-28401	their	_	
156-19	28402-28408	neural	_	
156-20	28409-28417	response	_	
156-21	28418-28420	to	_	
156-22	28421-28427	infant	_	
156-23	28428-28432	cues	_	
156-24	28432-28433	,	_	
156-25	28434-28440	rather	_	
156-26	28441-28445	than	_	
156-27	28446-28448	as	_	
156-28	28449-28457	evidence	_	
156-29	28458-28460	of	_	
156-30	28461-28470	substance	_	
156-31	28471-28474	use	_	
156-32	28475-28482	leading	_	
156-33	28483-28485	to	_	
156-34	28486-28494	changing	_	
156-35	28495-28501	neural	_	
156-36	28502-28511	responses	_	
156-37	28512-28514	to	_	
156-38	28515-28521	infant	_	
156-39	28522-28526	cues	_	
156-40	28526-28527	.	_	

#Text=Furthermore, there may be other factors that co-occur with substance use that might be associated with neuroanatomical and functional differences in neural responses to infant affective cues, such as differences in attachment or unresolved trauma.
157-1	28528-28539	Furthermore	_	
157-2	28539-28540	,	_	
157-3	28541-28546	there	_	
157-4	28547-28550	may	_	
157-5	28551-28553	be	_	
157-6	28554-28559	other	_	
157-7	28560-28567	factors	_	
157-8	28568-28572	that	_	
157-9	28573-28581	co-occur	_	
157-10	28582-28586	with	_	
157-11	28587-28596	substance	_	
157-12	28597-28600	use	_	
157-13	28601-28605	that	_	
157-14	28606-28611	might	_	
157-15	28612-28614	be	_	
157-16	28615-28625	associated	_	
157-17	28626-28630	with	_	
157-18	28631-28646	neuroanatomical	_	
157-19	28647-28650	and	_	
157-20	28651-28661	functional	_	
157-21	28662-28673	differences	_	
157-22	28674-28676	in	_	
157-23	28677-28683	neural	_	
157-24	28684-28693	responses	_	
157-25	28694-28696	to	_	
157-26	28697-28703	infant	_	
157-27	28704-28713	affective	_	
157-28	28714-28718	cues	_	
157-29	28718-28719	,	_	
157-30	28720-28724	such	_	
157-31	28725-28727	as	_	
157-32	28728-28739	differences	_	
157-33	28740-28742	in	_	
157-34	28743-28753	attachment	_	
157-35	28754-28756	or	_	
157-36	28757-28767	unresolved	_	
157-37	28768-28774	trauma	_	
157-38	28774-28775	.	_	

#Text=This warrants further investigation in future research – both within the substance-using group and in comparison with the non-substance-using group.
158-1	28776-28780	This	_	
158-2	28781-28789	warrants	_	
158-3	28790-28797	further	_	
158-4	28798-28811	investigation	_	
158-5	28812-28814	in	_	
158-6	28815-28821	future	_	
158-7	28822-28830	research	_	
158-8	28831-28832	–	_	
158-9	28833-28837	both	_	
158-10	28838-28844	within	_	
158-11	28845-28848	the	_	
158-12	28849-28864	substance-using	_	
158-13	28865-28870	group	_	
158-14	28871-28874	and	_	
158-15	28875-28877	in	_	
158-16	28878-28888	comparison	_	
158-17	28889-28893	with	_	
158-18	28894-28897	the	_	
158-19	28898-28917	non-substance-using	_	
158-20	28918-28923	group	_	
158-21	28923-28924	.	_	

#Text=In contrast to our hypothesis, our findings were not consistent with prior work which evidenced that when substance-using mothers viewed their own infant’s happy face, relative to an unknown infant, there was decreased activation in the ventromedial PFC, hypothalamus, and ventral striatum.
159-1	28925-28927	In	_	
159-2	28928-28936	contrast	_	
159-3	28937-28939	to	_	
159-4	28940-28943	our	_	
159-5	28944-28954	hypothesis	_	
159-6	28954-28955	,	_	
159-7	28956-28959	our	_	
159-8	28960-28968	findings	_	
159-9	28969-28973	were	_	
159-10	28974-28977	not	_	
159-11	28978-28988	consistent	_	
159-12	28989-28993	with	_	
159-13	28994-28999	prior	_	
159-14	29000-29004	work	_	
159-15	29005-29010	which	_	
159-16	29011-29020	evidenced	_	
159-17	29021-29025	that	_	
159-18	29026-29030	when	_	
159-19	29031-29046	substance-using	_	
159-20	29047-29054	mothers	_	
159-21	29055-29061	viewed	_	
159-22	29062-29067	their	_	
159-23	29068-29071	own	_	
159-24	29072-29078	infant	_	
159-25	29078-29079	’	_	
159-26	29079-29080	s	_	
159-27	29081-29086	happy	_	
159-28	29087-29091	face	_	
159-29	29091-29092	,	_	
159-30	29093-29101	relative	_	
159-31	29102-29104	to	_	
159-32	29105-29107	an	_	
159-33	29108-29115	unknown	_	
159-34	29116-29122	infant	_	
159-35	29122-29123	,	_	
159-36	29124-29129	there	_	
159-37	29130-29133	was	_	
159-38	29134-29143	decreased	_	
159-39	29144-29154	activation	_	
159-40	29155-29157	in	_	
159-41	29158-29161	the	_	
159-42	29162-29174	ventromedial	_	
159-43	29175-29178	PFC	_	
159-44	29178-29179	,	_	
159-45	29180-29192	hypothalamus	_	
159-46	29192-29193	,	_	
159-47	29194-29197	and	_	
159-48	29198-29205	ventral	_	
159-49	29206-29214	striatum	_	
159-50	29214-29215	.	_	

#Text=There may be two reasons for these differences.
160-1	29216-29221	There	_	
160-2	29222-29225	may	_	
160-3	29226-29228	be	_	
160-4	29229-29232	two	_	
160-5	29233-29240	reasons	_	
160-6	29241-29244	for	_	
160-7	29245-29250	these	_	
160-8	29251-29262	differences	_	
160-9	29262-29263	.	_	

#Text=The first reflects differences between the maternal samples; the current study employed poly-substance-using mothers living in the community with only 7 women reporting receiving current substance-use treatment.
161-1	29264-29267	The	_	
161-2	29268-29273	first	_	
161-3	29274-29282	reflects	_	
161-4	29283-29294	differences	_	
161-5	29295-29302	between	_	
161-6	29303-29306	the	_	
161-7	29307-29315	maternal	_	
161-8	29316-29323	samples	_	
161-9	29323-29324	;	_	
161-10	29325-29328	the	_	
161-11	29329-29336	current	_	
161-12	29337-29342	study	_	
161-13	29343-29351	employed	_	
161-14	29352-29372	poly-substance-using	_	
161-15	29373-29380	mothers	_	
161-16	29381-29387	living	_	
161-17	29388-29390	in	_	
161-18	29391-29394	the	_	
161-19	29395-29404	community	_	
161-20	29405-29409	with	_	
161-21	29410-29414	only	_	
161-22	29415-29416	7	_	
161-23	29417-29422	women	_	
161-24	29423-29432	reporting	_	
161-25	29433-29442	receiving	_	
161-26	29443-29450	current	_	
161-27	29451-29464	substance-use	_	
161-28	29465-29474	treatment	_	
161-29	29474-29475	.	_	

#Text=In contrast, all mothers were receiving inpatient treatment for substance-use disorders in the study by.
162-1	29476-29478	In	_	
162-2	29479-29487	contrast	_	
162-3	29487-29488	,	_	
162-4	29489-29492	all	_	
162-5	29493-29500	mothers	_	
162-6	29501-29505	were	_	
162-7	29506-29515	receiving	_	
162-8	29516-29525	inpatient	_	
162-9	29526-29535	treatment	_	
162-10	29536-29539	for	_	
162-11	29540-29553	substance-use	_	
162-12	29554-29563	disorders	_	
162-13	29564-29566	in	_	
162-14	29567-29570	the	_	
162-15	29571-29576	study	_	
162-16	29577-29579	by	_	
162-17	29579-29580	.	_	

#Text=Secondly, we examined data collected across at least four functional runs in our maternal sample, whereas prior work examined functional data from only two runs.
163-1	29581-29589	Secondly	_	
163-2	29589-29590	,	_	
163-3	29591-29593	we	_	
163-4	29594-29602	examined	_	
163-5	29603-29607	data	_	
163-6	29608-29617	collected	_	
163-7	29618-29624	across	_	
163-8	29625-29627	at	_	
163-9	29628-29633	least	_	
163-10	29634-29638	four	_	
163-11	29639-29649	functional	_	
163-12	29650-29654	runs	_	
163-13	29655-29657	in	_	
163-14	29658-29661	our	_	
163-15	29662-29670	maternal	_	
163-16	29671-29677	sample	_	
163-17	29677-29678	,	_	
163-18	29679-29686	whereas	_	
163-19	29687-29692	prior	_	
163-20	29693-29697	work	_	
163-21	29698-29706	examined	_	
163-22	29707-29717	functional	_	
163-23	29718-29722	data	_	
163-24	29723-29727	from	_	
163-25	29728-29732	only	_	
163-26	29733-29736	two	_	
163-27	29737-29741	runs	_	
163-28	29741-29742	.	_	

#Text=Future work should examine the time course of maternal neural responses to infant faces in the presence (and absence) of addictive behaviors.
164-1	29743-29749	Future	_	
164-2	29750-29754	work	_	
164-3	29755-29761	should	_	
164-4	29762-29769	examine	_	
164-5	29770-29773	the	_	
164-6	29774-29778	time	_	
164-7	29779-29785	course	_	
164-8	29786-29788	of	_	
164-9	29789-29797	maternal	_	
164-10	29798-29804	neural	_	
164-11	29805-29814	responses	_	
164-12	29815-29817	to	_	
164-13	29818-29824	infant	_	
164-14	29825-29830	faces	_	
164-15	29831-29833	in	_	
164-16	29834-29837	the	_	
164-17	29838-29846	presence	_	
164-18	29847-29848	(	_	
164-19	29848-29851	and	_	
164-20	29852-29859	absence	_	
164-21	29859-29860	)	_	
164-22	29861-29863	of	_	
164-23	29864-29873	addictive	_	
164-24	29874-29883	behaviors	_	
164-25	29883-29884	.	_	

#Text=Although we examined a poly-substance-using sample of mothers, we were not sufficiently powered to disentangle contributions of individual substances to our findings.
165-1	29885-29893	Although	_	
165-2	29894-29896	we	_	
165-3	29897-29905	examined	_	
165-4	29906-29907	a	_	
165-5	29908-29928	poly-substance-using	_	
165-6	29929-29935	sample	_	
165-7	29936-29938	of	_	
165-8	29939-29946	mothers	_	
165-9	29946-29947	,	_	
165-10	29948-29950	we	_	
165-11	29951-29955	were	_	
165-12	29956-29959	not	_	
165-13	29960-29972	sufficiently	_	
165-14	29973-29980	powered	_	
165-15	29981-29983	to	_	
165-16	29984-29995	disentangle	_	
165-17	29996-30009	contributions	_	
165-18	30010-30012	of	_	
165-19	30013-30023	individual	_	
165-20	30024-30034	substances	_	
165-21	30035-30037	to	_	
165-22	30038-30041	our	_	
165-23	30042-30050	findings	_	
165-24	30050-30051	.	_	

#Text=Despite this limitation, it is important to note that, among substance-using mothers, polysubstance use (as opposed to limited use of only one substance) is common (e.g.,).
166-1	30052-30059	Despite	_	
166-2	30060-30064	this	_	
166-3	30065-30075	limitation	_	
166-4	30075-30076	,	_	
166-5	30077-30079	it	_	
166-6	30080-30082	is	_	
166-7	30083-30092	important	_	
166-8	30093-30095	to	_	
166-9	30096-30100	note	_	
166-10	30101-30105	that	_	
166-11	30105-30106	,	_	
166-12	30107-30112	among	_	
166-13	30113-30128	substance-using	_	
166-14	30129-30136	mothers	_	
166-15	30136-30137	,	_	
166-16	30138-30151	polysubstance	_	
166-17	30152-30155	use	_	
166-18	30156-30157	(	_	
166-19	30157-30159	as	_	
166-20	30160-30167	opposed	_	
166-21	30168-30170	to	_	
166-22	30171-30178	limited	_	
166-23	30179-30182	use	_	
166-24	30183-30185	of	_	
166-25	30186-30190	only	_	
166-26	30191-30194	one	_	
166-27	30195-30204	substance	_	
166-28	30204-30205	)	_	
166-29	30206-30208	is	_	
166-30	30209-30215	common	_	
166-31	30216-30217	(	_	
166-32	30217-30220	e.g	_	
166-33	30220-30221	.	_	
166-34	30221-30222	,	_	
166-35	30222-30223	)	_	
166-36	30223-30224	.	_	

#Text=In addition, while inconsistencies across studies of maternal substance use may relate to differences in substance use across samples, they may also reflect the absence of stability in responding to infant affective cues, which may vary at a within-subjects level, as well as at a group level, when considering the maternal substance-using group.
167-1	30225-30227	In	_	
167-2	30228-30236	addition	_	
167-3	30236-30237	,	_	
167-4	30238-30243	while	_	
167-5	30244-30259	inconsistencies	_	
167-6	30260-30266	across	_	
167-7	30267-30274	studies	_	
167-8	30275-30277	of	_	
167-9	30278-30286	maternal	_	
167-10	30287-30296	substance	_	
167-11	30297-30300	use	_	
167-12	30301-30304	may	_	
167-13	30305-30311	relate	_	
167-14	30312-30314	to	_	
167-15	30315-30326	differences	_	
167-16	30327-30329	in	_	
167-17	30330-30339	substance	_	
167-18	30340-30343	use	_	
167-19	30344-30350	across	_	
167-20	30351-30358	samples	_	
167-21	30358-30359	,	_	
167-22	30360-30364	they	_	
167-23	30365-30368	may	_	
167-24	30369-30373	also	_	
167-25	30374-30381	reflect	_	
167-26	30382-30385	the	_	
167-27	30386-30393	absence	_	
167-28	30394-30396	of	_	
167-29	30397-30406	stability	_	
167-30	30407-30409	in	_	
167-31	30410-30420	responding	_	
167-32	30421-30423	to	_	
167-33	30424-30430	infant	_	
167-34	30431-30440	affective	_	
167-35	30441-30445	cues	_	
167-36	30445-30446	,	_	
167-37	30447-30452	which	_	
167-38	30453-30456	may	_	
167-39	30457-30461	vary	_	
167-40	30462-30464	at	_	
167-41	30465-30466	a	_	
167-42	30467-30482	within-subjects	_	
167-43	30483-30488	level	_	
167-44	30488-30489	,	_	
167-45	30490-30492	as	_	
167-46	30493-30497	well	_	
167-47	30498-30500	as	_	
167-48	30501-30503	at	_	
167-49	30504-30505	a	_	
167-50	30506-30511	group	_	
167-51	30512-30517	level	_	
167-52	30517-30518	,	_	
167-53	30519-30523	when	_	
167-54	30524-30535	considering	_	
167-55	30536-30539	the	_	
167-56	30540-30548	maternal	_	
167-57	30549-30564	substance-using	_	
167-58	30565-30570	group	_	
167-59	30570-30571	.	_	

#Text=Such variability may present as decreased reactivity (consistent with, and) as well as the increased reactivity observed here.
168-1	30572-30576	Such	_	
168-2	30577-30588	variability	_	
168-3	30589-30592	may	_	
168-4	30593-30600	present	_	
168-5	30601-30603	as	_	
168-6	30604-30613	decreased	_	
168-7	30614-30624	reactivity	_	
168-8	30625-30626	(	_	
168-9	30626-30636	consistent	_	
168-10	30637-30641	with	_	
168-11	30641-30642	,	_	
168-12	30643-30646	and	_	
168-13	30646-30647	)	_	
168-14	30648-30650	as	_	
168-15	30651-30655	well	_	
168-16	30656-30658	as	_	
168-17	30659-30662	the	_	
168-18	30663-30672	increased	_	
168-19	30673-30683	reactivity	_	
168-20	30684-30692	observed	_	
168-21	30693-30697	here	_	
168-22	30697-30698	.	_	

#Text=This interpretation is consistent with behavioral studies demonstrating associations between substance use and mother-child interactions.
169-1	30699-30703	This	_	
169-2	30704-30718	interpretation	_	
169-3	30719-30721	is	_	
169-4	30722-30732	consistent	_	
169-5	30733-30737	with	_	
169-6	30738-30748	behavioral	_	
169-7	30749-30756	studies	_	
169-8	30757-30770	demonstrating	_	
169-9	30771-30783	associations	_	
169-10	30784-30791	between	_	
169-11	30792-30801	substance	_	
169-12	30802-30805	use	_	
169-13	30806-30809	and	_	
169-14	30810-30822	mother-child	_	
169-15	30823-30835	interactions	_	
169-16	30835-30836	.	_	

#Text=Namely, past research has demonstrated that, while substance-using mothers may be passive and disengaged during their interactions with their child (e.g.,), they may also be hostile and intrusive (e.g.,).
170-1	30837-30843	Namely	_	
170-2	30843-30844	,	_	
170-3	30845-30849	past	_	
170-4	30850-30858	research	_	
170-5	30859-30862	has	_	
170-6	30863-30875	demonstrated	_	
170-7	30876-30880	that	_	
170-8	30880-30881	,	_	
170-9	30882-30887	while	_	
170-10	30888-30903	substance-using	_	
170-11	30904-30911	mothers	_	
170-12	30912-30915	may	_	
170-13	30916-30918	be	_	
170-14	30919-30926	passive	_	
170-15	30927-30930	and	_	
170-16	30931-30941	disengaged	_	
170-17	30942-30948	during	_	
170-18	30949-30954	their	_	
170-19	30955-30967	interactions	_	
170-20	30968-30972	with	_	
170-21	30973-30978	their	_	
170-22	30979-30984	child	_	
170-23	30985-30986	(	_	
170-24	30986-30989	e.g	_	
170-25	30989-30990	.	_	
170-26	30990-30991	,	_	
170-27	30991-30992	)	_	
170-28	30992-30993	,	_	
170-29	30994-30998	they	_	
170-30	30999-31002	may	_	
170-31	31003-31007	also	_	
170-32	31008-31010	be	_	
170-33	31011-31018	hostile	_	
170-34	31019-31022	and	_	
170-35	31023-31032	intrusive	_	
170-36	31033-31034	(	_	
170-37	31034-31037	e.g	_	
170-38	31037-31038	.	_	
170-39	31038-31039	,	_	
170-40	31039-31040	)	_	
170-41	31040-31041	.	_	

#Text=Therefore, it is important to acknowledge that variability in reactivity to infant affective cues (with respect to brain function or behavior) associated with maternal substance use may reflect differing points in the cycle of addiction, which warrant concurrent measurement and/or explicit manipulation (e.g., through completing experimental protocols during abstinent and satiated states) in future research.
171-1	31042-31051	Therefore	_	
171-2	31051-31052	,	_	
171-3	31053-31055	it	_	
171-4	31056-31058	is	_	
171-5	31059-31068	important	_	
171-6	31069-31071	to	_	
171-7	31072-31083	acknowledge	_	
171-8	31084-31088	that	_	
171-9	31089-31100	variability	_	
171-10	31101-31103	in	_	
171-11	31104-31114	reactivity	_	
171-12	31115-31117	to	_	
171-13	31118-31124	infant	_	
171-14	31125-31134	affective	_	
171-15	31135-31139	cues	_	
171-16	31140-31141	(	_	
171-17	31141-31145	with	_	
171-18	31146-31153	respect	_	
171-19	31154-31156	to	_	
171-20	31157-31162	brain	_	
171-21	31163-31171	function	_	
171-22	31172-31174	or	_	
171-23	31175-31183	behavior	_	
171-24	31183-31184	)	_	
171-25	31185-31195	associated	_	
171-26	31196-31200	with	_	
171-27	31201-31209	maternal	_	
171-28	31210-31219	substance	_	
171-29	31220-31223	use	_	
171-30	31224-31227	may	_	
171-31	31228-31235	reflect	_	
171-32	31236-31245	differing	_	
171-33	31246-31252	points	_	
171-34	31253-31255	in	_	
171-35	31256-31259	the	_	
171-36	31260-31265	cycle	_	
171-37	31266-31268	of	_	
171-38	31269-31278	addiction	_	
171-39	31278-31279	,	_	
171-40	31280-31285	which	_	
171-41	31286-31293	warrant	_	
171-42	31294-31304	concurrent	_	
171-43	31305-31316	measurement	_	
171-44	31317-31320	and	_	
171-45	31320-31321	/	_	
171-46	31321-31323	or	_	
171-47	31324-31332	explicit	_	
171-48	31333-31345	manipulation	_	
171-49	31346-31347	(	_	
171-50	31347-31350	e.g	_	
171-51	31350-31351	.	_	
171-52	31351-31352	,	_	
171-53	31353-31360	through	_	
171-54	31361-31371	completing	_	
171-55	31372-31384	experimental	_	
171-56	31385-31394	protocols	_	
171-57	31395-31401	during	_	
171-58	31402-31411	abstinent	_	
171-59	31412-31415	and	_	
171-60	31416-31424	satiated	_	
171-61	31425-31431	states	_	
171-62	31431-31432	)	_	
171-63	31433-31435	in	_	
171-64	31436-31442	future	_	
171-65	31443-31451	research	_	
171-66	31451-31452	.	_	

#Text=This work will be advanced by examining maternal brain function and behavior within the same session to more adequately inform whether changing neural responses to infant cues may translate to maternal behavior and child outcomes.
172-1	31453-31457	This	_	
172-2	31458-31462	work	_	
172-3	31463-31467	will	_	
172-4	31468-31470	be	_	
172-5	31471-31479	advanced	_	
172-6	31480-31482	by	_	
172-7	31483-31492	examining	_	
172-8	31493-31501	maternal	_	
172-9	31502-31507	brain	_	
172-10	31508-31516	function	_	
172-11	31517-31520	and	_	
172-12	31521-31529	behavior	_	
172-13	31530-31536	within	_	
172-14	31537-31540	the	_	
172-15	31541-31545	same	_	
172-16	31546-31553	session	_	
172-17	31554-31556	to	_	
172-18	31557-31561	more	_	
172-19	31562-31572	adequately	_	
172-20	31573-31579	inform	_	
172-21	31580-31587	whether	_	
172-22	31588-31596	changing	_	
172-23	31597-31603	neural	_	
172-24	31604-31613	responses	_	
172-25	31614-31616	to	_	
172-26	31617-31623	infant	_	
172-27	31624-31628	cues	_	
172-28	31629-31632	may	_	
172-29	31633-31642	translate	_	
172-30	31643-31645	to	_	
172-31	31646-31654	maternal	_	
172-32	31655-31663	behavior	_	
172-33	31664-31667	and	_	
172-34	31668-31673	child	_	
172-35	31674-31682	outcomes	_	
172-36	31682-31683	.	_	

#Text=Furthermore, as this work continues, it will also be important to address whether differential patterns of maternal brain activity (and behavior) vary as a function of the experimental context and/or task demands.
173-1	31684-31695	Furthermore	_	
173-2	31695-31696	,	_	
173-3	31697-31699	as	_	
173-4	31700-31704	this	_	
173-5	31705-31709	work	_	
173-6	31710-31719	continues	_	
173-7	31719-31720	,	_	
173-8	31721-31723	it	_	
173-9	31724-31728	will	_	
173-10	31729-31733	also	_	
173-11	31734-31736	be	_	
173-12	31737-31746	important	_	
173-13	31747-31749	to	_	
173-14	31750-31757	address	_	
173-15	31758-31765	whether	_	
173-16	31766-31778	differential	_	
173-17	31779-31787	patterns	_	
173-18	31788-31790	of	_	
173-19	31791-31799	maternal	_	
173-20	31800-31805	brain	_	
173-21	31806-31814	activity	_	
173-22	31815-31816	(	_	
173-23	31816-31819	and	_	
173-24	31820-31828	behavior	_	
173-25	31828-31829	)	_	
173-26	31830-31834	vary	_	
173-27	31835-31837	as	_	
173-28	31838-31839	a	_	
173-29	31840-31848	function	_	
173-30	31849-31851	of	_	
173-31	31852-31855	the	_	
173-32	31856-31868	experimental	_	
173-33	31869-31876	context	_	
173-34	31877-31880	and	_	
173-35	31880-31881	/	_	
173-36	31881-31883	or	_	
173-37	31884-31888	task	_	
173-38	31889-31896	demands	_	
173-39	31896-31897	.	_	

#Text=In conclusion, this is one of the first studies to examine how mothers with and without substance use respond to cues from own and unknown infants and of varying affective states.
174-1	31898-31900	In	_	
174-2	31901-31911	conclusion	_	
174-3	31911-31912	,	_	
174-4	31913-31917	this	_	
174-5	31918-31920	is	_	
174-6	31921-31924	one	_	
174-7	31925-31927	of	_	
174-8	31928-31931	the	_	
174-9	31932-31937	first	_	
174-10	31938-31945	studies	_	
174-11	31946-31948	to	_	
174-12	31949-31956	examine	_	
174-13	31957-31960	how	_	
174-14	31961-31968	mothers	_	
174-15	31969-31973	with	_	
174-16	31974-31977	and	_	
174-17	31978-31985	without	_	
174-18	31986-31995	substance	_	
174-19	31996-31999	use	_	
174-20	32000-32007	respond	_	
174-21	32008-32010	to	_	
174-22	32011-32015	cues	_	
174-23	32016-32020	from	_	
174-24	32021-32024	own	_	
174-25	32025-32028	and	_	
174-26	32029-32036	unknown	_	
174-27	32037-32044	infants	_	
174-28	32045-32048	and	_	
174-29	32049-32051	of	_	
174-30	32052-32059	varying	_	
174-31	32060-32069	affective	_	
174-32	32070-32076	states	_	
174-33	32076-32077	.	_	

#Text=Our findings suggest overlapping cortical and subcortical (e.g., striatal) brain regions are involved in responding to infant faces, and responses are influenced by infant familiarity, emotional expression, and maternal substance-use status.
175-1	32078-32081	Our	_	
175-2	32082-32090	findings	_	
175-3	32091-32098	suggest	_	
175-4	32099-32110	overlapping	_	
175-5	32111-32119	cortical	_	
175-6	32120-32123	and	_	
175-7	32124-32135	subcortical	_	
175-8	32136-32137	(	_	
175-9	32137-32140	e.g	_	
175-10	32140-32141	.	_	
175-11	32141-32142	,	_	
175-12	32143-32151	striatal	_	
175-13	32151-32152	)	_	
175-14	32153-32158	brain	_	
175-15	32159-32166	regions	_	
175-16	32167-32170	are	_	
175-17	32171-32179	involved	_	
175-18	32180-32182	in	_	
175-19	32183-32193	responding	_	
175-20	32194-32196	to	_	
175-21	32197-32203	infant	_	
175-22	32204-32209	faces	_	
175-23	32209-32210	,	_	
175-24	32211-32214	and	_	
175-25	32215-32224	responses	_	
175-26	32225-32228	are	_	
175-27	32229-32239	influenced	_	
175-28	32240-32242	by	_	
175-29	32243-32249	infant	_	
175-30	32250-32261	familiarity	_	
175-31	32261-32262	,	_	
175-32	32263-32272	emotional	_	
175-33	32273-32283	expression	_	
175-34	32283-32284	,	_	
175-35	32285-32288	and	_	
175-36	32289-32297	maternal	_	
175-37	32298-32311	substance-use	_	
175-38	32312-32318	status	_	
175-39	32318-32319	.	_	

#Text=These findings advance our understanding of the neurobiology of parenting and addiction and highlight the need to more explicitly include in theoretical models and in empirical research increased reactivity to salient infant affective cues, in addition to attenuated neural responses, which are often the focus of this work.
176-1	32320-32325	These	_	
176-2	32326-32334	findings	_	
176-3	32335-32342	advance	_	
176-4	32343-32346	our	_	
176-5	32347-32360	understanding	_	
176-6	32361-32363	of	_	
176-7	32364-32367	the	_	
176-8	32368-32380	neurobiology	_	
176-9	32381-32383	of	_	
176-10	32384-32393	parenting	_	
176-11	32394-32397	and	_	
176-12	32398-32407	addiction	_	
176-13	32408-32411	and	_	
176-14	32412-32421	highlight	_	
176-15	32422-32425	the	_	
176-16	32426-32430	need	_	
176-17	32431-32433	to	_	
176-18	32434-32438	more	_	
176-19	32439-32449	explicitly	_	
176-20	32450-32457	include	_	
176-21	32458-32460	in	_	
176-22	32461-32472	theoretical	_	
176-23	32473-32479	models	_	
176-24	32480-32483	and	_	
176-25	32484-32486	in	_	
176-26	32487-32496	empirical	_	
176-27	32497-32505	research	_	
176-28	32506-32515	increased	_	
176-29	32516-32526	reactivity	_	
176-30	32527-32529	to	_	
176-31	32530-32537	salient	_	
176-32	32538-32544	infant	_	
176-33	32545-32554	affective	_	
176-34	32555-32559	cues	_	
176-35	32559-32560	,	_	
176-36	32561-32563	in	_	
176-37	32564-32572	addition	_	
176-38	32573-32575	to	_	
176-39	32576-32586	attenuated	_	
176-40	32587-32593	neural	_	
176-41	32594-32603	responses	_	
176-42	32603-32604	,	_	
176-43	32605-32610	which	_	
176-44	32611-32614	are	_	
176-45	32615-32620	often	_	
176-46	32621-32624	the	_	
176-47	32625-32630	focus	_	
176-48	32631-32633	of	_	
176-49	32634-32638	this	_	
176-50	32639-32643	work	_	
176-51	32643-32644	.	_	

#Text=Furthermore, future research should include multiple levels of assessment, including brain, self-report, and behavioral indices of parenting.
177-1	32645-32656	Furthermore	_	
177-2	32656-32657	,	_	
177-3	32658-32664	future	_	
177-4	32665-32673	research	_	
177-5	32674-32680	should	_	
177-6	32681-32688	include	_	
177-7	32689-32697	multiple	_	
177-8	32698-32704	levels	_	
177-9	32705-32707	of	_	
177-10	32708-32718	assessment	_	
177-11	32718-32719	,	_	
177-12	32720-32729	including	_	
177-13	32730-32735	brain	_	
177-14	32735-32736	,	_	
177-15	32737-32748	self-report	_	
177-16	32748-32749	,	_	
177-17	32750-32753	and	_	
177-18	32754-32764	behavioral	_	
177-19	32765-32772	indices	_	
177-20	32773-32775	of	_	
177-21	32776-32785	parenting	_	
177-22	32785-32786	.	_	

#Text=Supplementary Material
#Text=This is a PDF file of an unedited manuscript that has been accepted for publication.
178-1	32787-32800	Supplementary	_	
178-2	32801-32809	Material	_	
178-3	32810-32814	This	_	
178-4	32815-32817	is	_	
178-5	32818-32819	a	_	
178-6	32820-32823	PDF	_	
178-7	32824-32828	file	_	
178-8	32829-32831	of	_	
178-9	32832-32834	an	_	
178-10	32835-32843	unedited	_	
178-11	32844-32854	manuscript	_	
178-12	32855-32859	that	_	
178-13	32860-32863	has	_	
178-14	32864-32868	been	_	
178-15	32869-32877	accepted	_	
178-16	32878-32881	for	_	
178-17	32882-32893	publication	_	
178-18	32893-32894	.	_	

#Text=As a service to our customers we are providing this early version of the manuscript.
179-1	32895-32897	As	_	
179-2	32898-32899	a	_	
179-3	32900-32907	service	_	
179-4	32908-32910	to	_	
179-5	32911-32914	our	_	
179-6	32915-32924	customers	_	
179-7	32925-32927	we	_	
179-8	32928-32931	are	_	
179-9	32932-32941	providing	_	
179-10	32942-32946	this	_	
179-11	32947-32952	early	_	
179-12	32953-32960	version	_	
179-13	32961-32963	of	_	
179-14	32964-32967	the	_	
179-15	32968-32978	manuscript	_	
179-16	32978-32979	.	_	

#Text=The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form.
180-1	32980-32983	The	_	
180-2	32984-32994	manuscript	_	
180-3	32995-32999	will	_	
180-4	33000-33007	undergo	_	
180-5	33008-33019	copyediting	_	
180-6	33019-33020	,	_	
180-7	33021-33032	typesetting	_	
180-8	33032-33033	,	_	
180-9	33034-33037	and	_	
180-10	33038-33044	review	_	
180-11	33045-33047	of	_	
180-12	33048-33051	the	_	
180-13	33052-33061	resulting	_	
180-14	33062-33067	proof	_	
180-15	33068-33074	before	_	
180-16	33075-33077	it	_	
180-17	33078-33080	is	_	
180-18	33081-33090	published	_	
180-19	33091-33093	in	_	
180-20	33094-33097	its	_	
180-21	33098-33103	final	_	
180-22	33104-33108	form	_	
180-23	33108-33109	.	_	

#Text=Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
181-1	33110-33116	Please	_	
181-2	33117-33121	note	_	
181-3	33122-33126	that	_	
181-4	33127-33133	during	_	
181-5	33134-33137	the	_	
181-6	33138-33148	production	_	
181-7	33149-33156	process	_	
181-8	33157-33163	errors	_	
181-9	33164-33167	may	_	
181-10	33168-33170	be	_	
181-11	33171-33181	discovered	_	
181-12	33182-33187	which	_	
181-13	33188-33193	could	_	
181-14	33194-33200	affect	_	
181-15	33201-33204	the	_	
181-16	33205-33212	content	_	
181-17	33212-33213	,	_	
181-18	33214-33217	and	_	
181-19	33218-33221	all	_	
181-20	33222-33227	legal	_	
181-21	33228-33239	disclaimers	_	
181-22	33240-33244	that	_	
181-23	33245-33250	apply	_	
181-24	33251-33253	to	_	
181-25	33254-33257	the	_	
181-26	33258-33265	journal	_	
181-27	33266-33273	pertain	_	
181-28	33273-33274	.	_	

#Text=Conflict of Interest
#Text=The authors declare no conflicts of interest with respect to the content of this manuscript.
182-1	33275-33283	Conflict	_	
182-2	33284-33286	of	_	
182-3	33287-33295	Interest	_	
182-4	33296-33299	The	_	
182-5	33300-33307	authors	_	
182-6	33308-33315	declare	_	
182-7	33316-33318	no	_	
182-8	33319-33328	conflicts	_	
182-9	33329-33331	of	_	
182-10	33332-33340	interest	_	
182-11	33341-33345	with	_	
182-12	33346-33353	respect	_	
182-13	33354-33356	to	_	
182-14	33357-33360	the	_	
182-15	33361-33368	content	_	
182-16	33369-33371	of	_	
182-17	33372-33376	this	_	
182-18	33377-33387	manuscript	_	
182-19	33387-33388	.	_	

#Text=Dr.
183-1	33389-33391	Dr	_	
183-2	33391-33392	.	_	

#Text=Potenza has: consulted for and advised Game Day Data, the Addiction Policy Forum, Rivermend Health, Opiant/Lightlake Therapeutics and Jazz Pharmaceuticals; received research support from the Mohegan Sun Casino and the National Center for Responsible Gaming; and consulted for legal and gambling entities on issues related to impulse-control disorders and addictions.
184-1	33393-33400	Potenza	_	
184-2	33401-33404	has	_	
184-3	33404-33405	:	_	
184-4	33406-33415	consulted	_	
184-5	33416-33419	for	_	
184-6	33420-33423	and	_	
184-7	33424-33431	advised	_	
184-8	33432-33436	Game	_	
184-9	33437-33440	Day	_	
184-10	33441-33445	Data	_	
184-11	33445-33446	,	_	
184-12	33447-33450	the	_	
184-13	33451-33460	Addiction	_	
184-14	33461-33467	Policy	_	
184-15	33468-33473	Forum	_	
184-16	33473-33474	,	_	
184-17	33475-33484	Rivermend	_	
184-18	33485-33491	Health	_	
184-19	33491-33492	,	_	
184-20	33493-33499	Opiant	_	
184-21	33499-33500	/	_	
184-22	33500-33509	Lightlake	_	
184-23	33510-33522	Therapeutics	_	
184-24	33523-33526	and	_	
184-25	33527-33531	Jazz	_	
184-26	33532-33547	Pharmaceuticals	_	
184-27	33547-33548	;	_	
184-28	33549-33557	received	_	
184-29	33558-33566	research	_	
184-30	33567-33574	support	_	
184-31	33575-33579	from	_	
184-32	33580-33583	the	_	
184-33	33584-33591	Mohegan	_	
184-34	33592-33595	Sun	_	
184-35	33596-33602	Casino	_	
184-36	33603-33606	and	_	
184-37	33607-33610	the	_	
184-38	33611-33619	National	_	
184-39	33620-33626	Center	_	
184-40	33627-33630	for	_	
184-41	33631-33642	Responsible	_	
184-42	33643-33649	Gaming	_	
184-43	33649-33650	;	_	
184-44	33651-33654	and	_	
184-45	33655-33664	consulted	_	
184-46	33665-33668	for	_	
184-47	33669-33674	legal	_	
184-48	33675-33678	and	_	
184-49	33679-33687	gambling	_	
184-50	33688-33696	entities	_	
184-51	33697-33699	on	_	
184-52	33700-33706	issues	_	
184-53	33707-33714	related	_	
184-54	33715-33717	to	_	
184-55	33718-33733	impulse-control	_	
184-56	33734-33743	disorders	_	
184-57	33744-33747	and	_	
184-58	33748-33758	addictions	_	
184-59	33758-33759	.	_	

#Text=The other authors report no disclosures.
185-1	33760-33763	The	_	
185-2	33764-33769	other	_	
185-3	33770-33777	authors	_	
185-4	33778-33784	report	_	
185-5	33785-33787	no	_	
185-6	33788-33799	disclosures	_	
185-7	33799-33800	.	_	

#Text=References
#Text=A developmental model of addictions: integrating neurobiological and psychodynamic theories through the lens of attachment
#Text=
#Text=A conceptual model for maternal behavior among polydrug cocaine-using mothers: The role of postnatal cocaine use and maternal depression
#Text=Cluster failure: why fMRI inferences for spatial extent have inflated false-positive rates
#Text=The adaptive human parental brain: implications for children’s social development
#Text=
#Text=Perinatal substance use: a prospective evaluation of abstinence and relapse
#Text=The role of substance use in child welfare caseloads
#Text=The neural bases of emotion regulation: reappraisal and suppression of negative emotion
#Text=The effects of prenatal cocaine exposure on mother--infant interaction and infant arousal in the newborn period
#Text=Maternal smoking during pregnancy and long-term neurological morbidity of the offspring
#Text=The reward circuit: Linking primate anatomy and human imaging
#Text=Quality of caregiving in mothers with illicit substance use: A systematic review and meta-analysis.
186-1	33801-33811	References	_	
186-2	33812-33813	A	_	
186-3	33814-33827	developmental	_	
186-4	33828-33833	model	_	
186-5	33834-33836	of	_	
186-6	33837-33847	addictions	_	
186-7	33847-33848	:	_	
186-8	33849-33860	integrating	_	
186-9	33861-33876	neurobiological	_	
186-10	33877-33880	and	_	
186-11	33881-33894	psychodynamic	_	
186-12	33895-33903	theories	_	
186-13	33904-33911	through	_	
186-14	33912-33915	the	_	
186-15	33916-33920	lens	_	
186-16	33921-33923	of	_	
186-17	33924-33934	attachment	_	
186-18	33936-33937	A	_	
186-19	33938-33948	conceptual	_	
186-20	33949-33954	model	_	
186-21	33955-33958	for	_	
186-22	33959-33967	maternal	_	
186-23	33968-33976	behavior	_	
186-24	33977-33982	among	_	
186-25	33983-33991	polydrug	_	
186-26	33992-34005	cocaine-using	_	
186-27	34006-34013	mothers	_	
186-28	34013-34014	:	_	
186-29	34015-34018	The	_	
186-30	34019-34023	role	_	
186-31	34024-34026	of	_	
186-32	34027-34036	postnatal	_	
186-33	34037-34044	cocaine	_	
186-34	34045-34048	use	_	
186-35	34049-34052	and	_	
186-36	34053-34061	maternal	_	
186-37	34062-34072	depression	_	
186-38	34073-34080	Cluster	_	
186-39	34081-34088	failure	_	
186-40	34088-34089	:	_	
186-41	34090-34093	why	_	
186-42	34094-34098	fMRI	_	
186-43	34099-34109	inferences	_	
186-44	34110-34113	for	_	
186-45	34114-34121	spatial	_	
186-46	34122-34128	extent	_	
186-47	34129-34133	have	_	
186-48	34134-34142	inflated	_	
186-49	34143-34157	false-positive	_	
186-50	34158-34163	rates	_	
186-51	34164-34167	The	_	
186-52	34168-34176	adaptive	_	
186-53	34177-34182	human	_	
186-54	34183-34191	parental	_	
186-55	34192-34197	brain	_	
186-56	34197-34198	:	_	
186-57	34199-34211	implications	_	
186-58	34212-34215	for	_	
186-59	34216-34224	children	_	
186-60	34224-34225	’	_	
186-61	34225-34226	s	_	
186-62	34227-34233	social	_	
186-63	34234-34245	development	_	
186-64	34247-34256	Perinatal	_	
186-65	34257-34266	substance	_	
186-66	34267-34270	use	_	
186-67	34270-34271	:	_	
186-68	34272-34273	a	_	
186-69	34274-34285	prospective	_	
186-70	34286-34296	evaluation	_	
186-71	34297-34299	of	_	
186-72	34300-34310	abstinence	_	
186-73	34311-34314	and	_	
186-74	34315-34322	relapse	_	
186-75	34323-34326	The	_	
186-76	34327-34331	role	_	
186-77	34332-34334	of	_	
186-78	34335-34344	substance	_	
186-79	34345-34348	use	_	
186-80	34349-34351	in	_	
186-81	34352-34357	child	_	
186-82	34358-34365	welfare	_	
186-83	34366-34375	caseloads	_	
186-84	34376-34379	The	_	
186-85	34380-34386	neural	_	
186-86	34387-34392	bases	_	
186-87	34393-34395	of	_	
186-88	34396-34403	emotion	_	
186-89	34404-34414	regulation	_	
186-90	34414-34415	:	_	
186-91	34416-34427	reappraisal	_	
186-92	34428-34431	and	_	
186-93	34432-34443	suppression	_	
186-94	34444-34446	of	_	
186-95	34447-34455	negative	_	
186-96	34456-34463	emotion	_	
186-97	34464-34467	The	_	
186-98	34468-34475	effects	_	
186-99	34476-34478	of	_	
186-100	34479-34487	prenatal	_	
186-101	34488-34495	cocaine	_	
186-102	34496-34504	exposure	_	
186-103	34505-34507	on	_	
186-104	34508-34514	mother	_	
186-105	34514-34515	-	_	
186-106	34515-34516	-	_	
186-107	34516-34522	infant	_	
186-108	34523-34534	interaction	_	
186-109	34535-34538	and	_	
186-110	34539-34545	infant	_	
186-111	34546-34553	arousal	_	
186-112	34554-34556	in	_	
186-113	34557-34560	the	_	
186-114	34561-34568	newborn	_	
186-115	34569-34575	period	_	
186-116	34576-34584	Maternal	_	
186-117	34585-34592	smoking	_	
186-118	34593-34599	during	_	
186-119	34600-34609	pregnancy	_	
186-120	34610-34613	and	_	
186-121	34614-34623	long-term	_	
186-122	34624-34636	neurological	_	
186-123	34637-34646	morbidity	_	
186-124	34647-34649	of	_	
186-125	34650-34653	the	_	
186-126	34654-34663	offspring	_	
186-127	34664-34667	The	_	
186-128	34668-34674	reward	_	
186-129	34675-34682	circuit	_	
186-130	34682-34683	:	_	
186-131	34684-34691	Linking	_	
186-132	34692-34699	primate	_	
186-133	34700-34707	anatomy	_	
186-134	34708-34711	and	_	
186-135	34712-34717	human	_	
186-136	34718-34725	imaging	_	
186-137	34726-34733	Quality	_	
186-138	34734-34736	of	_	
186-139	34737-34747	caregiving	_	
186-140	34748-34750	in	_	
186-141	34751-34758	mothers	_	
186-142	34759-34763	with	_	
186-143	34764-34771	illicit	_	
186-144	34772-34781	substance	_	
186-145	34782-34785	use	_	
186-146	34785-34786	:	_	
186-147	34787-34788	A	_	
186-148	34789-34799	systematic	_	
186-149	34800-34806	review	_	
186-150	34807-34810	and	_	
186-151	34811-34824	meta-analysis	_	
186-152	34824-34825	.	_	

#Text=Substance Abuse
#Text=The Fagerstrom Test for Nicotine Dependence: A revision of the Fagerstrom Tolerance Questionnaire
#Text=Maternal Cocaine Use: Estimated Effects on Mother-Child Play Interactions in the Preschool Period
#Text=Does parental substance use always engender risk for children?
187-1	34826-34835	Substance	_	
187-2	34836-34841	Abuse	_	
187-3	34842-34845	The	_	
187-4	34846-34856	Fagerstrom	_	
187-5	34857-34861	Test	_	
187-6	34862-34865	for	_	
187-7	34866-34874	Nicotine	_	
187-8	34875-34885	Dependence	_	
187-9	34885-34886	:	_	
187-10	34887-34888	A	_	
187-11	34889-34897	revision	_	
187-12	34898-34900	of	_	
187-13	34901-34904	the	_	
187-14	34905-34915	Fagerstrom	_	
187-15	34916-34925	Tolerance	_	
187-16	34926-34939	Questionnaire	_	
187-17	34940-34948	Maternal	_	
187-18	34949-34956	Cocaine	_	
187-19	34957-34960	Use	_	
187-20	34960-34961	:	_	
187-21	34962-34971	Estimated	_	
187-22	34972-34979	Effects	_	
187-23	34980-34982	on	_	
187-24	34983-34995	Mother-Child	_	
187-25	34996-35000	Play	_	
187-26	35001-35013	Interactions	_	
187-27	35014-35016	in	_	
187-28	35017-35020	the	_	
187-29	35021-35030	Preschool	_	
187-30	35031-35037	Period	_	
187-31	35038-35042	Does	_	
187-32	35043-35051	parental	_	
187-33	35052-35061	substance	_	
187-34	35062-35065	use	_	
187-35	35066-35072	always	_	
187-36	35073-35081	engender	_	
187-37	35082-35086	risk	_	
187-38	35087-35090	for	_	
187-39	35091-35099	children	_	
187-40	35099-35100	?	_	

#Text=Comparing incidence rate ratios of abusive and neglectful behaviors across substance use behavior patterns
#Text=Mothers with substance addictions show reduced reward responses when viewing their own infant’s face
#Text=Early adverse experience and substance addiction: dopamine, oxytocin, and glucocorticoid pathways
#Text=Functional magnetic resonance imaging of reward prediction
#Text=Neurocircuitry of Addiction
#Text=Maternal neural responses to infant cries and faces: Relationships with substance use
#Text=Emotional arousal and activation of the visual cortex: an fMRI analysis
#Text=A cry in the dark: depressed mothers show reduced neural activation to their own infant’s cry
#Text=
#Text=The neural substrates of reward processing in humans: the modern role of FMRI
#Text=Characteristics of drug use among pregnant women in the United States: Opioid and non-opioid illegal drug use
#Text=
#Text=Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012
#Text=Patterns of polydrug use among pregnant substance abusers
#Text=Parenting and Addiction: Neurobiological Insights
#Text=
#Text=Disruption of maternal parenting circuitry by addictive process: rewiring of reward and stress systems
#Text=
#Text=Differential sex-independent amygdala response to infant crying and laughing in parents versus nonparents
#Text=The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10
#Text=A common role of insula in feelings, empathy and uncertainty
#Text=Functional MRI and parental responsiveness: a new avenue into parental psychopathology and early parent-child interactions?
188-1	35101-35110	Comparing	_	
188-2	35111-35120	incidence	_	
188-3	35121-35125	rate	_	
188-4	35126-35132	ratios	_	
188-5	35133-35135	of	_	
188-6	35136-35143	abusive	_	
188-7	35144-35147	and	_	
188-8	35148-35158	neglectful	_	
188-9	35159-35168	behaviors	_	
188-10	35169-35175	across	_	
188-11	35176-35185	substance	_	
188-12	35186-35189	use	_	
188-13	35190-35198	behavior	_	
188-14	35199-35207	patterns	_	
188-15	35208-35215	Mothers	_	
188-16	35216-35220	with	_	
188-17	35221-35230	substance	_	
188-18	35231-35241	addictions	_	
188-19	35242-35246	show	_	
188-20	35247-35254	reduced	_	
188-21	35255-35261	reward	_	
188-22	35262-35271	responses	_	
188-23	35272-35276	when	_	
188-24	35277-35284	viewing	_	
188-25	35285-35290	their	_	
188-26	35291-35294	own	_	
188-27	35295-35301	infant	_	
188-28	35301-35302	’	_	
188-29	35302-35303	s	_	
188-30	35304-35308	face	_	
188-31	35309-35314	Early	_	
188-32	35315-35322	adverse	_	
188-33	35323-35333	experience	_	
188-34	35334-35337	and	_	
188-35	35338-35347	substance	_	
188-36	35348-35357	addiction	_	
188-37	35357-35358	:	_	
188-38	35359-35367	dopamine	_	
188-39	35367-35368	,	_	
188-40	35369-35377	oxytocin	_	
188-41	35377-35378	,	_	
188-42	35379-35382	and	_	
188-43	35383-35397	glucocorticoid	_	
188-44	35398-35406	pathways	_	
188-45	35407-35417	Functional	_	
188-46	35418-35426	magnetic	_	
188-47	35427-35436	resonance	_	
188-48	35437-35444	imaging	_	
188-49	35445-35447	of	_	
188-50	35448-35454	reward	_	
188-51	35455-35465	prediction	_	
188-52	35466-35480	Neurocircuitry	_	
188-53	35481-35483	of	_	
188-54	35484-35493	Addiction	_	
188-55	35494-35502	Maternal	_	
188-56	35503-35509	neural	_	
188-57	35510-35519	responses	_	
188-58	35520-35522	to	_	
188-59	35523-35529	infant	_	
188-60	35530-35535	cries	_	
188-61	35536-35539	and	_	
188-62	35540-35545	faces	_	
188-63	35545-35546	:	_	
188-64	35547-35560	Relationships	_	
188-65	35561-35565	with	_	
188-66	35566-35575	substance	_	
188-67	35576-35579	use	_	
188-68	35580-35589	Emotional	_	
188-69	35590-35597	arousal	_	
188-70	35598-35601	and	_	
188-71	35602-35612	activation	_	
188-72	35613-35615	of	_	
188-73	35616-35619	the	_	
188-74	35620-35626	visual	_	
188-75	35627-35633	cortex	_	
188-76	35633-35634	:	_	
188-77	35635-35637	an	_	
188-78	35638-35642	fMRI	_	
188-79	35643-35651	analysis	_	
188-80	35652-35653	A	_	
188-81	35654-35657	cry	_	
188-82	35658-35660	in	_	
188-83	35661-35664	the	_	
188-84	35665-35669	dark	_	
188-85	35669-35670	:	_	
188-86	35671-35680	depressed	_	
188-87	35681-35688	mothers	_	
188-88	35689-35693	show	_	
188-89	35694-35701	reduced	_	
188-90	35702-35708	neural	_	
188-91	35709-35719	activation	_	
188-92	35720-35722	to	_	
188-93	35723-35728	their	_	
188-94	35729-35732	own	_	
188-95	35733-35739	infant	_	
188-96	35739-35740	’	_	
188-97	35740-35741	s	_	
188-98	35742-35745	cry	_	
188-99	35747-35750	The	_	
188-100	35751-35757	neural	_	
188-101	35758-35768	substrates	_	
188-102	35769-35771	of	_	
188-103	35772-35778	reward	_	
188-104	35779-35789	processing	_	
188-105	35790-35792	in	_	
188-106	35793-35799	humans	_	
188-107	35799-35800	:	_	
188-108	35801-35804	the	_	
188-109	35805-35811	modern	_	
188-110	35812-35816	role	_	
188-111	35817-35819	of	_	
188-112	35820-35824	FMRI	_	
188-113	35825-35840	Characteristics	_	
188-114	35841-35843	of	_	
188-115	35844-35848	drug	_	
188-116	35849-35852	use	_	
188-117	35853-35858	among	_	
188-118	35859-35867	pregnant	_	
188-119	35868-35873	women	_	
188-120	35874-35876	in	_	
188-121	35877-35880	the	_	
188-122	35881-35887	United	_	
188-123	35888-35894	States	_	
188-124	35894-35895	:	_	
188-125	35896-35902	Opioid	_	
188-126	35903-35906	and	_	
188-127	35907-35917	non-opioid	_	
188-128	35918-35925	illegal	_	
188-129	35926-35930	drug	_	
188-130	35931-35934	use	_	
188-131	35936-35946	Increasing	_	
188-132	35947-35956	incidence	_	
188-133	35957-35960	and	_	
188-134	35961-35971	geographic	_	
188-135	35972-35984	distribution	_	
188-136	35985-35987	of	_	
188-137	35988-35996	neonatal	_	
188-138	35997-36007	abstinence	_	
188-139	36008-36016	syndrome	_	
188-140	36016-36017	:	_	
188-141	36018-36024	United	_	
188-142	36025-36031	States	_	
188-143	36032-36036	2009	_	
188-144	36037-36039	to	_	
188-145	36040-36044	2012	_	
188-146	36045-36053	Patterns	_	
188-147	36054-36056	of	_	
188-148	36057-36065	polydrug	_	
188-149	36066-36069	use	_	
188-150	36070-36075	among	_	
188-151	36076-36084	pregnant	_	
188-152	36085-36094	substance	_	
188-153	36095-36102	abusers	_	
188-154	36103-36112	Parenting	_	
188-155	36113-36116	and	_	
188-156	36117-36126	Addiction	_	
188-157	36126-36127	:	_	
188-158	36128-36143	Neurobiological	_	
188-159	36144-36152	Insights	_	
188-160	36154-36164	Disruption	_	
188-161	36165-36167	of	_	
188-162	36168-36176	maternal	_	
188-163	36177-36186	parenting	_	
188-164	36187-36196	circuitry	_	
188-165	36197-36199	by	_	
188-166	36200-36209	addictive	_	
188-167	36210-36217	process	_	
188-168	36217-36218	:	_	
188-169	36219-36227	rewiring	_	
188-170	36228-36230	of	_	
188-171	36231-36237	reward	_	
188-172	36238-36241	and	_	
188-173	36242-36248	stress	_	
188-174	36249-36256	systems	_	
188-175	36258-36270	Differential	_	
188-176	36271-36286	sex-independent	_	
188-177	36287-36295	amygdala	_	
188-178	36296-36304	response	_	
188-179	36305-36307	to	_	
188-180	36308-36314	infant	_	
188-181	36315-36321	crying	_	
188-182	36322-36325	and	_	
188-183	36326-36334	laughing	_	
188-184	36335-36337	in	_	
188-185	36338-36345	parents	_	
188-186	36346-36352	versus	_	
188-187	36353-36363	nonparents	_	
188-188	36364-36367	The	_	
188-189	36368-36386	Mini-International	_	
188-190	36387-36403	Neuropsychiatric	_	
188-191	36404-36413	Interview	_	
188-192	36414-36415	(	_	
188-193	36415-36419	MINI	_	
188-194	36419-36420	)	_	
188-195	36420-36421	:	_	
188-196	36422-36425	the	_	
188-197	36426-36437	development	_	
188-198	36438-36441	and	_	
188-199	36442-36452	validation	_	
188-200	36453-36455	of	_	
188-201	36456-36457	a	_	
188-202	36458-36468	structured	_	
188-203	36469-36479	diagnostic	_	
188-204	36480-36491	psychiatric	_	
188-205	36492-36501	interview	_	
188-206	36502-36505	for	_	
188-207	36506-36512	DSM-IV	_	
188-208	36513-36516	and	_	
188-209	36517-36520	ICD	_	
188-210	36520-36521	-	_	
188-211	36521-36523	10	_	
188-212	36524-36525	A	_	
188-213	36526-36532	common	_	
188-214	36533-36537	role	_	
188-215	36538-36540	of	_	
188-216	36541-36547	insula	_	
188-217	36548-36550	in	_	
188-218	36551-36559	feelings	_	
188-219	36559-36560	,	_	
188-220	36561-36568	empathy	_	
188-221	36569-36572	and	_	
188-222	36573-36584	uncertainty	_	
188-223	36585-36595	Functional	_	
188-224	36596-36599	MRI	_	
188-225	36600-36603	and	_	
188-226	36604-36612	parental	_	
188-227	36613-36627	responsiveness	_	
188-228	36627-36628	:	_	
188-229	36629-36630	a	_	
188-230	36631-36634	new	_	
188-231	36635-36641	avenue	_	
188-232	36642-36646	into	_	
188-233	36647-36655	parental	_	
188-234	36656-36671	psychopathology	_	
188-235	36672-36675	and	_	
188-236	36676-36681	early	_	
188-237	36682-36694	parent-child	_	
188-238	36695-36707	interactions	_	
188-239	36707-36708	?	_	

#Text=Adult Attachment Predicts Maternal Brain and Oxytocin Response to Infant Cues
#Text=What’s in a Smile?
189-1	36709-36714	Adult	_	
189-2	36715-36725	Attachment	_	
189-3	36726-36734	Predicts	_	
189-4	36735-36743	Maternal	_	
189-5	36744-36749	Brain	_	
189-6	36750-36753	and	_	
189-7	36754-36762	Oxytocin	_	
189-8	36763-36771	Response	_	
189-9	36772-36774	to	_	
189-10	36775-36781	Infant	_	
189-11	36782-36786	Cues	_	
189-12	36787-36791	What	_	
189-13	36791-36792	’	_	
189-14	36792-36793	s	_	
189-15	36794-36796	in	_	
189-16	36797-36798	a	_	
189-17	36799-36804	Smile	_	
189-18	36804-36805	?	_	

#Text=Maternal Brain Responses to Infant Facial Cues
#Text=
#Text=Reflective functioning in mothers with drug use disorders: Implications for dyadic interactions with infants and toddlers
#Text=Mothering From the Inside Out: Results of a second randomized clinical trial testing a mentalization-based intervention for mothers in addiction treatment
#Text=Parent–child intervention decreases stress and increases maternal brain activity and connectivity during own baby-cry: An exploratory study
#Text=Brain basis of early parent–infant interactions: psychology, physiology, and in vivo functional neuroimaging studies
#Text=Maternal brain response to own baby-cry is affected by cesarean section delivery
#Text=Differential prefrontal cortex and amygdala habituation to repeatedly presented emotional stimuli
#Text=Brain activation in the infant-face-familiarity-by-maternal-substance-use-status interaction (A) with representative interaction term plotted for the cluster incorporating the left and right medial frontal, superior frontal, precentral and postcentral gyri, cingulate gyrus, and supplementary motor area (B).
190-1	36806-36814	Maternal	_	
190-2	36815-36820	Brain	_	
190-3	36821-36830	Responses	_	
190-4	36831-36833	to	_	
190-5	36834-36840	Infant	_	
190-6	36841-36847	Facial	_	
190-7	36848-36852	Cues	_	
190-8	36854-36864	Reflective	_	
190-9	36865-36876	functioning	_	
190-10	36877-36879	in	_	
190-11	36880-36887	mothers	_	
190-12	36888-36892	with	_	
190-13	36893-36897	drug	_	
190-14	36898-36901	use	_	
190-15	36902-36911	disorders	_	
190-16	36911-36912	:	_	
190-17	36913-36925	Implications	_	
190-18	36926-36929	for	_	
190-19	36930-36936	dyadic	_	
190-20	36937-36949	interactions	_	
190-21	36950-36954	with	_	
190-22	36955-36962	infants	_	
190-23	36963-36966	and	_	
190-24	36967-36975	toddlers	_	
190-25	36976-36985	Mothering	_	
190-26	36986-36990	From	_	
190-27	36991-36994	the	_	
190-28	36995-37001	Inside	_	
190-29	37002-37005	Out	_	
190-30	37005-37006	:	_	
190-31	37007-37014	Results	_	
190-32	37015-37017	of	_	
190-33	37018-37019	a	_	
190-34	37020-37026	second	_	
190-35	37027-37037	randomized	_	
190-36	37038-37046	clinical	_	
190-37	37047-37052	trial	_	
190-38	37053-37060	testing	_	
190-39	37061-37062	a	_	
190-40	37063-37082	mentalization-based	_	
190-41	37083-37095	intervention	_	
190-42	37096-37099	for	_	
190-43	37100-37107	mothers	_	
190-44	37108-37110	in	_	
190-45	37111-37120	addiction	_	
190-46	37121-37130	treatment	_	
190-47	37131-37143	Parent–child	_	
190-48	37144-37156	intervention	_	
190-49	37157-37166	decreases	_	
190-50	37167-37173	stress	_	
190-51	37174-37177	and	_	
190-52	37178-37187	increases	_	
190-53	37188-37196	maternal	_	
190-54	37197-37202	brain	_	
190-55	37203-37211	activity	_	
190-56	37212-37215	and	_	
190-57	37216-37228	connectivity	_	
190-58	37229-37235	during	_	
190-59	37236-37239	own	_	
190-60	37240-37248	baby-cry	_	
190-61	37248-37249	:	_	
190-62	37250-37252	An	_	
190-63	37253-37264	exploratory	_	
190-64	37265-37270	study	_	
190-65	37271-37276	Brain	_	
190-66	37277-37282	basis	_	
190-67	37283-37285	of	_	
190-68	37286-37291	early	_	
190-69	37292-37305	parent–infant	_	
190-70	37306-37318	interactions	_	
190-71	37318-37319	:	_	
190-72	37320-37330	psychology	_	
190-73	37330-37331	,	_	
190-74	37332-37342	physiology	_	
190-75	37342-37343	,	_	
190-76	37344-37347	and	_	
190-77	37348-37350	in	_	
190-78	37351-37355	vivo	_	
190-79	37356-37366	functional	_	
190-80	37367-37379	neuroimaging	_	
190-81	37380-37387	studies	_	
190-82	37388-37396	Maternal	_	
190-83	37397-37402	brain	_	
190-84	37403-37411	response	_	
190-85	37412-37414	to	_	
190-86	37415-37418	own	_	
190-87	37419-37427	baby-cry	_	
190-88	37428-37430	is	_	
190-89	37431-37439	affected	_	
190-90	37440-37442	by	_	
190-91	37443-37451	cesarean	_	
190-92	37452-37459	section	_	
190-93	37460-37468	delivery	_	
190-94	37469-37481	Differential	_	
190-95	37482-37492	prefrontal	_	
190-96	37493-37499	cortex	_	
190-97	37500-37503	and	_	
190-98	37504-37512	amygdala	_	
190-99	37513-37524	habituation	_	
190-100	37525-37527	to	_	
190-101	37528-37538	repeatedly	_	
190-102	37539-37548	presented	_	
190-103	37549-37558	emotional	_	
190-104	37559-37566	stimuli	_	
190-105	37567-37572	Brain	_	
190-106	37573-37583	activation	_	
190-107	37584-37586	in	_	
190-108	37587-37590	the	_	
190-109	37591-37647	infant-face-familiarity-by-maternal-substance-use-status	_	
190-110	37648-37659	interaction	_	
190-111	37660-37661	(	_	
190-112	37661-37662	A	_	
190-113	37662-37663	)	_	
190-114	37664-37668	with	_	
190-115	37669-37683	representative	_	
190-116	37684-37695	interaction	_	
190-117	37696-37700	term	_	
190-118	37701-37708	plotted	_	
190-119	37709-37712	for	_	
190-120	37713-37716	the	_	
190-121	37717-37724	cluster	_	
190-122	37725-37738	incorporating	_	
190-123	37739-37742	the	_	
190-124	37743-37747	left	_	
190-125	37748-37751	and	_	
190-126	37752-37757	right	_	
190-127	37758-37764	medial	_	
190-128	37765-37772	frontal	_	
190-129	37772-37773	,	_	
190-130	37774-37782	superior	_	
190-131	37783-37790	frontal	_	
190-132	37790-37791	,	_	
190-133	37792-37802	precentral	_	
190-134	37803-37806	and	_	
190-135	37807-37818	postcentral	_	
190-136	37819-37823	gyri	_	
190-137	37823-37824	,	_	
190-138	37825-37834	cingulate	_	
190-139	37835-37840	gyrus	_	
190-140	37840-37841	,	_	
190-141	37842-37845	and	_	
190-142	37846-37859	supplementary	_	
190-143	37860-37865	motor	_	
190-144	37866-37870	area	_	
190-145	37871-37872	(	_	
190-146	37872-37873	B	_	
190-147	37873-37874	)	_	
190-148	37874-37875	.	_	

#Text=For interaction plots across all clusters, see supplementary materials.
191-1	37876-37879	For	_	
191-2	37880-37891	interaction	_	
191-3	37892-37897	plots	_	
191-4	37898-37904	across	_	
191-5	37905-37908	all	_	
191-6	37909-37917	clusters	_	
191-7	37917-37918	,	_	
191-8	37919-37922	see	_	
191-9	37923-37936	supplementary	_	
191-10	37937-37946	materials	_	
191-11	37946-37947	.	_	

#Text=Brain activation for the main effect of substance-use status when viewing sad infant faces, incorporating the caudate.
192-1	37948-37953	Brain	_	
192-2	37954-37964	activation	_	
192-3	37965-37968	for	_	
192-4	37969-37972	the	_	
192-5	37973-37977	main	_	
192-6	37978-37984	effect	_	
192-7	37985-37987	of	_	
192-8	37988-38001	substance-use	_	
192-9	38002-38008	status	_	
192-10	38009-38013	when	_	
192-11	38014-38021	viewing	_	
192-12	38022-38025	sad	_	
192-13	38026-38032	infant	_	
192-14	38033-38038	faces	_	
192-15	38038-38039	,	_	
192-16	38040-38053	incorporating	_	
192-17	38054-38057	the	_	
192-18	38058-38065	caudate	_	
192-19	38065-38066	.	_	

#Text=Demographic characteristics of the maternal sample as a function of substance-use status.
193-1	38067-38078	Demographic	_	
193-2	38079-38094	characteristics	_	
193-3	38095-38097	of	_	
193-4	38098-38101	the	_	
193-5	38102-38110	maternal	_	
193-6	38111-38117	sample	_	
193-7	38118-38120	as	_	
193-8	38121-38122	a	_	
193-9	38123-38131	function	_	
193-10	38132-38134	of	_	
193-11	38135-38148	substance-use	_	
193-12	38149-38155	status	_	
193-13	38155-38156	.	_	

#Text=Maternal age and education are measured in years, means (standard deviation).
194-1	38157-38165	Maternal	_	
194-2	38166-38169	age	_	
194-3	38170-38173	and	_	
194-4	38174-38183	education	_	
194-5	38184-38187	are	_	
194-6	38188-38196	measured	_	
194-7	38197-38199	in	_	
194-8	38200-38205	years	_	
194-9	38205-38206	,	_	
194-10	38207-38212	means	_	
194-11	38213-38214	(	_	
194-12	38214-38222	standard	_	
194-13	38223-38232	deviation	_	
194-14	38232-38233	)	_	
194-15	38233-38234	.	_	

#Text=Substance-Using Mothers (n=32)\tNon-Substance-Using Mothers (n=22)\t \tMaternal Age\t28.17 (5.33)\t28.76 (4.27)\t \tMaternal Education*\t12.63 (1.96)\t14.67 (2.71)\t \tMaternal Ethnicity\t12 African American\t9 African American\t \t10 Caucasian\t3 Caucasian\t \t3 Hispanic/Latino\t4 Hispanic/Latino\t \t3 Other\t2 Other\t \t1 Prefer not to answer\t3 Asian\t \t3 Did not report\t1 Did not report\t \tParity*\t6 Primiparous\t12 Primiparous\t \t24 Multiparous\t9 Multiparous\t \tHours another person looks after baby\t7 Never\t6 Never\t \t15 Less than 4 hours\t4 Less than 4 hours\t \t6 5–20 hours\t6 5–20 hours\t \t2 21–40 hours\t3 21–40 hours\t \t1 More than 40 hours\t2 More than 40 hours\t \tBreastfeeding Duration*\t3 Still breastfeeding\t11 Still breastfeeding\t \t4 4–6 months\t1 4–6 months\t \t6 7 weeks to 3 months\t2 7 weeks to 3 months\t \t3 3–6 weeks\t2 3–6 weeks\t \t5 2 weeks or less\t1 2 weeks or less\t \t11 Not at all\t3 Not at all\t \t\t2 Did not report\t \t
#Text=Note.
195-1	38236-38251	Substance-Using	_	
195-2	38252-38259	Mothers	_	
195-3	38260-38261	(	_	
195-4	38261-38262	n	_	
195-5	38262-38263	=	_	
195-6	38263-38265	32	_	
195-7	38265-38266	)	_	
195-8	38267-38286	Non-Substance-Using	_	
195-9	38287-38294	Mothers	_	
195-10	38295-38296	(	_	
195-11	38296-38297	n	_	
195-12	38297-38298	=	_	
195-13	38298-38300	22	_	
195-14	38300-38301	)	_	
195-15	38304-38312	Maternal	_	
195-16	38313-38316	Age	_	
195-17	38317-38322	28.17	_	
195-18	38323-38324	(	_	
195-19	38324-38328	5.33	_	
195-20	38328-38329	)	_	
195-21	38330-38335	28.76	_	
195-22	38336-38337	(	_	
195-23	38337-38341	4.27	_	
195-24	38341-38342	)	_	
195-25	38345-38353	Maternal	_	
195-26	38354-38363	Education	_	
195-27	38363-38364	*	_	
195-28	38365-38370	12.63	_	
195-29	38371-38372	(	_	
195-30	38372-38376	1.96	_	
195-31	38376-38377	)	_	
195-32	38378-38383	14.67	_	
195-33	38384-38385	(	_	
195-34	38385-38389	2.71	_	
195-35	38389-38390	)	_	
195-36	38393-38401	Maternal	_	
195-37	38402-38411	Ethnicity	_	
195-38	38412-38414	12	_	
195-39	38415-38422	African	_	
195-40	38423-38431	American	_	
195-41	38432-38433	9	_	
195-42	38434-38441	African	_	
195-43	38442-38450	American	_	
195-44	38453-38455	10	_	
195-45	38456-38465	Caucasian	_	
195-46	38466-38467	3	_	
195-47	38468-38477	Caucasian	_	
195-48	38480-38481	3	_	
195-49	38482-38490	Hispanic	_	
195-50	38490-38491	/	_	
195-51	38491-38497	Latino	_	
195-52	38498-38499	4	_	
195-53	38500-38508	Hispanic	_	
195-54	38508-38509	/	_	
195-55	38509-38515	Latino	_	
195-56	38518-38519	3	_	
195-57	38520-38525	Other	_	
195-58	38526-38527	2	_	
195-59	38528-38533	Other	_	
195-60	38536-38537	1	_	
195-61	38538-38544	Prefer	_	
195-62	38545-38548	not	_	
195-63	38549-38551	to	_	
195-64	38552-38558	answer	_	
195-65	38559-38560	3	_	
195-66	38561-38566	Asian	_	
195-67	38569-38570	3	_	
195-68	38571-38574	Did	_	
195-69	38575-38578	not	_	
195-70	38579-38585	report	_	
195-71	38586-38587	1	_	
195-72	38588-38591	Did	_	
195-73	38592-38595	not	_	
195-74	38596-38602	report	_	
195-75	38605-38611	Parity	_	
195-76	38611-38612	*	_	
195-77	38613-38614	6	_	
195-78	38615-38626	Primiparous	_	
195-79	38627-38629	12	_	
195-80	38630-38641	Primiparous	_	
195-81	38644-38646	24	_	
195-82	38647-38658	Multiparous	_	
195-83	38659-38660	9	_	
195-84	38661-38672	Multiparous	_	
195-85	38675-38680	Hours	_	
195-86	38681-38688	another	_	
195-87	38689-38695	person	_	
195-88	38696-38701	looks	_	
195-89	38702-38707	after	_	
195-90	38708-38712	baby	_	
195-91	38713-38714	7	_	
195-92	38715-38720	Never	_	
195-93	38721-38722	6	_	
195-94	38723-38728	Never	_	
195-95	38731-38733	15	_	
195-96	38734-38738	Less	_	
195-97	38739-38743	than	_	
195-98	38744-38745	4	_	
195-99	38746-38751	hours	_	
195-100	38752-38753	4	_	
195-101	38754-38758	Less	_	
195-102	38759-38763	than	_	
195-103	38764-38765	4	_	
195-104	38766-38771	hours	_	
195-105	38774-38775	6	_	
195-106	38776-38777	5	_	
195-107	38777-38778	–	_	
195-108	38778-38780	20	_	
195-109	38781-38786	hours	_	
195-110	38787-38788	6	_	
195-111	38789-38790	5	_	
195-112	38790-38791	–	_	
195-113	38791-38793	20	_	
195-114	38794-38799	hours	_	
195-115	38802-38803	2	_	
195-116	38804-38806	21	_	
195-117	38806-38807	–	_	
195-118	38807-38809	40	_	
195-119	38810-38815	hours	_	
195-120	38816-38817	3	_	
195-121	38818-38820	21	_	
195-122	38820-38821	–	_	
195-123	38821-38823	40	_	
195-124	38824-38829	hours	_	
195-125	38832-38833	1	_	
195-126	38834-38838	More	_	
195-127	38839-38843	than	_	
195-128	38844-38846	40	_	
195-129	38847-38852	hours	_	
195-130	38853-38854	2	_	
195-131	38855-38859	More	_	
195-132	38860-38864	than	_	
195-133	38865-38867	40	_	
195-134	38868-38873	hours	_	
195-135	38876-38889	Breastfeeding	_	
195-136	38890-38898	Duration	_	
195-137	38898-38899	*	_	
195-138	38900-38901	3	_	
195-139	38902-38907	Still	_	
195-140	38908-38921	breastfeeding	_	
195-141	38922-38924	11	_	
195-142	38925-38930	Still	_	
195-143	38931-38944	breastfeeding	_	
195-144	38947-38948	4	_	
195-145	38949-38950	4	_	
195-146	38950-38951	–	_	
195-147	38951-38952	6	_	
195-148	38953-38959	months	_	
195-149	38960-38961	1	_	
195-150	38962-38963	4	_	
195-151	38963-38964	–	_	
195-152	38964-38965	6	_	
195-153	38966-38972	months	_	
195-154	38975-38976	6	_	
195-155	38977-38978	7	_	
195-156	38979-38984	weeks	_	
195-157	38985-38987	to	_	
195-158	38988-38989	3	_	
195-159	38990-38996	months	_	
195-160	38997-38998	2	_	
195-161	38999-39000	7	_	
195-162	39001-39006	weeks	_	
195-163	39007-39009	to	_	
195-164	39010-39011	3	_	
195-165	39012-39018	months	_	
195-166	39021-39022	3	_	
195-167	39023-39024	3	_	
195-168	39024-39025	–	_	
195-169	39025-39026	6	_	
195-170	39027-39032	weeks	_	
195-171	39033-39034	2	_	
195-172	39035-39036	3	_	
195-173	39036-39037	–	_	
195-174	39037-39038	6	_	
195-175	39039-39044	weeks	_	
195-176	39047-39048	5	_	
195-177	39049-39050	2	_	
195-178	39051-39056	weeks	_	
195-179	39057-39059	or	_	
195-180	39060-39064	less	_	
195-181	39065-39066	1	_	
195-182	39067-39068	2	_	
195-183	39069-39074	weeks	_	
195-184	39075-39077	or	_	
195-185	39078-39082	less	_	
195-186	39085-39087	11	_	
195-187	39088-39091	Not	_	
195-188	39092-39094	at	_	
195-189	39095-39098	all	_	
195-190	39099-39100	3	_	
195-191	39101-39104	Not	_	
195-192	39105-39107	at	_	
195-193	39108-39111	all	_	
195-194	39115-39116	2	_	
195-195	39117-39120	Did	_	
195-196	39121-39124	not	_	
195-197	39125-39131	report	_	
195-198	39135-39139	Note	_	
195-199	39139-39140	.	_	

#Text=Data missing from three participants for parity, maternal age, and maternal education and data are missing from two participants from hours another person looks after the baby and breastfeeding duration;
#Text=p<.05
#Text=Substance-use information for mothers included in the substance-using group (n=32).
196-1	39141-39145	Data	_	
196-2	39146-39153	missing	_	
196-3	39154-39158	from	_	
196-4	39159-39164	three	_	
196-5	39165-39177	participants	_	
196-6	39178-39181	for	_	
196-7	39182-39188	parity	_	
196-8	39188-39189	,	_	
196-9	39190-39198	maternal	_	
196-10	39199-39202	age	_	
196-11	39202-39203	,	_	
196-12	39204-39207	and	_	
196-13	39208-39216	maternal	_	
196-14	39217-39226	education	_	
196-15	39227-39230	and	_	
196-16	39231-39235	data	_	
196-17	39236-39239	are	_	
196-18	39240-39247	missing	_	
196-19	39248-39252	from	_	
196-20	39253-39256	two	_	
196-21	39257-39269	participants	_	
196-22	39270-39274	from	_	
196-23	39275-39280	hours	_	
196-24	39281-39288	another	_	
196-25	39289-39295	person	_	
196-26	39296-39301	looks	_	
196-27	39302-39307	after	_	
196-28	39308-39311	the	_	
196-29	39312-39316	baby	_	
196-30	39317-39320	and	_	
196-31	39321-39334	breastfeeding	_	
196-32	39335-39343	duration	_	
196-33	39343-39344	;	_	
196-34	39345-39346	p	_	
196-35	39346-39347	<	_	
196-36	39347-39350	.05	_	
196-37	39351-39364	Substance-use	_	
196-38	39365-39376	information	_	
196-39	39377-39380	for	_	
196-40	39381-39388	mothers	_	
196-41	39389-39397	included	_	
196-42	39398-39400	in	_	
196-43	39401-39404	the	_	
196-44	39405-39420	substance-using	_	
196-45	39421-39426	group	_	
196-46	39427-39428	(	_	
196-47	39428-39429	n	_	
196-48	39429-39430	=	_	
196-49	39430-39432	32	_	
196-50	39432-39433	)	_	
196-51	39433-39434	.	_	

#Text=Urine toxicology was assessed at the time of the fMRI scan.
197-1	39435-39440	Urine	_	
197-2	39441-39451	toxicology	_	
197-3	39452-39455	was	_	
197-4	39456-39464	assessed	_	
197-5	39465-39467	at	_	
197-6	39468-39471	the	_	
197-7	39472-39476	time	_	
197-8	39477-39479	of	_	
197-9	39480-39483	the	_	
197-10	39484-39488	fMRI	_	
197-11	39489-39493	scan	_	
197-12	39493-39494	.	_	

#Text=Mothers may be represented in more than one category given their poly-substance use.
198-1	39495-39502	Mothers	_	
198-2	39503-39506	may	_	
198-3	39507-39509	be	_	
198-4	39510-39521	represented	_	
198-5	39522-39524	in	_	
198-6	39525-39529	more	_	
198-7	39530-39534	than	_	
198-8	39535-39538	one	_	
198-9	39539-39547	category	_	
198-10	39548-39553	given	_	
198-11	39554-39559	their	_	
198-12	39560-39574	poly-substance	_	
198-13	39575-39578	use	_	
198-14	39578-39579	.	_	

#Text=N\t \tSmoking\tCurrent smoker*\t20\t \t\tDoes not smoke\t11\t \t\tMissing\t1\t \t\t\t\t \tMINI\tSubstance use**\t2\t \t\tNo substance use\t17\t \t\tMissing data\t13\t \t\t\t\t \tFTND\tScore above 5\t\t \t\tScore below 5\t26\t \t\t\t\t \tUrine Toxicology\tPositive\t15\t \t\tNegative\t3\t \t\tMissing\t14\t \t\t\t\t \tMethadone\tCurrent\t4\t \t\tPast use\t2\t \t\tNot using\t25\t \t\t\t\t \tAddiction Detoxification or Treatment Program\tCurrent\t7\t \tPast\t7\t \tNone reported\t18\t \t
#Text=Note.
199-1	39581-39582	N	_	
199-2	39585-39592	Smoking	_	
199-3	39593-39600	Current	_	
199-4	39601-39607	smoker	_	
199-5	39607-39608	*	_	
199-6	39609-39611	20	_	
199-7	39615-39619	Does	_	
199-8	39620-39623	not	_	
199-9	39624-39629	smoke	_	
199-10	39630-39632	11	_	
199-11	39636-39643	Missing	_	
199-12	39644-39645	1	_	
199-13	39653-39657	MINI	_	
199-14	39658-39667	Substance	_	
199-15	39668-39671	use	_	
199-16	39671-39672	*	_	
199-17	39672-39673	*	_	
199-18	39674-39675	2	_	
199-19	39679-39681	No	_	
199-20	39682-39691	substance	_	
199-21	39692-39695	use	_	
199-22	39696-39698	17	_	
199-23	39702-39709	Missing	_	
199-24	39710-39714	data	_	
199-25	39715-39717	13	_	
199-26	39725-39729	FTND	_	
199-27	39730-39735	Score	_	
199-28	39736-39741	above	_	
199-29	39742-39743	5	_	
199-30	39748-39753	Score	_	
199-31	39754-39759	below	_	
199-32	39760-39761	5	_	
199-33	39762-39764	26	_	
199-34	39772-39777	Urine	_	
199-35	39778-39788	Toxicology	_	
199-36	39789-39797	Positive	_	
199-37	39798-39800	15	_	
199-38	39804-39812	Negative	_	
199-39	39813-39814	3	_	
199-40	39818-39825	Missing	_	
199-41	39826-39828	14	_	
199-42	39836-39845	Methadone	_	
199-43	39846-39853	Current	_	
199-44	39854-39855	4	_	
199-45	39859-39863	Past	_	
199-46	39864-39867	use	_	
199-47	39868-39869	2	_	
199-48	39873-39876	Not	_	
199-49	39877-39882	using	_	
199-50	39883-39885	25	_	
199-51	39893-39902	Addiction	_	
199-52	39903-39917	Detoxification	_	
199-53	39918-39920	or	_	
199-54	39921-39930	Treatment	_	
199-55	39931-39938	Program	_	
199-56	39939-39946	Current	_	
199-57	39947-39948	7	_	
199-58	39951-39955	Past	_	
199-59	39956-39957	7	_	
199-60	39960-39964	None	_	
199-61	39965-39973	reported	_	
199-62	39974-39976	18	_	
199-63	39980-39984	Note	_	
199-64	39984-39985	.	_	

#Text=Only one mother used solely tobacco (and her FTND score was > 5).
200-1	39986-39990	Only	_	
200-2	39991-39994	one	_	
200-3	39995-40001	mother	_	
200-4	40002-40006	used	_	
200-5	40007-40013	solely	_	
200-6	40014-40021	tobacco	_	
200-7	40022-40023	(	_	
200-8	40023-40026	and	_	
200-9	40027-40030	her	_	
200-10	40031-40035	FTND	_	
200-11	40036-40041	score	_	
200-12	40042-40045	was	_	
200-13	40046-40047	>	_	
200-14	40048-40049	5	_	
200-15	40049-40050	)	_	
200-16	40050-40051	.	_	

#Text=All other tobacco-smoking mothers reported using additional substances though varied in their FTND scores being above or below 5.
201-1	40052-40055	All	_	
201-2	40056-40061	other	_	
201-3	40062-40077	tobacco-smoking	_	
201-4	40078-40085	mothers	_	
201-5	40086-40094	reported	_	
201-6	40095-40100	using	_	
201-7	40101-40111	additional	_	
201-8	40112-40122	substances	_	
201-9	40123-40129	though	_	
201-10	40130-40136	varied	_	
201-11	40137-40139	in	_	
201-12	40140-40145	their	_	
201-13	40146-40150	FTND	_	
201-14	40151-40157	scores	_	
201-15	40158-40163	being	_	
201-16	40164-40169	above	_	
201-17	40170-40172	or	_	
201-18	40173-40178	below	_	
201-19	40179-40180	5	_	
201-20	40180-40181	.	_	

#Text=Illicit drugs recorded on the MINI included marijuana, cannabis, cocaine, vicodin, phencyclidine (PCP), and diet pills.
202-1	40182-40189	Illicit	_	
202-2	40190-40195	drugs	_	
202-3	40196-40204	recorded	_	
202-4	40205-40207	on	_	
202-5	40208-40211	the	_	
202-6	40212-40216	MINI	_	
202-7	40217-40225	included	_	
202-8	40226-40235	marijuana	_	
202-9	40235-40236	,	_	
202-10	40237-40245	cannabis	_	
202-11	40245-40246	,	_	
202-12	40247-40254	cocaine	_	
202-13	40254-40255	,	_	
202-14	40256-40263	vicodin	_	
202-15	40263-40264	,	_	
202-16	40265-40278	phencyclidine	_	
202-17	40279-40280	(	_	
202-18	40280-40283	PCP	_	
202-19	40283-40284	)	_	
202-20	40284-40285	,	_	
202-21	40286-40289	and	_	
202-22	40290-40294	diet	_	
202-23	40295-40300	pills	_	
202-24	40300-40301	.	_	

#Text=FTND=Fagerstrom Test for Nicotine Dependence; MINI=Mini-International Neuropsychiatric Interview
#Text=Brain activation in substance-using and non-substance-using mothers viewing infant
#Text=Cluster Description\tk\tx\ty\tz\tF\t \tBrain activation in the infant-face-familiarity-by-maternal-substance-use-status interaction\t \tLeft and right medial frontal, superior frontal, precentral and postcentral gyri, cingulate gyrus, supplementary motor area\t1123\t6\t−22\t68\t26.57\t \tLeft inferior parietal lobule, insula, postcentral gyrus\t263\t−48\t−37\t32\t26.43\t \tRight inferior parietal lobule, insula, postcentral gyrus\t256\t51\t−28\t32\t20.54\t \tLeft middle temporal gyrus, occipital gyrus, cuneus\t231\t−39\t−67\t8\t23.37\t \tRight lingual gyrus and bilateral cuneus\t186\t−3\t−91\t2\t17.60\t \tRight cuneus, precuneus, superior occipital\t156\t12\t−82\t35\t17.80\t \tLeft lingual gyrus\t105\t−21\t−76\t−4\t16.33\t \tBrain activation for the main effect of substance-use status on sad-infant faces\t \tCaudate\t197\t−21\t29\t5\t24.92\t \t
#Text=faces (p<.001, pFWE<.05).
203-1	40302-40306	FTND	_	
203-2	40306-40307	=	_	
203-3	40307-40317	Fagerstrom	_	
203-4	40318-40322	Test	_	
203-5	40323-40326	for	_	
203-6	40327-40335	Nicotine	_	
203-7	40336-40346	Dependence	_	
203-8	40346-40347	;	_	
203-9	40348-40352	MINI	_	
203-10	40352-40353	=	_	
203-11	40353-40371	Mini-International	_	
203-12	40372-40388	Neuropsychiatric	_	
203-13	40389-40398	Interview	_	
203-14	40399-40404	Brain	_	
203-15	40405-40415	activation	_	
203-16	40416-40418	in	_	
203-17	40419-40434	substance-using	_	
203-18	40435-40438	and	_	
203-19	40439-40458	non-substance-using	_	
203-20	40459-40466	mothers	_	
203-21	40467-40474	viewing	_	
203-22	40475-40481	infant	_	
203-23	40482-40489	Cluster	_	
203-24	40490-40501	Description	_	
203-25	40502-40503	k	_	
203-26	40504-40505	x	_	
203-27	40506-40507	y	_	
203-28	40508-40509	z	_	
203-29	40510-40511	F	_	
203-30	40514-40519	Brain	_	
203-31	40520-40530	activation	_	
203-32	40531-40533	in	_	
203-33	40534-40537	the	_	
203-34	40538-40594	infant-face-familiarity-by-maternal-substance-use-status	_	
203-35	40595-40606	interaction	_	
203-36	40609-40613	Left	_	
203-37	40614-40617	and	_	
203-38	40618-40623	right	_	
203-39	40624-40630	medial	_	
203-40	40631-40638	frontal	_	
203-41	40638-40639	,	_	
203-42	40640-40648	superior	_	
203-43	40649-40656	frontal	_	
203-44	40656-40657	,	_	
203-45	40658-40668	precentral	_	
203-46	40669-40672	and	_	
203-47	40673-40684	postcentral	_	
203-48	40685-40689	gyri	_	
203-49	40689-40690	,	_	
203-50	40691-40700	cingulate	_	
203-51	40701-40706	gyrus	_	
203-52	40706-40707	,	_	
203-53	40708-40721	supplementary	_	
203-54	40722-40727	motor	_	
203-55	40728-40732	area	_	
203-56	40733-40737	1123	_	
203-57	40738-40739	6	_	
203-58	40740-40741	−	_	
203-59	40741-40743	22	_	
203-60	40744-40746	68	_	
203-61	40747-40752	26.57	_	
203-62	40755-40759	Left	_	
203-63	40760-40768	inferior	_	
203-64	40769-40777	parietal	_	
203-65	40778-40784	lobule	_	
203-66	40784-40785	,	_	
203-67	40786-40792	insula	_	
203-68	40792-40793	,	_	
203-69	40794-40805	postcentral	_	
203-70	40806-40811	gyrus	_	
203-71	40812-40815	263	_	
203-72	40816-40817	−	_	
203-73	40817-40819	48	_	
203-74	40820-40821	−	_	
203-75	40821-40823	37	_	
203-76	40824-40826	32	_	
203-77	40827-40832	26.43	_	
203-78	40835-40840	Right	_	
203-79	40841-40849	inferior	_	
203-80	40850-40858	parietal	_	
203-81	40859-40865	lobule	_	
203-82	40865-40866	,	_	
203-83	40867-40873	insula	_	
203-84	40873-40874	,	_	
203-85	40875-40886	postcentral	_	
203-86	40887-40892	gyrus	_	
203-87	40893-40896	256	_	
203-88	40897-40899	51	_	
203-89	40900-40901	−	_	
203-90	40901-40903	28	_	
203-91	40904-40906	32	_	
203-92	40907-40912	20.54	_	
203-93	40915-40919	Left	_	
203-94	40920-40926	middle	_	
203-95	40927-40935	temporal	_	
203-96	40936-40941	gyrus	_	
203-97	40941-40942	,	_	
203-98	40943-40952	occipital	_	
203-99	40953-40958	gyrus	_	
203-100	40958-40959	,	_	
203-101	40960-40966	cuneus	_	
203-102	40967-40970	231	_	
203-103	40971-40972	−	_	
203-104	40972-40974	39	_	
203-105	40975-40976	−	_	
203-106	40976-40978	67	_	
203-107	40979-40980	8	_	
203-108	40981-40986	23.37	_	
203-109	40989-40994	Right	_	
203-110	40995-41002	lingual	_	
203-111	41003-41008	gyrus	_	
203-112	41009-41012	and	_	
203-113	41013-41022	bilateral	_	
203-114	41023-41029	cuneus	_	
203-115	41030-41033	186	_	
203-116	41034-41035	−	_	
203-117	41035-41036	3	_	
203-118	41037-41038	−	_	
203-119	41038-41040	91	_	
203-120	41041-41042	2	_	
203-121	41043-41048	17.60	_	
203-122	41051-41056	Right	_	
203-123	41057-41063	cuneus	_	
203-124	41063-41064	,	_	
203-125	41065-41074	precuneus	_	
203-126	41074-41075	,	_	
203-127	41076-41084	superior	_	
203-128	41085-41094	occipital	_	
203-129	41095-41098	156	_	
203-130	41099-41101	12	_	
203-131	41102-41103	−	_	
203-132	41103-41105	82	_	
203-133	41106-41108	35	_	
203-134	41109-41114	17.80	_	
203-135	41117-41121	Left	_	
203-136	41122-41129	lingual	_	
203-137	41130-41135	gyrus	_	
203-138	41136-41139	105	_	
203-139	41140-41141	−	_	
203-140	41141-41143	21	_	
203-141	41144-41145	−	_	
203-142	41145-41147	76	_	
203-143	41148-41149	−	_	
203-144	41149-41150	4	_	
203-145	41151-41156	16.33	_	
203-146	41159-41164	Brain	_	
203-147	41165-41175	activation	_	
203-148	41176-41179	for	_	
203-149	41180-41183	the	_	
203-150	41184-41188	main	_	
203-151	41189-41195	effect	_	
203-152	41196-41198	of	_	
203-153	41199-41212	substance-use	_	
203-154	41213-41219	status	_	
203-155	41220-41222	on	_	
203-156	41223-41233	sad-infant	_	
203-157	41234-41239	faces	_	
203-158	41242-41249	Caudate	_	
203-159	41250-41253	197	_	
203-160	41254-41255	−	_	
203-161	41255-41257	21	_	
203-162	41258-41260	29	_	
203-163	41261-41262	5	_	
203-164	41263-41268	24.92	_	
203-165	41272-41277	faces	_	
203-166	41278-41279	(	_	
203-167	41279-41280	p	_	
203-168	41280-41281	<	_	
203-169	41281-41285	.001	_	
203-170	41285-41286	,	_	
203-171	41287-41291	pFWE	_	
203-172	41291-41292	<	_	
203-173	41292-41295	.05	_	
203-174	41295-41296	)	_	
203-175	41296-41297	.	_	

#Text=Highlights
#Text=Maternal substance use (SU) can impact caregiving and child development
#Text=SU may also shape maternal brain activation to salient infant cues
#Text=Greater activity to own vs. unknown infant faces was observed in SU mothers
#Text=Decreased activity to sad infant faces was present in SU mothers vs. non-SU mothers
#Text=No effect of maternal SU on listening to own vs. unknown infant cries
204-1	41298-41308	Highlights	_	
204-2	41309-41317	Maternal	_	
204-3	41318-41327	substance	_	
204-4	41328-41331	use	_	
204-5	41332-41333	(	_	
204-6	41333-41335	SU	_	
204-7	41335-41336	)	_	
204-8	41337-41340	can	_	
204-9	41341-41347	impact	_	
204-10	41348-41358	caregiving	_	
204-11	41359-41362	and	_	
204-12	41363-41368	child	_	
204-13	41369-41380	development	_	
204-14	41381-41383	SU	_	
204-15	41384-41387	may	_	
204-16	41388-41392	also	_	
204-17	41393-41398	shape	_	
204-18	41399-41407	maternal	_	
204-19	41408-41413	brain	_	
204-20	41414-41424	activation	_	
204-21	41425-41427	to	_	
204-22	41428-41435	salient	_	
204-23	41436-41442	infant	_	
204-24	41443-41447	cues	_	
204-25	41448-41455	Greater	_	
204-26	41456-41464	activity	_	
204-27	41465-41467	to	_	
204-28	41468-41471	own	_	
204-29	41472-41474	vs	_	
204-30	41474-41475	.	_	
204-31	41476-41483	unknown	_	
204-32	41484-41490	infant	_	
204-33	41491-41496	faces	_	
204-34	41497-41500	was	_	
204-35	41501-41509	observed	_	
204-36	41510-41512	in	_	
204-37	41513-41515	SU	_	
204-38	41516-41523	mothers	_	
204-39	41524-41533	Decreased	_	
204-40	41534-41542	activity	_	
204-41	41543-41545	to	_	
204-42	41546-41549	sad	_	
204-43	41550-41556	infant	_	
204-44	41557-41562	faces	_	
204-45	41563-41566	was	_	
204-46	41567-41574	present	_	
204-47	41575-41577	in	_	
204-48	41578-41580	SU	_	
204-49	41581-41588	mothers	_	
204-50	41589-41591	vs	_	
204-51	41591-41592	.	_	
204-52	41593-41599	non-SU	_	
204-53	41600-41607	mothers	_	
204-54	41608-41610	No	_	
204-55	41611-41617	effect	_	
204-56	41618-41620	of	_	
204-57	41621-41629	maternal	_	
204-58	41630-41632	SU	_	
204-59	41633-41635	on	_	
204-60	41636-41645	listening	_	
204-61	41646-41648	to	_	
204-62	41649-41652	own	_	
204-63	41653-41655	vs	_	
204-64	41655-41656	.	_	
204-65	41657-41664	unknown	_	
204-66	41665-41671	infant	_	
204-67	41672-41677	cries	_	
